

VOLUME 10 ISSUE 1

JUNE 2016



University of Duhok  
College of Medicine

# Duhok Medical Journal

The Official Journal of Duhok College of Medicine



ISSN: 2071 - 7326

*Photo on the cover page*

**Baroshka Saadon Village - Doski zone**

***The journal is also available at the college website (Online ISSN 2071-7334)***

***<http://web.uod.ac/academic/colleges/college-medicine/duhok-medical-journal/>***

VOLUME 10 ISSUE 1

JUNE 2016



**University of Duhok  
College of Medicine**

# **Duhok Medical Journal**

**The Official Journal of Duhok College of Medicine**

*This page is left intentionally*

# Duhok Med J

## EDITORIAL BOARD

### PATRON

**Prof. QASIM HASSO ABDULLAH, MBChB, MSC, PhD**  
Dean, College of Medicine, University of Duhok

### EDITOR-IN-CHIEF

**Prof. SAMIM A. AL-DABBAGH, MBChB, DTM&H, D. Phil, FFPH**  
Head, Department of Family and Community Medicine, Duhok College of Medicine

### MEMBER

**Prof. DHIA J. AL-TIMIMI, BSc (pharm), Mphil, PhD**  
Department of Clinical Biochemistry, Duhok College of Medicine

### MEMBER

**Prof. NASIR A. AL-ALLAWI, MBChB, MSc, PhD**  
Department of Pathology, Duhok College of Medicine

### MEMBER

**Dr. FARHAD K. SULAYVANI, MBChB, CABS, FRCS**  
Assistant professor, Department of Surgery, Duhok College of Medicine

### MEMBER

**Prof. MAIDA Y. SHAMDEEN, MBChB, MRCOG, RECOG**  
Department of Obstetrics and Gynecology, Duhok College of Medicine

### MEMBER

**Dr. MOHAMMED T. RASOOL, MBChB, FRCPG, FRCP (London)**  
Assistant professor, Department of Internal Medicine, Duhok College of Medicine

**MEMBER**

**Dr. ABDULGHAFOOR S. ABDULKAREEM, MBChB, FICMS**

**Assistant professor of Urology, Department of Surgery, Duhok College of Medicine**

**MEMBER**

**Dr. MOWAFAK M. SH. BAHADDIN, MBChB, DS, CABS, FICS, FRCS**

**Assistant professor, Department of Surgery, Duhok College of Medicine**

**MEMBER**

**Dr. SEFAR MOHAMAD HAJ, MBChB, MRCP, FRCP**

**Assistant professor, Department of Internal Medicine, Duhok College of Medicine**

**MEMBER**

**Dr. WAHID M. HASSAN, MBChB, FIBMS (Ortho)**

**Assistant professor, of Orthopedic Surgery, Department of Surgery,  
Duhok College of Medicine**

**EDITORIAL ASSISTANT**

**Dr. ABDULLA J. RAJAB, MBChB, MPH, PhD**

**Duhok Directorate of Health**

**Dr. HUSHYAR M. SULAIMAN, MBChB, MSc, MHS (Health Policy)**

**Head of Department of Planning, Duhok Directorate of Health**

**Dr. SOUZAN H. EASSA, BVM&S, MSc, PhD**

**Department of Microbiology, Duhok College of Medicine**

**Dr. ARY HABEEB MOHAMMED, MBChB, MSc, PhD**

**Department of Family and Community Medicine, Duhok College of Medicine**

**Submission of Manuscript:**

Manuscripts should be submitted to:

The Editor,  
Duhok Medical Journal,  
Duhok College of Medicine,

Post address: Nakhoshkhana Road 9, 1014, AM, Duhok, Iraq.

Telephone No.: 00964-62-7224268 EXT 115

E-mail: dmj@uod.ac

Electronic submission of articles is also accepted

# Duhok Med J

## ADVISORY BOARD

**Prof. GAZI ZIBARI, MD, FACS, FICS**

**Director of W.K./L.S.U. Regional Transplant Program, Louisiana, USA**

**Prof. FARHAD U. HUWEZ, MBChB, PhD, MRCPI, FRCP, FRCPG**

**Professor Consultant Physician / Head Physician of Stroke Services, Basildon & Thurrock NHS Trust, Basildon Hospital, United Kingdom**

**Prof. ADNAN M. HASAN, MBChB, CABP,**

**Department of Pediatrics, College of Medicine, University of Sulaimaniya**

**Prof. ABBAS ALRABATY, MBChB, CABS**

**Pediatrics Program Director, Kurdistan Board for Medical Specialties**

**Prof. FAYSIL A. ALNASIR, FPC, FRCGP, MICGP, PhD**

**Family and Community Medicine Director, Arabian Gulf University, Bahrain**

**Dr. ASAD A. ZOMA FRCP, FRCPG, FACR**

**Consultant Physician in Rheumatology and Senior Clinical Lecturer  
Lanarkshire Health Board and Glasgow University, Scotland, United Kingdom**

**Dr. CHRISTINE M. EVANS, MBChB, MD Ed, FRCS, FRCS Ed**

**Urologist, North Wales, United Kingdom**

**Dr. ABDULBAGHI AHMAD, MD, PhD**

**Consultant Child Psychiatrist and Director of Studies, Department of Neuroscience,  
Child and Adolescence Psychiatry, Uppsala University Hospital, Sweden**

*This page is left intentionally*

# Duhok Med J

## INSTRUCTIONS FOR AUTHORS

**Aims and Scope** Duhok Medical Journal is a peer reviewed journal issued bi – annually by Duhok College of Medicine. Scientific and clinical researches are the main issues. The journal also publishes short articles, letters to editors, review articles and case reports.

**General** The Duhok Medical Journal is a signatory journal to the uniform requirement for manuscripts submitted to biomedical journals, February 2006 [updated 2009] (<http://www.icmje.org>).

To present your original work for consideration three manuscript copies written in English together with Kurdish and Arabic abstracts should be submitted to the editor. All authors are required to provide the manuscript on a CD labeled with the name and title of the paper.

**Preparation of the manuscript** The manuscript should be typed double spaced as normal text on one side of the paper in single column format, font size 14 pt, paper type A4, 1" margin at each side and each of the following sections should begin on a new page in the following sequence:

- 1- **Title page**; should include the following: title, font size 16 pt, each author's full name, academic degree(s), scientific title (if available), institutional affiliation, full contact information including emails. If there are more than one author, article should include author to whom correspondence should be addressed including the scientific title (if available), institution affiliation, address, email, telephone.
- 2- **Structured abstract**; of no more than 250 words including background and objectives, methods, results, and conclusions.  
3 – 10 keywords or phrases should be put at the end of each abstract (Printed in bold font; size 12 pt).
- 3- **Body of the text**; structured in an IMRAD style;  
(Introduction, Methods, Results and Discussion).
- 4- **Acknowledgment** (if any.)
- 5- **References.**
- 6- **Tables with legends.**
- 7- **Illustrations with legends.**
- 8- **Structured Kurdish abstract including title in Kurdish.**  
بێشەکی و ئارمانج، رێکێن فه کولینۆ، ئه نجام، ده ره نه نجام
- 9- **Structured Arabic abstract including title in Arabic.**  
خلفية وأهداف البحث، طرق البحث، النتائج، الاستنتاجات

**Tables** Each table must be typed on separate page and should follow the reference list. All the tables must be numbered consecutively in the order of their first citation in the text. Supply a brief title for each on top and place explanatory matter in foot notes not in the heading (if needed). Tables should be simple and not duplicated in the text. Percentages are included with numbers in the same cells but in brackets.

**Illustrations** Graphs, line drawing, photographs, printed x rays and other illustrations are accepted only if they add to the evidence of the text. They should be of a high quality and suitable for reproduction. They should be numbered consecutively according to the order in which they have been first cited in the text. Supply a brief title beneath each illustration. Graphs should have white background; should be colored and non 3-dimensional figure; and should have labels for X and Y axis.

**Numbers and Units** Measurements of length, height, weight and volume should be reported in metric units. Temperature in degrees Celsius, blood pressure should be expressed in mmHg and all hematologic and clinical chemistry measurements in SI units.

**Abbreviations** should be defined on first use and then applied consistently throughout the article. Avoid abbreviations in the title and abstract.

**References** should be numbered both in text and in the list of references in the order in which they appear in the text. The punctuation of the Vancouver style should be followed; if the original reference is not verified by the author, it should be given in the list of references followed by (cited by) and the paper it was referring to. The titles of journals should be abbreviated according to the style used in Index Medicus. This can be obtained from website (<http://www.nlm.nih.gov/>). The author is responsible for the accuracy of references. The following are examples of the three most common types of citations:

The article citation: if six authors or fewer list all; if seven or more authors list the first six and then add "et al":

1- Nuwayhid IA, Yamout B, Azar G, Kambris MA. Narghile (hubble bubble) smoking, low birth weight, and other pregnancy outcomes. *Am J Epidemiol.* 1998;148(4):375-83.

Book citation, noting chapter and authors:

2- Arevalo JA, Nesbitt TS. Medical problems during pregnancy. In: Taylor RB, editor. *Family medicine: principles and practice.* 6th ed. New York: Springer – Verlag; 2003. p. 109-16.

Electronic source:

3- Garfinkel PE, Lin E, Goering P. Should amenorrhoea be necessary for the diagnosis of anorexia nervosa? *Br J Psych [Internet].* 1996 [cited 1999 Aug 17];168(4):500-6. Available from: URL:<http://biomed.niss.ac.uk>

**Authorship and consent form** All authors must give signed consent (Form No.1- Submission Form), which should accompany the manuscript. The letter should say "this manuscript is an unpublished work, which is not under consideration elsewhere in the record. Authors are requested to state an approximate estimate of their contribution in the study, sign the form and send it with the manuscript.

Authors must declare if they have any competing interests in the study and to specify any funds given to conduct the study.

**Ethical considerations** When experiments on humans are being reported the whole work in the manuscript should conform to the ethical standards of the responsible committee on human experimentation.

### Submission of manuscript

Manuscripts should be submitted to:

The Editor,

Duhok Medical Journal,

Duhok College of Medicine,

Post address: Nakhoshkhana Road 9, 1014, AM, Duhok, Iraq.

Telephone no.: 00964-62-7224268 EXT 115

E-mail: [dmj@uod.ac](mailto:dmj@uod.ac)

Electronic submission of articles is also accepted

### N.B.

\* Accepted manuscripts may be altered by the editorial board of Duhok Medical Journal to conform to details of the journal publication style.

\*\* The Editorial Board of Duhok Medical Journal accepts no responsibility for statement made by authors in articles published by the journal.

# Duhok Med J

## CONTENTS

<b>IMPACT OF SERUM AMYLOID A IN EARLY DETECTION OF ENDOTHELIAL DYSFUNCTION BY PERCUTANEOUS CORONARY INTERVENTION</b> <i>CHRO S. M. ZANGANA, ARAM J. MIRZA, DHIA J. AL-TIMIMI</i> .....	1-9
<b>SERUM GAMMA GLUTAMYL TRANSFERASE LEVELS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME; RELATION TO OXIDATIVE STRESS</b> <i>SHIREEN A. IBRAHIM, SHELAN H. RASOOL, HAZHMAT A. ALI</i> .....	10-19
<b>A STUDY OF SODIUM CONCENTRATION IN DIFFERENT BREAD CONSUMED IN DUHOK CITY –KURDISTAN REGION –IRAQ</b> <i>MASOOD ABDULKAREEM ABDULRAHMAN</i> .....	20-30
<b>VITAMIN D STATUS AMONG APPARENTLY HEALTHY POPULATION IN DUHOK, KURDISTAN REGION, IRAQ</b> <i>DHIA J. AL-TIMIMI, SHERWAN F. SALIH</i> .....	31-39
<b>CAN PERIODONTAL THERAPY REDUCES THE SEVERITY OF ACTIVE RHEUMATOID ARTHRITIS?</b> <i>HASHIM D. MOUSA</i> .....	40-48
<b>VITAMIN D STATUS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME</b> <i>SHEREEN A. IBRAHIM</i> .....	49-57
<b>ACNE VULGARIS: THE PREVALENCE, SEVERITY AND THE ASSOCIATED FACTORS AMONG SECONDARY SCHOOL STUDENTS IN A DISTRICT OF KURDISTAN REGION /IRAQ</b> <i>KAMIL R. F. CHALKY, SAMIM A. AL-DABBAGH, ZEYAD S. AL-DABBAGH</i> .....	58-68
<b>SPECTRUM OF BONE MARROW PATHOLOGY AT HEVI PEDIATRIC HOSPITAL: SIX YEARS EXPERIENCE</b> <i>ADNAN A. AL-DOSKI</i> .....	69-80
<b>ZINC DEFICIENCY AMONG WOMEN DURING CHILD BEARING AGE</b> <i>KAJEEN R. HUSSEN, DHIA J. AL-TIMIMI</i> .....	81-89
<b>IS FINE NEEDLE ASPIRATION CYTOLOGY A VALID DIAGNOSTIC TOOL IN NODULAR GOITER?</b> <i>HAYDER HUSSEIN IBRAHIM, MOWAFAQ M. BAHADIN</i> .....	90-98
<b>EVALUATION OF SERUM ZINC LEVEL IN LIVER CIRRHOSIS PATIENTS IN DUHOK GOVERNORATE</b> <i>BAYAR A. QASIM, AZAD SALIH, MALAVAN HABEEB, REZVAN F. ABDULJABBAR</i> .....	99- 109

*This page is left intentionally*

**IMPACT OF SERUM AMYLOID A IN EARLY DETECTION OF ENDOTHELIAL INJURY BY PERCUTANEOUS CORONARY INTERVENTION**

**CHRO S. M. ZANGANA, M.B.Ch.B, KMBS\***  
**ARAM J. MIRZA, MSc, MRCP (Gls.), FACC\*\***  
**DHIA J. AL-TIMIMI, MPhil, PhD\*\***

*Submitted 24 April 2016; accepted 30 June 2016*

**ABSTRACT**

**Background:** Evidence of elevated serum levels of inflammatory and restenosis markers after percutaneous coronary intervention (PCI), including balloon angioplasty and stenting has been reported in various population. The utility of serum amyloid A in early diagnosis of endothelial cell damage of coronary arteries by cardiac ballooning and stenting still uncertain. The aim of the present study was to determine the validity of serum amyloid A in early diagnosis of endothelial cell damage of coronary arteries by cardiac ballooning and stenting. Methods Serum amyloid A and high sensitive c-reactive protein (Hs-CRP) was determined in a sample of 137 patients attended diagnostic cardiac angiography unit at Sulaimaniyah Center of Heart disease, 68 cases were previously diagnosed with coronary artery lesions, underwent coronary ballooning and stenting, and 69 patients with chest pain underwent diagnostic angiography, free of coronary artery lesion participated in this study. The alteration in serum amyloid A and Hs-CRP levels was estimated before and after 4 hours from procedure.

**Results:** The comparison between cases and controls showed that the 2 groups did not differ significantly with respect to age, gender, ethnicity, hypertension, diabetes mellitus and smoking. The pre- and post-operative mean values of Hs-CRP were similar in cases and controls. The post-operative cases exhibited significantly higher serum amyloid A levels than controls and the difference was statistically significant ( $p=0.001$ ). The usefulness of serum amyloid as a screening test for endothelial injury was assessed by calculating its validity with regard to cut-off point of Hs-CRP. The post-operative cases with Hs-CRP  $> 3$  mg/l had a higher prevalence 54.0% of amyloid A compared with those of Hs-CRP  $< 3$  mg/l. (46.0%,  $p=0.001$ ).

**Conclusions:** It is evident from this study that post-operative cases underwent coronary ballooning and stenting had high serum amyloid A protein levels. It thus indicates the need for determining serum amyloid A in patients at risk of early coronary endothelial injury.

**Duhok Med J 2016; 10 (1): 1-9.**

**Keywords:** Amyloid A, Hs-CRP, Coronary endothelial damage

**S**erum amyloid A (SAA) is protein which regarded as a major component of the acute-phase inflammatory response synthesized by the liver and also from some extrahepatic source response to infection, inflammation, injury, and stress dramatically 1000-fold greater than normal within 5-6 hours after

\*Specialist Chemical Pathologist, Sulaimaniyah Teaching Hospital, College of Medicine, Kurdistan region of Iraq.

\*\*Consultant interventional cardiologist, Slemany Cardiac Hospital, Sulaimaniyah, Kurdistan region of Iraq.

\*\*\*Professor of Clinical Biochemistry, Department of Chemistry and Clinical Biochemistry, College of Medicine, University of Duhok, Kurdistan region of Iraq

Corresponding author: Dhia J. Al-Timimi: Phone: +9647504228908; Email: altmimidj@yahoo.com

stimuli. It can be regarded as proatherogenic and proinflammatory marker<sup>1</sup>. Percutaneous coronary intervention (PCI) including balloon angioplasty and stenting has become a first line management of stable angina and acute coronary syndromes; however restenosis is still occurring in approximately 30% of all patients after procedure as unfavorable physiological response to stent implantation<sup>2</sup>.

Serum cardiac markers provide diagnostic and prognostic information that may reflect critical elements involved in the evolution of an acute coronary syndrome. With inflammation now recognized as contributing to atherogenesis, inflammatory proteins have been investigated as potential indicators of underlying atherosclerosis as well as unstable atheromatous lesions<sup>3</sup>. Elevated levels of C-reactive protein (CRP), the prototypical acute phase protein are associated with adverse cardiovascular outcomes in patients with stable and unstable ischemic heart disease and as well as healthy men without clinical vascular disease. Similar to CRP, serum amyloid A is found to identify a population of patients who remain at increased mortality risk<sup>4</sup>. It has been reported that amyloid A represent the inflammatory marker of the coronary stenosis with highly predictive of the risk for cardiovascular events even within 3

years, while the level of Hs-CRP was not associated with cardiovascular heart disease<sup>5</sup>. Serum amyloid A, also an important acute phase protein, has an expanded dynamic range with different kinetics compared with CRP and is reported to be a more sensitive indicator of inflammation in some non-cardiovascular inflammatory conditions<sup>6</sup>. However, serum amyloid A has not been examined as extensively in endothelial damage of coronary arteries by cardiac ballooning and stenting.

## **METHODS**

A case control study was conducted at Sulaimaniyah Center of Heart Disease, Sulaimaniyah Teaching Hospital in Kurdistan Region during the period November 2014 to February 2015. A heterogeneous group of 137 adult patients of both sexes (91 males and 46 females) who attended cardiac angiography unit in the above center were included. Of these 68 patients previously diagnosed with coronary artery lesions (48 males and 20 females), underwent coronary ballooning and stenting (case group). The remainder (n=69) were patients with chest pain admitted to the center for diagnostic coronary angiography (43 males and 26 females), served as a control group. Protocol involved that: all patients undergo percutaneous cardiac angiography; during the period of the study were interviewed

and informed about the nature of the study. After the patients signed an informed consent form, pre and post cardiac intervention blood samples were collected for Amyloid A and Hs-CRP measurement. The study protocol was approved by the scientific research and ethics committee of the Kurdistan Board of Medical Sciences. Permission was obtained from administrative authorities of Sulaimaniyah Center of Heart Disease and Sulaimaniyah Central laboratory and doctor Saman laboratory.

The specimen collection from the patients was carried out using venous blood collected in two different times, first one were taken before patients undergoing cardiac interventions, usually were around 7:30 AM to 10:30 AM, while the second specimen were taken after 4 hours from cardiac intervention, usually were around 12 PM to 4 PM. Five millers of blood has been taken from each patient and transfer in plain tube. The blood specimens left a room temperature for 20 mints, and then centrifuged at 3000 rpm for 10 minutes. Serums were separated and pipetted in to plain tubes for storage at -40 0C, till the day of analysis. Serum amyloid A was measured using enzyme-linked immune sorbent assay (ELISA),kit assay manufactured by Shanghai YEHUA biological technology Company. Quantitative Hs-CRP protein measurement

was done by using Cobas Hs-CRP reagent kit in c 311 Cobas analyzer. The assay system uses immune-turbidometric method through latex particles coated with antibody specific to human CRP (monoclonal anti CRP antibody) aggregated in the presence of CRP from the sample forming immune complex.

Statistical analysis was performed using SPSS version 18 software for windows. Data are presented as mean+SDE. Differences in frequencies for categorical variables were assessed by the chi-square test. We compared the groups using the independent-sample t-test. A p-value of less than 0.05 was considered statistically significant in all data analyses.

## RESULTS

The baseline characteristics of the 137 men and women included in the analysis are shown in table 1. Overall, males comprised 66.4% of the study subjects and females comprised 33.6% of the study population. Age group subjects in 50-69 years had a higher incidence as compared to the other age groups. The majority of the study subjects were Kurd ethnicity. The cases and controls did not differ significantly with respect to age, gender, ethnicity, hypertension, diabetes mellitus and smoking.

Baseline characteristics for the cases and controls with previous cardiac history are presented in table 2. None of the control

had any history of traditional cardiac intervention including previous and current stent implantation number. Increasing mean stent number values were exhibited in the study cases (0.26 to 1.87).

**Table 1: Baseline characteristics of controls and cases**

Variables n (%) n (%)	Controls (n =69)	Cases (n=68)	P value
<b>Age (years)</b>			
<50	16(23.2)	10(14.7)	0.289
50-59	21(30.4)	20(29.4)	
60-69	25(36.2)	24(35.3)	
≥70	7(10.1)	14(20.6)	
<b>Gender</b>			
Males	43(62.3)	48(70.6)	0.305
Females	26(37.7)	20(29.4)	
<b>Ethnicity</b>			
Kurd	66(95.7)	48(70.6)	0.11
Others	3(4.3)	8(11.8)	
<b>Hypertension</b>			
Yes	43 (62.3)	41(60.3)	0.808
No	26 (37.7)	27(39.7)	
<b>Diabetes mellitus</b>			
Yes	23(33.3)	23(33.8)	0.952
No	46(66.7)	45(66.2)	
<b>Smoking</b>			
Yes	11(15.9)	15(22.1)	0.361
No	58(84.1)	53(77.9)	

**Table 2: Baseline characteristics of cardiac history in cases and controls**

Variable	Controls (n=69)	Cases (n=68)	P value
Previous stent number	0.00 ± 0.00	0.26±0.07	0.002
Operated vessel number	0.00 ± 0.00	1.35±0.04	0.001
Current stent number	0.00 ± 0.00	1.87±0.09	0.001
Balloon inflation mean pressure	0.00 ± 0.00	15.84±0.13	0.001

Results: SEM

The comparison between cases and controls are summarized in table 3. As expected, the post-operative cases exhibited significantly higher serum amyloid A levels compared to controls. However the difference was not statistically significant (p=0.064). A significant difference has been noted in amyloid A levels (p=0.01) in post-operative cases as compared to pre-operative group.

**Table 3: Serum Hs-CRP and Amyloid A levels in cases and controls**

Markers	Controls (n=69)	Cases (n=68)	P value
<b>Hs-CRP (mg/l)</b>			
Pre-operative	9.30±2.75	7.72±2.06	0.705
Post-operative	9.20±2.71	8.18 ±2.19	0.809
Difference	-0.10 ±0.02	0.45±0.02	0.180
<b>Amyloid A (mg/dl)</b>			
Pre-operative	9.50±0.69	10.65±1.09*	0.405
Post-operative	9.86 ±0.68	12.59±1.20	0.064
Difference	0.36±0.01	1.94±0.38	0.001

Results: SEM, \* Pre- vs post-operative, p=0.01

The usefulness of serum amyloid as a screening test for endothelial injury was assessed by calculating its validity with regard to cut-off point of Hs-CRP (table 4). The post-operative cases with Hs-CRP > 3 mg/l had a higher prevalence 54.0% of amyloid A compared with those of Hs-CRP <3 mg/l. (46.0%, p=0.001).

**Table 4: Comparison of post-operative Serum Amyloid A with cut-off value of Hs-CRP among the studied subjects**

	Hs-CRP post-operative		Total	P value
	≤3mg/L	>3mg/L		
Amyloid post-operative,	n(%)	n(%)	n(%)	
Normal	54(43.9)	69(56.1)	123(100.0)	0.001
High	9(64.3)	5(35.7)	14(100.0)	
Total	63(46.0)	74(54.0)	137(100.0)	

## DISCUSSION

This study provided definitive evidence that post-operative cases underwent coronary ballooning and stenting had high serum amyloid A levels. The best difference of amyloid A was in the pre- and post-operative cases. However, no such a difference was observed with regard to Hs-CRP.

As percutaneous coronary angiography is a novel non-surgical technique for opening coronary arteries occlusion, by using a set of specialized balloons and stents, the procedure may stimulate immune system and causing variable degree of inflammation response upon inflation by balloon and implanting the stent<sup>7,8</sup>. Restenosis has been occur in many patients after percutaneous coronary intervention, as a result of inflammatory process, which is start by endothelial injury followed by intimal proliferation, and smooth muscle migration in the corresponding vessel<sup>9</sup>. So inflammatory proteins will be a hall mark of prediction of early endothelial injury and expectation for late outcome. It is

therefore, in this study the impact of serum amyloid A in early detection of endothelial injury in comparison with Hs-CRP was carried out. For both, cases who underwent coronary artery angioplasty by inserting balloon or stent and controls who underwent only diagnostic coronary angiography, serum amyloid A and Hs-CRP were estimated before and after 4 hours from procedure. The pre- and post-operative serum amyloid A values ranged from 1.25 to 13.75 mg/dl and from 3.1 to 48.79 mg/dl, respectively. In addition, the post-operative cases exhibited significantly higher serum amyloid A levels than controls and the difference was statistically significant with a p value=0.001.

Considering the difference in risk factors across countries, cases underwent coronary ballooning and stenting have significantly higher levels of acute phase proteins compared with non-ballooning or stenting (control group). This withstanding that the majority of study population are Kurdish ethnicity (92%), hypertensive (61.3%), and with diabetes mellitus (33.6%). This will associated with higher coronary plaque burden aggressive coronary disease<sup>10</sup>.

Because Kurdish ethnicity were more contribute in this study, this may lead us to have a queries for looking to other unmeasured underlying risk factors associated with aggressive coronary disease, regarding this ethnicity for

example negative emotion and anxiety, and this is in agreement with other studies in different ethnicity specially Hispanic<sup>11</sup>. However, none of the control group has history of previous stent, whereas some of cases had history of previous stent with P value =0.002.

As the inflammatory proteins are circulating freely in the serum of patients in response to much acute or chronic inflammatory process, we collected a blood sample in two occasions for each control and case group, to exclude any baseline elevation of inflammatory protein. Our results shows Pre- and post-operative serum Hs-CRP values ranged from 0.7 to 224.3 mg/l and from 0.81 to 221.1 mg/l, respectively. The mean values of Hs-CRP were similar in cases and controls with p value =0.180, which was statistically not significant, in agreement with other study that show decreasing inflammation response by using drug eluting stent<sup>12</sup>. The finding was also in agreement with other study that shows a decrease inflammatory response by clopidogrel preoperatively<sup>13</sup>.

Additionally all patients in case group were treated with unfractionated heparin as an anticoagulation agent to prevent coagulation and lead to inhibition of inflammatory response<sup>14</sup>.

The usefulness of serum amyloid A protein as a screening test for endothelial injury was assessed by calculating its validity

with regard to cut-off point of Hs-CRP. We noticed that post-operative cases with Hs-CRP>3mg/l (as a high risk for coronary artery injury) had a higher prevalence 54.0% of amyloid A by comparison with those of Hs-CRP <3 mg/l. (46.0%, p=0.001), which was statistically significant.

These finding is a positive step to support serum amyloid A as better sensitive marker for early inflammatory process and endothelial injury in comparison with Hs-CRP for late coronary stent outcome.

#### **REFERENCES**

1. Han CY, Tang C, Guevara ME, Wei H, Wietecha T, Shao B, et al. Serum amyloid A impairs the anti-inflammatory properties of HDL. *J Clin Invest.* 2016; 126(1):266-81.
2. Odeberg J, Freitag M, Forssell H, Vaara I, Persson ML, Odeberg H, et al. Influence of pre-existing inflammation on the outcome of acute coronary syndrome: a cross-sectional study. *BMJ.* 2016;6(1):e009968.
3. Hajsadeghi S, Chitsazan M, Salehi N, Amin A, Maleki M, Babaali N, et al. Changes of High Sensitivity C-Reactive Protein During Clopidogrel Therapy in Patients Undergoing Percutaneous Coronary Intervention. *Res Cardiovasc Med.* 2016; 5(1):e28997.
4. Kosuge M, Ebina T, Ishikawa T, Hibi K, Tsukahara K, Okuda J, et al. Serum amyloid A is a better predictor of clinical outcomes than C-reactive

- protein in non-ST-segment elevation acute coronary syndromes. *Circ J*. 2007;71(2):186-90.
5. Chen GL, Liu LW, Xie S, Liu H, Liu YQ, Li YS. High-density lipoprotein associated factors apoA-I and serum amyloid A in Chinese non-diabetic patients with coronary heart disease. *Chin Med J (Engl)*. 2010;123(6):658-63.
  6. Maier W, Altwegg LA, Corti R, Gay S, Hersberger M, Maly FE, et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. *Circulation*. 2005;111(11):1355-61.
  7. Kozinski M, Krzewina-Kowalska A, Kubica J, Zbikowska-Gotz M, Dymek G, Piasecki R, et al. Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis - comparison with stable and unstable angina. *Inflamm Res*. 2005;54(5):187-93.
  8. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. *Circulation*. 2002;105(25):2974-80.
  9. Nawarskas JJ, Osborn LA. Paclitaxel-eluting stents in coronary artery disease. *Am J Health Syst Pharm*. 2005;62(21):2241-51.
  10. Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. *Heart*. 2014;100(2):153-9.
  11. Castaneda SF, Buelna C, Giacinto RE, Gallo LC, Sotres-Alvarez D, Gonzalez P, et al. Cardiovascular disease risk factors and psychological distress among Hispanics/Latinos: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL). *Prev Med*. 2016;87:144-50.
  12. Garcia-Garcia HM, Vaina S, Tsuchida K, Serruys PW. Drug-eluting stents. *Arch Cardiol Mex*. 2006;76(3):297-319.
  13. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. *Int J Cardiol*. 2013;168(6):5126-34.
  14. Whang W, Peacock J, Soliman EZ, Alcantara C, Nazarian S, Shah AJ, et al. Relations between depressive symptoms, anxiety, and T Wave abnormalities in subjects without clinically-apparent cardiovascular disease (from the Multi-Ethnic Study of Atherosclerosis [MESA]). *Am J Cardiol*. 2014; 114(12): 1917-22.

پوخته

ناستی (Amyloid A) دناف خوینیدا ژبو دهست نیشانکرنا پیشوهخت یا پیچبونا دهمارین دلی لدهف نه خوشین پیداجون ددهمارین دلی دا (PCI) بو هاتیه نهجامدان

**پاشهکی و نارمانج:** بلندبونا ناستی هیمايین کولبونوی و دوباره تهنگونوی پشتی نشتهرگه ریا پیداجونوی ددهمارین دلی دا وهک بالون و توروی یا هاتیه تومارکرن ل دهف گهلهک جفاکان. بکارئینانا ناستی (Amyloid A) دناف خوینیدا ژ بو دهست نیشانکرنا پیشوهخت یا پیچبونا دهمارین دلی لدهف نه خوشین پیداجون ددهمارین دلی دا (PCI) بو هاته نهجامدان ب ریکا بالون و توروی ههتا فی دهمی نه یا دوپاتکره.

**ریکین فهکولینی:** ناستی (Amyloid A) و (Hs-CRP) هاته سنورکرن دنمونهیهکا پیکهاتی ۱۳۷ نه خوشان ئهوین سهردهانا هوبا وینهکرنا دهمارین دلی ل سهنتهروی سلیمانوی یی نه خوشین دلی پشکاری دئی فهکولینیدا کریو. ۶۸ نه خوش بهری دهمی فهکولینی هاتبونه دهستنیشانکرن کو ئیشین دهمارین دلی هه نه و پیداجون ددهمارین دلی دا ب ریکا بالون و توروی بو هاتبو نهجامدان، ئو ۶۹ نه خوش نیشانا سینگی هه بو وینهکرنا دهماران یا دهستنیشانکرنی بو هاتبو نهجامدان به لی بیئت فالو بوون ژ ئیشین دهمارین دلی. گورانکاری د ناستی (Amyloid A) ئو (Hs-CRP) هاتنه هه ژمارتن بهری و چوار دهه ژمیران پشتی نشتهرگه ریی.

**نهجام:** بهراوردیکرن دناقبهرا نه خوشین دلی ئو یین فالو ژوان دیارکر کوچ جودایی ب رهنهکی بهرچاڤ نینه دگه ل ژیی، رهگهزی، نفشی، بلندبونا فشارا خوینی، نه خوشیا شهکری، ئو جگاره کیشانی تیکرایی ناستی (Hs-CRP) یی وهک هه فبول دهف ههردوو گروپان بهری و پشتی نشتهرگه ریی، ناستی (Amyloid A) بلندتر هاته دیارکرن ب شیوهکی بهرچاڤ ل دهف نه خوشین دلی پشتی نشتهرگه ریی ژ ئهوین فالو ژنه خوشین دهمارین دلی (p=0.001). مفاداریا بکارئینانا ناستی (Amyloid A) دناف خوینیدا وهکو پشکینهکا لیگه ریانی بو برینداربونا شانین ژناقدا یین دهمارین دلی هاته ههلسهنگاندن ب هه ژمارتنا فالیدیتیا وی دگه ل خولهکا هه فبرینی یا (Hs-CRP). نه خوشین پشتی نشتهرگه ریی ئهوین ناستی (Hs-CRP) پتر ژ (3 mg/L) ریژهکا بلندتر یا بهر به لاقبونوی (54.0%) یا (Amyloid A) پشتی بهراوردی کرن دگه ل وان که سان یین ناستی (Hs-CRP) کیمتر ژ (3 mg/L) (P=0.001, 46.0%).

**دهرئه انجام:** ناستی پروتینی (Amyloid A) بلند هاته بهرچاڤ کرن دئی فهکولینیدا لدهف نه خوشین پیداجون ددهمارین دلی دا (PCI) بو هاتیه نهجامدان ب ریکا بالون و توروی. ژبه ر فی چه ندی یا گرنه ناستی (Amyloid A) بهیته سنورکرن ل دهف نه خوشین مهترسی هه ی بو برینداربونا شانین ژناقدا یین دهمارین دلی یا پیشوهخت.

## الخلاصة

مستوى (Amyloid A) في مصل الدم في التشخيص المبكر لتلف الشرايين القلبية  
عند مرضى التداخل القسطاري (PCI)

**المقدمة والاهداف:** ارتفاع مستويات مؤشرات الالتهاب وإعادة التضيق بعد التداخل القسطاري (PCI) كالبالون والشبكية أصبحت مؤشرات مدونة في مجتمعات مختلفة. استخدام مستوى (Amyloid A) في مصل الدم في التشخيص المبكر لتلف الخلايا المبطنة للشرايين القلبية بسبب البالون و الشبكية غير مؤكدة لحد الان.

**طرق البحث:** حددت مستوى (Amyloid A) و (Hs-CRP) في نموذج من ١٣٧ مريض زارو وحدة تلويين الشرايين القلبية التشخيصي في مركز السليمانية لأمراض القلب ٦٨ منهم تم تشخيصهم قبل ذلك بمرض الشرايين القلبية وخضعوا للتداخل القسطاري بواسطة البالون والشبكية و ٦٩ منهم عانوا آلام في الصدر وخضعوا لتلويين الشرايين القلبية ولكن لم يكن لديهم أمراض الشرايين القلبية شاركوا في هذه الدراسة. تم قياس التغيير في مستوى مصل الدم لكل من (Amyloid A) و (Hs-CRP) قبل وبعد أربعة ساعات من العملية.

**النتائج:** بينت المقارنة انه لا يوجد اختلاف ملحوظ بين المجموعتين أخذاً بنظر الاعتبار كل من العمر، الجنس، العرق، ارتفاع ضغط الدم، مرض السكر والتدخين. معدل القيمة لـ (Hs-CRP) قبل وبعد العملية كان متشابها بين المجموعتين. مرضى الشرايين القلبية بعد العملية أظهروا مستوى أعلى للـ (Amyloid A) من اللذين ليس لديهم مرض الشرايين القلبية وكان الاختلاف ملحوظاً احصائياً (P=0.001). تم تقييم فائدة فحص الدم للـ (Amyloid A) كفحص مسحي لتلف الخلايا المبطنة للشرايين القلبية بواسطة حساب صلاحية الفحص مع الاخذ بنظر الاعتبار نقطة حد الفصل لـ (Hs-CRP). مرضى الشرايين القلبية بعد العملية مع مستوى (Hs-CRP) أكثر من (3 mg/L) كانت لديهم نسبة انتشار اعلى (54.0%) من مستوى (Amyloid A) مقارنة مع اللذين لديهم مستوى (Hs-CRP) اقل من (3 mg/L) (46.0%, P=0.001).

**الاستنتاج:** شوهدت في هذه الدراسة أن مرضى الشرايين القلبية الذين خضعوا للبالون والشبكية كان لديهم ارتفاع مستوى البروتين (Amyloid A) في مصل الدم بعد عملية التداخل القسطاري، ولذلك تحديد مستوى الـ (Amyloid A) أصبح مشروطاً في المرضى الذين لديهم نسبة خطورة عالية لجرح الخلايا المبطنة للشرايين القلبية المبكر.

SERUM GAMMA GLUTAMYL TRANSFERASE LEVELS IN WOMEN WITH  
POLYCYSTIC OVARY SYNDROME; RELATION TO OXIDATIVE STRESS

SHIREEN A. IBRAHIM, MBChB, MSc, PhD\*

SHELAN H. RASOOL, BSc, M.Sc\*\*

HAZHMAT A. ALI, BVM&S, M.Sc (UK)\*\*\*

*Submitted 16 March 2016; accepted 30 June 2016*

---

**ABSTRACT**

**Background:** There is increasing evidence on the association between high serum gamma glutamyl transferase (GGT) levels and oxidative stress in women with polycystic ovary syndrome (PCOS). The aim of this study was to examine serum GGT levels in a sample of women with PCOS and to ascertain the relation to oxidative stress.

**Methods:** A case control study included forty women who were clinically diagnosed with PCOS according to Rotterdam criteria and twenty apparently healthy women served as a control group. Following clinical diagnosis, anthropometric measurement was calculated including height, weight and body mass index (BMI). Serum gamma glutamyl transferase, high sensitive C-reactive protein (hs-CRP) and malonyldialdehyde (MDA) were measured.

**Results:** The women with PCOS exhibited significantly higher serum GGT, hs-CRP and MDA levels than did the healthy women ( $p=0.04$ ,  $p=0.05$ ,  $p=0.05$ ) respectively. The correlation between serum GGT levels and hs-CRP was significant among women with PCOS ( $p=0.05$ ).

**Conclusion:** Our results suggest that mild elevation of serum GGT may be related to oxidative stress in women with PCOS particularly obese.

**Duhok Med J 2016; 10 (1): 10-19.**

**Keywords:** Polycystic ovary syndrome, gamma glutamyl transferase and oxidative stress.

---

**P**olycystic Ovary Syndrome (PCOS) is a common metabolic endocrinopathy of the female reproductive system characterized mainly by chronic anovulation associated with other symptoms such as elevated androgen levels (hyperandrogenemia), insulin resistance and hirsutism<sup>1</sup>. Although the precise etiology of PCOS is not fully understood, studies indicate that both genetic and environmental factors results

in dysfunctions in hypothalamic pituitary axis (HPA) and excessive androgen levels leading to hormonal imbalance represented by decrease in follicular stimulating hormone (FSH) and elevation in luteinizing hormone (LH) which in turn eventually results in anovulation<sup>2,3</sup>.

Previous studies focused on a variety of PCOS aspects mainly the relationship between anovulation and oxidative stress.

Studies concluded that there is existence of

---

\* MD, PhD, Lecturer, Dept. of Physiology, College of Medicine, University of Duhok.

\*\* M.Sc, Assistant Lecturer, Dept. of Basic Medical Sciences, College of Medicine, University of Duhok.

\*\*\* M.Sc (UK), Assistant Lecturer, Dept. of Physiology, College of Medicine, University of Duhok.

Correspondent author: Dr. Hazhmat A. Ali, eMail: hazhmat.ali@uod.ac

low grade chronic inflammation as well as oxidative stress that contribute to the PCOS pathogenesis through altering LH/FSH ratio<sup>4</sup>. However, gamma glutamyl transferase (GGT) which is expressed in the cell membranes of various tissues and plays a pivotal role in glutathione and leukotriene metabolism, has been linked to various disorders including insulin resistance and cardiovascular diseases<sup>5,6,7</sup>. Studies suggest that both cellular and serum GGT levels may play an important role in generating reactive oxygen species (ROS) and subsequently considered as a predictable and sensitive marker for oxidative stress<sup>8,9</sup>. The aim of this study was to examine the serum GGT levels in women with polycystic ovary syndrome as well as examining its reliability as a marker for oxidative stress.

#### **METHODS:**

After receiving an approval letter from the research committee at Duhok College of Medicine, this case control study involved forty women who were clinically diagnosed with PCOS based on Rotterdam criteria<sup>10</sup> (oligo- and/or anovulation or clinical and/or biochemical hyperandrogenemia or polycystic ovaries on ultrasonography) and twenty apparently healthy women served as a control group. Anthropometric measurements were calculated including height and weight, and body mass index (BMI). Case history

and all relevant information were taken by a questionnaire. Upon their approval, five milliliters of venous blood was collected from each participant for necessary laboratory investigations.

Hormonal assays including follicular stimulating hormone (FSH) and luteinizing hormone (LH) were measured using enzyme immunoassay technique (Biomerieux manufacturer, France). Serum levels of high sensitivity C-reactive protein were assayed using ELISA (Monobind Inc., USA Kit). Quantitative measurement of Malondialdehyde (MDA, nmol/ml) was determined in serum samples using thiobarbituric acid method<sup>11</sup>. Serum levels of gamma glutamyl transferase (GGT) were measured by spectrophotometric method (Biolab Manufacturer, France).

SPSS version 18 (Chicago, USA) was used for statistical analysis of study values. All variables were expressed as mean  $\pm$  standard deviation (SD). The independent t-test was used to determine the statistical significance of difference in mean between study groups, p values of 0.05 or less were considered statistically significant.

#### **RESULTS:**

Both study groups had a mean age of 29 years while PCOS subjects had an average infertility duration of 3 years. Among PCOS patients, 90% were registered married versus 10% virgins. Study results showed a highly statistically significantly

**SERUM GAMMA GLUTAMYL TRANSFERASE LEVELS IN WOMEN WITH POLYCYSTIC**

increased BMI ( $p=0.005$ ) in PCOS women compared to control (28.14 vs. 22.9). Follicular stimulating hormone (FSH) displayed a statistically significant decrease in PCOS women compared to control ( $p=0.04$ ). Luteinizing hormone (LH) showed a statistically significant elevation ( $p=0.01$ ) in women with PCOS versus controls (Table1).

**Table 1: Basic characteristics of PCOS patients and control subjects**

Parameters	PCOS	Control	P value
Age (years)	29.1 ± 4.71	29.7 ± 3.88	0.91
Duration of infertility (years)	3.34 ± 2.57	NA	NA
Body Mass Index (BMI)	28.14 ± 3.12	22.9 ± 2.05	0.005
% and number of married vs. virgin	90% vs. 10% (36 vs. 4)	NA	NA
FSH	6.31 ± 2.44	10.59 ± 2.63	0.04
LH	13.23 ± 2.18	5.84 ± 1.95	0.01

Serum levels of high sensitivity C-reactive protein (hs-CRP) were statistically significantly elevated in PCOS women as compared to controls ( $p<0.05$ ). Moreover, both serum gamma glutamyl transferase (GGT) and malondialdehyde (MDA) displayed a significant increase in women with PCOS compared to control ( $p=0.04$  and  $p=0.05$  respectively). (Table 2)

**Table 2: Inflammatory and oxidative stress markers among study groups**

Parameters	PCOS (No. 40)	Control (No. 20)	p value
hs-CRP (mg / dL)	3.74 ± 1.85	1.38 ± 4.38	< 0.05
GGT (IU / L)	38.97 ± 3.07	23.09 ± 5.62	0.04
MDA (nmol / ml)	3.11 ± 1.98	0.82 ± 4.27	0.05

The women with POCS were further classified based on body mass index in to two groups; obese ( $n=20$ , BMI> 30) and lean ( $n=20$ , BMI<25). Results indicated a highly statistically significant differences in hs-CRP between study groups ( $p=0.003$ ). There were statistically significant differences in both GGT and MDA between study groups ( $p=0.001$  and  $p=0.023$  respectively), ( Table 3).

**Table 3: Comparison in parameters between patients subgroups vs. control**

Parameter s	Lean PCOS (No. 20)	Obese (No. 20 )	p value
hs-CRP (mg/dL)	2.77± 1.49	4.71±2.21	0.003
GGT (IU/L)	35.32 ± 2.31	42.62 ± 3.84	0.001
MDA (nmol/ml)	2.93 ± 2.4	3.28 ± 1.56	0.023

Pearson's correlation coefficient was used to determine the correlation between variables. There was a significant correlation between hs-CRP and GGT

( $p=0.05$ ) whereas both correlations hs-CRP-MDA and GGT-MDA were not significant (  $p=0.85$  and  $p=0.91$ ) respectively.

**Table 4: Pearson's correlation coefficient among variables.**

Variables	R value	P value
hs-CRP - GGT	0.352	0.05
hs-CRP - MDA	0.12	0.85
GGT - MDA	0.16	0.91

### DISCUSSION:

The majority of previous studies reported an association between obesity and hyperandrogenemia in PCOS women<sup>12</sup>. Results of the present study confirmed the same idea represented by significant elevation in BMI ( $p =0.005$ ). Although lack of androgen levels could be one of the possible limitation of this study but alternatively patients were clinically examined for presence or absence of hirsutism which is the consequence of excessive androgen levels. Hormonal profile of PCOS women displayed a significant reduction in FSH accompanied by a significant elevation in LH although both hormones were within their normal values. This is consistent with other studies concluding that dysfunction in hypothalamic pituitary adrenal axis represented by rapid short pulses in GnRH secretion may result in altering LH/FSH

ratio which eventually leads to FSH deficiency compared to LH and subsequently preventing follicular maturation during follicular phase of the menstrual cycle<sup>13,14</sup>. The existence of low grade chronic inflammation in the pathogenesis of PCOS and other diseases is well established in previous studies. Our results are consistent with previous literature concluding that there is a significant elevation in inflammatory markers mainly hs-CRP which is also regarded as a risk factor for a variety of diseases mainly cardiovascular disorders and diabetes<sup>15,16</sup>.

A variety of research have been focusing on the classical functions of GGT as a marker for excessive alcohol consumption as well as its contribution with cardiovascular, metabolic and liver diseases. It is indicated that GGT may be considered as a risk factor for cardiovascular disorders owing to its elevation and its association with other cardiovascular and metabolic disturbances<sup>17,18,19</sup>. Others reported that mild elevation of serum GGT is associated with incidence of diabetes and hypertension, these associations are consistent with a role for oxidative stress in risk for diabetes and hypertension<sup>20</sup>. Elevated fatty liver index (hypertriglyceridemia, elevated AST, ALT and GGT) is a commonly observed in

obese PCOS women, whereas normal weight PCOS showed no evidence for elevated FLI<sup>21,22</sup>.

Although the association between oxidative stress and PCOS is well documented in previous literature, there is conflicting results regarding evaluation of  $\gamma$ -glutamyl transferase as a marker for oxidative stress. Our study results are consistent with studies concluding that GGT could represent an early marker of sub-clinical inflammation and oxidative stress in obese PCOS patients<sup>23,24</sup>. Even though there is lack of evidence regarding the precise involvement of GGT in oxidative damage, there are few theories and explanations based on previous research. Recent experimental studies concluded that GGT may play an important role in generation of reactive oxygen species (ROS). In addition, the oxidative damage effects of GGT exacerbate in the presence of iron<sup>25,26,27</sup>. The possible mechanism underlying GGT capability of generating ROS could be due to cysteinylglycine, which has a strong ability to reduce Fe<sup>3</sup> to Fe<sup>2</sup> and subsequently promoting generation of free radical species. Moreover, GGT-mediated oxidative stress has been reported to be capable of inducing oxidation of lipids, thiol protein, alterations of the normal protein phosphorylation patterns in

addition to biological effects represented by activation of transcription factors<sup>28,29,30</sup>.

The second mechanism could be due to inverse relation between antioxidants and GGT. Studies examining on associations between dietary intake and serum GGT reported an inverse association between fruit intake and serum GGT in a dose-response manner. More specifically, dietary antioxidants such as vitamin C and beta-carotene showed inverse associations with serum GGT level, whereas dietary iron was positively related to serum GGT levels<sup>31,32,33</sup>. Our results also showed a significant correlation between hs-CRP and GGT which illustrates the role of both inflammation and oxidative stress in orchestrating PCOS pathogenesis<sup>34</sup>.

In conclusion, our results suggest that a mild elevation in GGT is indicated in the sera of women with PCOS particularly among obese. These findings may have clinical implications due to increased risk of oxidative stress. For that reason, targeting oxidative stress should be considered when treatment strategies are applied to PCOS patients.

#### **REFERENCES:**

1. Sharpless J. Polycystic ovary syndrome and metabolic syndrome. *Clinical Diabetes*. 2003; 21:4-11.
2. Richardson MR. Current Perspectives in Polycystic Ovary Syndrome. *Am Fam Physician*. 2003; 68(4): 697-704.

3. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. *Hum Reprod Update*. 2003;9(6):505-514.
4. Ali H, Mohammed H and Ibrahim S. The role of inflammation and oxidative stress in the pathogenesis of polycystic ovary syndrome. *WJPPS*. 2015; 9:4.
5. Maosn J, Stark R and Kirk J. Gamma-Glutamyl Transferase: A Novel Cardiovascular Risk Biomarker. *Preventive Cardiology*. 2009; 55: 36-41.
6. Onur S, Menke T and Doring F. Ubiquinol reduces  $\gamma$ -Glutamyl Transpeptidase as a marker for oxidative stress in humans. *BMC*. 2014;7:427.
7. Lee D, Blomhuff R and Jacobs D. Is serum  $\gamma$ -Glutamyl Transpeptidase a marker for oxidative stress. *Free Radical Research*. 2014; 38:6.
8. Huseby NE. Multiple forms of serum gamma-glutamyltransferase. Association of the enzyme with lipoproteins. *Clin Chim*. 1982; 124:103-112.
9. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril*. 2004, 81(1):19-25.
10. Nurten T, Husamettin E and LLgim S. Measurement of total malondiladehyde in plasma and tissues by high performance liquid chromatography and thiobarbituric acid assay. *Experimental Research*. 2006; 11: 88-92.
11. Li L, Yang D, Chen X, Chen Y, Feng S, Wang L. Clinical and metabolic features of polycystic ovary syndrome. *Int J Gynaecol Obstet* 2007; 97(2):129-134.
12. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. *Int J Obes*. 2002, 26(7):883-896.
13. Fink RI, Kolterman OG, Griffin J, Olefsky JM. Mechanisms of insulin resistance in aging. *J Clin Invest* 1983;71:1523-1535.
14. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. *Circulation* 2003;107:391-7.
15. Chris K, Helen L, John P, Gwyn G, John C and Naveed S. Low grade chronic inflammation in women with polycystic ovarian syndrome. *J Clin Endocrinol Metab*. 2001; 86: 2453-2455.
16. Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. *Diabetes Care*. 2005;28:1757-1762.
17. Emdin M, Pompella A, Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. *Circulation*. 2005;112:2078-2080.

18. Paolicchi A, Franzini M, Emdin M  
The potential roles of gamma-glutamyltransferase activity in the progression of atherosclerosis and cardiovascular diseases. *Vascular Disease Prevention*. 2006;3:205–209.
19. Targher G, Day CP and Bonora E.  
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *New England Journal of Medicine*. 2010; 363: 1341–1350.
20. Elisabeth Lerchbaum, Hans-Jurgen Gruber, Verena Schwetz, et al. Fatty liver index in polycystic ovary syndrome. *European Journal of Endocrinology*. 2011; 165: 935–943.
21. Utzschneider KM and Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. *Journal of Clinical Endocrinology and Metabolism*. 2006; 91: 4753–4761.
22. Forman, H.J., Liu, R.M. and Tian, L. Glutathione cycling in oxidative stress. *Lung Biol Health Dis*. 1997; 105: 99–121.
23. IRIE M, SOHDA T, IWATA K. Levels of the Oxidative Stress Marker  $\gamma$ -Glutamyl transpeptidase at Different Stages of Nonalcoholic Fatty Liver Disease. *The Journal of International Medical Research*. 2012; 40: 924 – 933.
24. Kugelman, A., Choy, H.A., Liu, R, et al. Gamma-glutamyl transpeptidase is increased by oxidative stress in rat alveolar L2 epithelial cells. *Am. J. Respir. Cell Mol. Biol*. 1994; 11: 586–592.
25. Takahashi Y., Oakes S.M, Williams, et al. Nitrogen dioxide exposure activates gamma-glutamyl transferase gene expression in rat lung. *Toxicol Appl Pharmacol*. 1997; 143: 388–396.
26. Kasai H, Crain PF, Kuchino Y, et al: Formation of 8-hydroxyguanine moiety in cellular DNA by agents producing oxygen radicals and evidence for its repair. *Carcinogenesis*. 1986; 7: 1849-1851.
27. Stark A, Russell J, Pagano A, et al. Localization of oxidative damage by a glutathione-gamma-glutamyl transpeptidase system in preneoplastic lesions in sections of livers from carcinogen-treated rats. 1994; *Carcinogenesis*. 15; 343–348.
28. Paolicchi, A, Tongiani R, Tonarelli P, et al. Gamma-glutamyl transpeptidase dependent lipid peroxidation in isolated hepatocytes and HepG2 hepatoma cells. *Free Radic. Biol. Med*. 1997; 22: 853–860.
29. Pieri, L., Dominici, S., Del Bello, B, et al. Redox modulation of protein kinase/phosphatase balance in melanoma cells: the role of endogenous and gamma-glutamyltransferase-dependent H<sub>2</sub>O<sub>2</sub> production. *Biochim. Biophys. Acta*. 2003; 1621(1), 76–83.
30. Lim J.S, Chun B.Y, Kam S, et al. (2004) “Inverse associations of gamma glutamyltransferase with serum antioxidants. *Free Radic. Biol. Med*. 2004; 140, 148–160.
31. Halliwell B and Gutteridge, J.M. Oxygen toxicity, oxygen radicals, transition metals and disease. *Biochem. J*. 1984; 219: 1–14.

32. Meneghini R. Iron homeostasis, oxidative stress, and DNA damage. *Free Radic. Biol. Med.* 1997; 23(5) 783–792.
33. Lee DH, Jacobs DR Jr. Association between serum gamma-glutamyltransferase and C-reactive protein. *Atherosclerosis.* 2005; 178:327–330.

## پوخته

ٺه نزميا كاما كلوتاميل ترانسفيراس و په يوه نديا وي ب كارى هيكلدانى ٺه لجه م نه ساخين كيسبونا هيكلدانى

**پيشه كى و نارمانج:** كيسبونا هيلكه دانى ٺيكه ٺنه خوشيپن به ربه لاق لجه م ٺنا و تا نوكه ٺه گهرين وي دديار نينن، ٺنا نه ساخ بځى نه خوشيپن ده ورا وي يا هه يقانه گرو دبیت و هيك دروست نا چيبيت. نارمانج ٺځى ٺه كولينى دياركرنا رولى ٺه نزميا كاما كلوتاميل ترانسفيراس و په يوه نديا وي ب كارى هيكلدانى ٺه لجه م نه ساخين كيسبونا هيكلدانى.

**ريكنن ٺه كولينى:** ٺه ٺه كولينه هاته ٺه نجامدان ل كولپڙا پزيشكى به شى فسيولوجى و پشكدار هاتنه دابه ش كرن لسره دوو گروپا: گروپى ٺيكي نه ساخ و ٺمارا وان ٤٠ كه س بون و گروپى دووى ٺنين نورمال بون و ٺمارا وان ٢٠ كه س بون. تاقيكرنن لاورى يين پيدځى هاتنه ٺه نجامدان و هرهوسا پيزانينن كلينيكى برىكا فورمه كا تايبه هاتنه وه رگرتن.

**ٺه نجام:** ٺه نجامين ٺه كولينى دياركرن كو خوينه نه ساخين كيسبونا هيلكه دانى ليقه لپن پتر ٺ نورمال يين ٺه نزميا كاما كلوتاميل ترانسفيراس هه يه و بتايبه هاتنه لجه م نه ساخين كيشا وان ٺيده وه رهوسا هه رده كه رسته يين مالون دايئه لدبهايد و سى ريئه كتف پروتين و ٺه ٺه چنده كارى گه ربه كا نه رينى لسره كارى هيكلدانى دكه ت.

**ده رٺه نجام:** ٺيده بونا ليقه لى ٺه نزميا كاما كلوتاميل ترانسفيراس په يوه نديه كا ٺيكره ب ٺوكسيده تځ ستريس ٺه هه يه و يا پيدځيه ٺه ٺه چنده پتر بيته رون و ٺاشكه را كرن د ٺه كولينن بهيت دا.

## الخلاصة

كما كلوتاميل ترانسفيراس لدى المرضى المصابين بمتلازمة تكيس المبايض: علاقتها بالاجهاد التأكسدي

**الخلفية والاهداف:** متلازمة تكيس المبايض هو خلل افرازي أبيض غير معروف السبب يتميز بعدم الاباضة و زيادة في مستوى الاندروجين في الدم وأحيانا خلل في افراز الانسولين. الهدف من هذه الدراسة هو قياس مستويات أنزيم كما كلوتاميل ترانسفيراس لدى المرضى وبيان علاقتها بالاجهاد التأكسدي.

**طرق البحث:** تضمنت هذه الدراسة تسعون مشاركات و قد تم تقسيمهن الى مجموعتين, المجموعة الاولى تألفت من اربعون مريضا مشخصاً كينيكي بمتلازمة تكيس المبايض أما المجموعة الثانية تضمنت عشرون اشخاصا أصحاء كمجموعة ضابطة. تم اجراء جميع التحليلات المختبرية في مختبر الفلسجة بكلية الطب والحصول على المعلومات الاكلينيكية الاضافية حول حالات المرضى من خلال أستبيان. تم تحليل المعلومات و اجراء الاحصاء الطبي باستعمال البرامج المختصة.

**النتائج:** أظهرت نتائج الدراسة وجود ازدياد ملحوظ في مستويات أنزيم كما كلوتاميل ترانسفيراس في دم المرضى مقارنة بالمجموعة الضابطة اضافة الى وجود ازدياد ملحوظ في المادة الموكسدة (مالون دايلديهايد) وسي ريكثف بروتين في دم المرضى المصابين بمتلازمة تكيس المبايض.

**الاستنتاج:** تلخصت الدراسة بأن هناك ازدياد ملحوظ في مستويات أنزيم كما كلوتاميل ترانسفيراس في دم المرضى المصابين بمتلازمة تكيس المبايض و خاصة المرصى اللواتي يعانون من السمنة. اضافة الى أن الانزيم المذكور لها علاقة مباشرة بالاجهاد التأكسدي والتي يجب الانتباه الى النقطة المذكورة وتحديد دورها في الابحاث القادمة.

**A STUDY OF SODIUM CONCENTRATION IN DIFFERENT BREAD CONSUMED  
IN DUHOK CITY –KURDISTAN REGION –IRAQ**

**MASOOD ABDULKAREEM ABDULRAHMAN, MBChB, MSc, KBMS\***

*Submitted 7 April 2016; accepted 20 June 2016*

---

**ABSTRACT**

**Background:** Cardiovascular disease is the main cause of death and disability worldwide. Hypertension is among the highly important major risk factors and up to 62% of cerebrovascular accidents and 49% of coronary heart disease are credited to raised Blood Pressure. There are strong evidences that present human consumption of salt is the major factor increasing Blood Pressure and thereby Cardiovascular diseases. Since bread is the main part in people diet, particularly in our country, the determination of sodium content of bread is of highest priority and needs further researches.

**Methods:** (120) samples of six types of bread were collected from (120) different bakeries in Duhok city and thereafter assessed for sodium content in the laboratories of the Institute of Nutrition Researches in Baghdad

**Results:** This study showed that 35% of bread's samples has sodium concentration overrides the standard level and the residual 65% is within the usual range. Average proportion of bread's sodium concentration was as 248.149 mg / 100g.

**Conclusions:** The sodium contents of one third of studied bread samples are higher than is acceptable limit and may be contributing to adverse health outcomes. Therefore, an urgent public health intervention is highly advisable

**Duhok Med J 2016; 10 (1): 20-30.**

**Keywords:** Sodium, bread, Duhok city.

---

**T**he daily salt consumption of human ancestors was less than 0.25g. But this rate increased when the Chinese discovered that salt could be used to preserve food (about 5000 years ago).<sup>1</sup> After World War II, refrigeration and deep freezing began to displace salt from being the main food preservative. In spite of that, salt consumption has increased in the past decades due to consumption of highly salted processed foods. About 75% of salt intake is estimated to come from processed food.<sup>2</sup>

The sodium content of processed foods is higher if compared with their natural counterparts. For example, chick peas, sweet corn and peas naturally have a very low sodium content, while processing them increases the sodium content by 10–100-fold; and foods such as corned beef, bran flakes or smoked salmon, have sodium intakes of 1–2%, equivalent to, or more than, the sodium concentration of Atlantic seawater.<sup>3</sup>

Sodium content is high in processed foods, such as bread (approximately 250

---

\*Lecturer in Community Medicine, Community Health Department, Shekhan Technical College of Health/ Duhok Polytechnic University. Email: [drmasood89@yahoo.com](mailto:drmasood89@yahoo.com)

mg/100g), processed meats (approximately 1500mg/100g), snack foods such as pretzels, cheese puffs and popcorn (approximately 1500 mg/100g), as well as in condiments such as soy sauce (approximately 7000mg/100g), and bouillon or stock cubes (approximately 20000mg/100g).<sup>4</sup>

Current data on sodium intake reveal that people all over the world are consuming much more sodium than their physiological needs (184-230mg/day).<sup>5</sup> Most individuals consume an excessive amount of salt-on average 9–12 grams per day,<sup>6</sup> or around double the advised upper limit of sodium intake by World Health Organization (WHO) for adults, which is less than two grams' sodium/day (equal to five grams' salt/day).<sup>7</sup>

Cardiovascular diseases (CVD) is the leading cause of mortality and morbidity globally. Elevated blood pressure is among the most significant major risk factors, and up to 62% of strokes and 49% of coronary heart disease are attributed to raised BP. There are strong evidences that existing human intake of salt is the major factor increasing BP and thereby CVD.<sup>1,8,9</sup> Hypertension is responsible for at least 45% of deaths due to heart disease and 51% of deaths due to stroke.<sup>4</sup> According to the Iraqi national survey for non-communicable diseases risk factors in

2006, 40.4% of Iraqi population are hypertensive.<sup>10</sup>

Bread, in its various forms, is the most widely consumed food in the world. It is the staple food and essential diet in many countries including Iraq and, because it is consumed so frequently, it is also the single biggest contributor of salt to our diet.<sup>11</sup> Recent findings from multiple studies conducted in several countries suggest that bread in Ireland provides 25.9% of total salt intake, with corresponding values of 25.5% for Turkey, 24.8% for Belgium, 24.2% for France, 19.1% for Spain, 19% for the UK, 26% for Lebanon, and 28.5% for Kuwait.<sup>12-14</sup>

Over the different eras the salt content of bread has grown gradually. The greatest increase occurred with the industrialization of bread making in the 20<sup>th</sup> century, when quick bulk manufacture techniques required salt to regulate the process and the resulting product, thereby lessening bread's lack of flavor and reaching values as high as 2%.<sup>15</sup>

This study assesses the concentration of sodium in samples of bread produced and consumed in Duhok city, Kurdistan Region, Iraq; the probable contributions of bread in population level exposure to salt; and draws attention to the need to develop effective strategies to ensure that reduction in salt consumption is achieved as the

bread provides up to one quarter of daily sodium intake.

**MATERIALS AND METHODS**

This is a cross sectional study designed to determine the sodium (salt) content of bread samples taken from 120 bakeries in different districts of Duhok city. For administrative purposes, Duhok city was divided into four districts and there are (268) bakeries at time of the study in Duhok city. Thirty samples from each district were collected in one day by 8 trained teams; each team was composed of two staff. The amount of bread that was collected from each bakery was more than 150grams and each sample of bread or Samoon saved in labelled air free plastic bag. Considering the numbers of bakeries in every district, samples were collected from six different types of bread. These are called flat bread (Naan) (Figure. 1a), Saj bread (Figure. 1b), Turkish flat bread (Figure. 1c), Samoon (Figure. 1d), Samoon hajari (Iraqi bread made on stone) (Figure. 1e) and Turkish pita samoon (Figure. 1f). Samples were sent to the Nutrition Research Institute laboratories in Baghdad for assessment of their sodium content. The technique utilized for measuring breads' sodium is Dry Ashing. The main objective of Dry Ashing procedure is to combust all of the organic material and to prepare the sample for subsequent treatment using fusion techniques.<sup>16</sup>

As to the a lot of pastry shops, gathered examples of every sort of bread was different. By using proportionate stratified sampling procedure, the largest samples were flat bread (Naan) and Samoon, while the smallest were Turkish pita Samoon (Table 1).

Due to the lack of any limitation of the highest permissible level of sodium in bread within the Iraqi standard specifications of the Bread No. (677), So Nutrition Researches Institution are relying on the Kuwaiti standard specifications of the Bread, which defines the 262.640mg/100g as a maximum permitted level of sodium in the bread.





c



d



e



f

**Figure 1. Different kinds of bread. flat bread (Naan) (Fig. 1a), Saj bread (Fig. 1b), Turkish flat bread (Fig. 1c), Samoon (Fig. 1d), Samoon hajari (Iraqi bread made on stone) (Fig.1e) and Turkish pita samoon (Fig. 1f).**

**Table 1: Bread Samples by Type**

Type of bread	No. of available bakeries	No. of selected samples	%
Flat bread (Naan)	120	54	45.0
Saj bread	9	4	3.3
Turkish flat bread	9	4	3.3
Samoon	109	49	40.8
Samoon Hajari	16	7	5.8
Turkish pita samoon	5	2	1.7
<b>Total</b>	<b>268</b>	<b>120</b>	<b>100.0</b>

#### Statistical analysis

Chi square test was done for statistical analysis of the data by practicing SPSS software version 23. P value  $\leq 0.05$  was considered significant.

#### RESULTS

This study showed that 35% (42) of the samples has sodium content higher than 262.640 mg /100g and the rest 65% (78) of the samples has sodium content less than 262.640 mg /100 g.

Up to 50% (28) of samples of flat bread (Naan) type and Turkish pita samoon showed higher sodium contents than standard level, in reducing order was found in Sammon, Saj bread, Turkish flat bread, Samoon and Samoon hajari Table 2. ( $p < 0.05$ )

## A STUDY OF SODIUM CONCENTRATION IN DIFFERENT BREAD CONSUMED IN DUHOK

**Table 2: Bread Samples by Type and Sodium contents**

Type of Bread	Sodium Content No. (%)		Total
	>262.64 mg / 100 g.	< 262.64 mg / 100 g.	
Flat bread (Naan)	28 (51.9)	26 (48.1)	54 (100)
Saj bread	1 (25)	3 (75)	4 (100)
Turkish flat bread	1 (25)	3 (75)	4 (100)
Samoon	10 (20.4)	39 (79.6)	49 (100)
Samoon hajari	1 (14.2)	6 (85.8)	7 (100)
Turkish pita samoon	1 (50)	1 (50)	2 (100)
<b>Total</b>	<b>42 (35)</b>	<b>78 (65)</b>	<b>120 (100)</b>

The mean sodium content of whole samples was 248.149g. The average mean sodium content in the samples of district IV was the highest (282.7mg/100g) while in the district I, samples were the lowest in sodium (216.5mg/ 100g). Table 3

**Table 3: Sodium Contents of Bread by Districts and Number of Bakeries**

Districts	Mean	No. of bakeries with	No. of bakeries with	Total
		Sodium content > 262.64 mg / 100 g.	Sodium content < 262.64 mg / 100 g.	
District I	216.5	6 (20)	24 (80)	30 (100)
District II	248.5	12 (40)	18 (60)	30 (100)
District III	241.9	12 (40)	18 (60)	30 (100)
District IV	282.7	12 (40)	18 (60)	30 (100)
	248.14	42 (35)	78 (65)	120 (100)

### DISCUSSION

Non -communicable diseases (NCDs) are the main contributor to mortality and morbidity globally<sup>17,18</sup> and interventions to reduce the burden of NCDs are highly cost-effective.<sup>19</sup> Elevated sodium intake has been associated with a number of NCDs (including hypertension,

cardiovascular diseases and stroke), Hence lowering sodium intake may reduce blood pressure and the risk of developing related NCDs.<sup>20</sup> Recent data on sodium intake show that populations around the world are consuming much more sodium than the physiological requirement. The estimated sodium intake in Jordan is up to 7623

mg/day,<sup>21</sup> while the estimated sodium intake in Turkey is 5905mg/ day<sup>22</sup>, On other hand, there is no available data on estimation of sodium intake in Iraq.

Bread is the unique processed food that is available, and consumed daily by, both low and high income people. Moreover, it is the largest sodium contributor to the Iraqi diet. Due to the fact that excess sodium consumption contributes to premature death and disability, therefore any reduction in the level of salt in bread would have a major impact on public health but unfortunately, there are no regulations or public laws in Iraq that regulate the salt or sodium contents in processed foods specially bread. This study which assumed to be the first of its kind in Kurdistan Region was conducted to determine sodium (salt) content in the bread.

The mean sodium content of whole samples was 248.149mg/100g which is lower than that obtained in a similar study conducted in Bagdad city in 2014 (293.812mg/100g).<sup>16</sup> The present study showed that (35%) or 42 samples out of 120 have sodium contents above permissible level. Meanwhile in Baghad study, the sodium content exceeded the permissible level in (61%) or 92 out of 150 of bread samples.<sup>22</sup> A similar study done in Nigeria showed that the mean sodium content of two brands of bread was

very high (660-716.7mg/100g) and 70% of the studied samples had considerably more sodium than the recommended limit in Nigeria which is 440mg/100g.<sup>23</sup> Silva and her colleagues did a study in Maputo, Mozambique, and they found that the mean sodium content of bread was 450.3mg/100g, with no significant differences between bakeries and traditional markets.<sup>24</sup> In Montero-Campos Mde study in Costa Rica, 99 samples of bread showed that sodium concentration was between 496 and 744mg/100g ,and 80% reported greater amount than found by direct analysis.<sup>25</sup>

The results of similar studies on salt levels of bread in Iran carried out from 1994 to 2009 indicated that the amount of salt in bread was higher than the standard level in Shiraz, Mashhad, Sanandaj and Isfahan<sup>26-28</sup> The current study showed that there is a wide variation in bread sodium content among bakeries from 31,725mg/100g to 948mg/100g. This may be due to the absence of unified standards, and in turn it will lead to disparity in the amount of daily- consumed salt in bread and other foods, As if a person eating four average slices of bread twice daily from two different bakers. First consumer may take 60mg sodium if they bought their bread from the craft baker with the lowest sodium levels compared with other one take 1820mg sodium from the craft baker

with the highest sodium level. There are also differences in bread sodium content among districts inside the same city

The sodium content of bread could be gradually decreased over 4-6 weeks without affecting consumer's palatability or acceptability of sensory characteristics, including overall liking, appearance, aroma, flavor, sweetness, salt level and texture, or purchase intent.<sup>29</sup> Bolhuis et al, found that salt reduction of up to 50% in bread does not decrease bread consumption.<sup>30</sup>

It seems that most bakers either do not have enough knowledge about the standard level of salt used for the production of bread, or they have some other reasons for using salt below or above the standard (e.g. type of flour) or some other factors which are needed to be investigated in further studies.

Finally, there should be a strict supervision and effective measures by relevant local authorities for bakeries to control the amount of salt in bread.

#### **ACKNOWLEDGEMENT**

The researcher highly appreciates in the assistance offered by Nutrition Researches Institute in Baghdad, Health Inspection and Nutrition departments in Directorate of Preventive Health Affairs in Duhok. Their help was necessary for completing the research.

#### **REFERENCES**

1. He FJ, MacGregor GA. A comprehensive review on salt and health and current experience of worldwide salt reduction programs. *J Hum Hypertens.* 2009; 23(6): 363-84.
2. Mattes RD, Donnelly D. Relative contributions of dietary sodium sources. *J Am Coll Nutr.* 1991; 10(4): 383-93.
3. MacGregor GA, de Wardener HE. *Salt, Diet and Health.* Cambridge, Cambridge University Press, 1998.
4. World Health Organization. A global brief on hypertension. WHO/DCO/WHD/2013.([http://apps.who.int/iris/bitstream/10665/79059/1/WHO\\_DCO\\_WHD\\_2013.2\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf)). Accessed March, 15 2016.
5. Brown IJ, Tzoulaki I, Candeias V, Elliott P. Salt intakes around the world: implications for public health. *Int J Epidemiol.*2009; 38(3): 791-813.
6. World Health Organization: Salt reduction. .Fact sheet; number 393, 2014 .
7. WHO. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. Geneva, World Health Organization (WHO), 2007 ([http://whqlibdoc.who.int/publications/2007/9789241547178\\_eng.pdf](http://whqlibdoc.who.int/publications/2007/9789241547178_eng.pdf))
8. Nagata C, Takatsuka N, Shimizu N, Shimizu H . Sodium intake and risk of death from stroke in Japanese men and women. *Stroke.*2004;35(7): 1543 -47.
9. He FJ, MacGregor GA. Reducing population salt intake world wide: from evidence

- to implementation. *Prog Cardiovasc Dis.* 2010; 52(5): 363-82.
10. MOH/ Iraq. Hypertention, prevention , diagnosis and treatment: National guidelines for Primary Health Care Physicians. Directorate of Public Health/ Non-Communicable Diseases Section/ Ministry of Health, Baghdad, Iraq, 2008. p.4.
  11. Belz MC, Ryan LA, Arendt EK .The impact of salt reduction in bread: a review. *Crit Rev Food Sci Nutr.* 2012; 52(6): 514-24.
  12. Quilez J, Salas-Salvado J. Salt in bread in Europe: potential benefits of reduction. *Nutr Rev.* 2012; 70(11): 666–78.
  13. Almedawar MM, Nasreddine L, Olabi A, Hamade H, Awad E, Toufeili I, et al. Sodium intake reduction efforts in Lebanon. *Cardiovasc Diagn Ther.* 2015; 5(3): 178-85.
  14. Alhamad N, Almalt E, Alamir N, Subhakaran M. An overview of salt intake reduction efforts in the Gulf cooperation Council countries. *Cardiovasc Diagn Ther.* 2015; 5(3): 172-7.
  15. <http://www.wildyeastblog.com/worth-its-salt/> accessed March 15, 2016.
  16. Nutrition Research Institution A Report on Sodium content in random samples from bakeries in Baghdad by using Dry Ashing method .Unpublished article. NRI, Baghdad, Iraq, 2014.
  17. Karppanen H, Mervaala E. Sodium intake and hypertension. *Prog Cardiovasc Dis.* 2006; 49(2): 59-75.
  18. Webster J, Trieu K, Dunford E, Hawkes C. Target salt 2025: a global overview of national programs to encourage the food industry to reduce salt in foods. *Nutrients.* 2014; 6(8): 3274-87.
  19. Girgis S, Neal B, Prescott J, Prendergast J, Dumbrell S, Turner C, et al. A one-quarter reduction in the salt content of bread can be made without detection. *Eur J Clin Nutr.* 2003; 57(4): 616-20.
  20. Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM. Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-Effectiveness analysis. *Ann Intern Med.* 2010; 152(8): 481-7.
  21. Alkurd RA. Estimated Intakes of Fats, Cholesterol, Fiber, Sodium, Calcium, Potassium, and Magnesium in Jordan . *Australian Journal of Basic and Applied Sciences.* 2011; 5(12): 3171-8.
  22. <http://www.euro.who.int/en/health-topics/disease-prevention /nutrition /news /news /2013/04/ progress-in-reducing-salt-consumption-in-turkey>.accessed March 16, 2016.
  23. Ejike CE, Amadi AJ, Nnabuko NR, Kalu OO, Egbom NS. Concentrations of sodium in, and moisture content of retail bread samples sold in Umuahia metropolis, Nigeria. *International Journal of Current Biochemistry Research.* 2013; 1(1): 1-8.
  24. GSilva V, Padrão P, Novela C, Damasceno A, Pinho O, Moreira P, et al.Sodium content of bread from

- bakeries and traditional markets in Maputo, Mozambique Public Health. Nutr. 2015; 18(4): 610-4.
25. RdMontero-Campos Mde L, Blanco-Metzler A, Chan VC. Sodium in breads and snacks of high consumption in Costa Rica. Basal content and verification of nutrition labeling. Arch Latinoam Nutr. 2015; 65(1): 36-43.
26. Zibaenezhad MJ, Hooshangi M, Abtahi F, Heydari ST .A Study of Salt (Sodium Chloride) Content in Different Bread Consumed in Shiraz City in Spring/ Summer 2009.ICRJ. 2010;4 (1): 17-21.
27. Rezaeimofrad M, Rangraz Jeddi F, Azarbad Z. Baking soda and salt in bakeries of Mehrdasht (Najafabad), Isfahan, Iran:a survey on a typical rural population in a developing country. J Prev Med Hyg. 2013; 54(1): 53-6
28. Habibi N and Fatemi A. Survey Amount of Salt in Consumptional Bread of Sanandaj. Aust J Basic Appl Sci.2012; 6(6): 90-3.
29. La Croix KW, Fiala SC, Colonna AE, Durham CA, Morrissey MT, Drum DK, et al. Consumer detection and acceptability of reduced-sodium bread. Public Health Nutr. 2015; 18(8): 1412-8.
30. Bolhuis DP, Temme EH, Koeman FT, Noort MW, Kremer S, Janssen AM. A salt reduction of 50% in bread does not decrease bread consumption or increase sodium intake by the choice of sandwich fillings. J Nutr. 2011; 141(12): 2249-55.

## پوخته

## فهكولینا ئاستی صودیومی لناف جورین نانی ئه وین دهینه بكارئینان ل باژیری دهوكی

**پیشهکی وئارمانج:** ئیشین دلی ولولین خوینی ئه گهرین سهره کینه بو مرنی وپه کفتنی ل جهانی. نیزیکه ۶۲٪ ل جهلتین میشیکی و ۴۹٪ ل ئیشین دهمارین خوینی یا دلی دهینه رویدان ژئه گهری زیده بونا فیشارا خوینی. وپه لگین به هیز هه نه دیار دکهن کو بكارئینانا مروقی بو خوبی خارنی ب ریژا نوکه، ئه گهرکی سهره کیه بو زیده بونا فیشارا خوینی ول ئه نجامدا زیده بونا ئیشین دلی ولولین خوینی. ژبه ر کو نان به شهکی سهره کی یه ل خارنی گه لئ مه یا روژانه ، دیار کرنا ئاستی صودیومی (خویی) گه له ک گرنگه و پیدقی هه یه بو فه کولینین زیده تر.

**ریکن فه کولینی:** (۱۲۰) نمونین ل شه ش جورین نانی ل (۱۲۰) نانپیزا وسه مونخا ل باژیری دهوكی هاتنه وه رگرتن وئاستی صودیومی هاتنه پشکین ل تاکیگه هین په یمانگه ها خوراکئ ل به غدا.

**ئه نجام:** ئه فه کولینا دیارکر کو ئاستی صودیومی ل ۳۵٪ ل نمونین نانی زیده تره ل ئاستی ستانده رد و ۶۵٪ نورمال بوون، و ریژا خویی ل هه می نمونا ۲۴۸.۱۴۹ ملیگرام / ۱۰۰ گرام.

**دهرئه نجام:** وه ک دهرئه نجام ریژا صودیومی ل سی یه کا نمونا نانی بلندتره ل ئاستی ستانده رد و دی ئه نجامین نه رینی هه بیت ل سه ر ساخله میا گشتی ژبه ر فی ئه گهری، پیدقیه پینگافین بله ز بهینه هافیتن ژلایی ده رگه هین پیوه ندیدار.

## الخلاصة

دراسة تركيز الصوديوم في عينات من مختلف انواع الخبز المستهلك في مدينة دهوك -أقليم كوردستان العراق

**الخلفية والاهداف:** أمراض القلب والأوعية الدموية هي السبب الرئيسي للوفاة والعجز في جميع أنحاء العالم. ارتفاع ضغط الدم هو من بين أهم عوامل الخطورة الرئيسية والهامة جداً، إن حوالي ٦٢٪ من الجلطات الوعائية الدماغية و ٤٩٪ من أمراض القلب التاجية تعزى إلى ارتفاع ضغط الدم. وهناك أدلة قوية على أن الاستهلاك الحالي للإنسان من الملح هو العامل الرئيسي لزيادة ارتفاع ضغط الدم وبالتالي زيادة الإصابة بأمراض القلب والأوعية الدموية. وحيث أن استهلاك الخبز هو جزء رئيسي في الوجبات الغذائية اليومية للناس ولاسيما في بلادنا، لذا فإن تحديد محتوى الصوديوم وبالتالي (الملح) في الخبز يعتبر من الأولويات القصوى ويحتاج إلى مزيد من الأبحاث.

**طرق البحث:** تم جمع (١٢٠) عينة من ستة أنواع مختلفة من الخبز من (١٢٠) مخبزاً مختلفاً في مدينة دهوك وتم بعد ذلك دراسة تركيز (محتوى) الصوديوم في مختبرات معهد بحوث التغذية في بغداد.

**النتائج:** أظهرت الدراسة أن ٣٥٪ من عينات الخبز تحتوي على تركيز الصوديوم تتجاوز المستوى القياسي المسموح بها في العراق وبينما كانت النسبة المتبقية ٦٥٪ ضمن النسب المسموحة. وكان متوسط نسبة تركيز الصوديوم في جميع عينات الخبز ١٤٩،٢٤٨ ملغ/ ١٠٠ غرام.

**الاستنتاجات:** تركيز الصوديوم في ثلث عينات الخبز المفحوصة كانت أعلى من الحد المقبول ويمكن أن تؤدي إلى نتائج صحية سلبية. ولذا فإن تدخل الجهات المسؤولة عن الصحة العامة يعتبر في غاية الأهمية.

## VITAMIN D STATUS AMONG APPARENTLY HEALTHY POPULATION IN DUHOK, KURDISTAN REGION, IRAQ

DHIA J. AL-TIMIMI, (MPhil, PhD)\*  
SHERWAN F. SALIH, (M.B.Ch.B., FIBMS)\*\*

*Submitted 24 April 2016; accepted 30 June 2016*

### ABSTRACT

**Background:** Vitamin D deficiency and insufficiency are a commonly reported health problem throughout the world. This cross sectional survey was conducted in Duhok governorate with an aim to assess vitamin D status in a sample of apparently healthy population.

**Methods:** Serum 25-hydroxyvitamin D was determined for all enrolled subjects (n=1270), including newborn babies and infants (n=24), primary school children (n=53), adolescents (n=85), adults (n=1086) and elderly (n=22).

**Results:** There was a statistically significant difference in mean 25-hydroxyvitamin D levels between different age groups (p= 0.02) and different gender (P= 0.001). Overall 731(57.6%) subjects were with low 25-hydroxyvitamin D < 30ng/ml, of these, 651(51.3%) subjects were vitamin D insufficient (10-29.9 ng/ml), while 80(6.3%) subjects had severe vitamin D deficiency (< 10 ng/ml), with a significant difference among age groups (p= 0.003).

**Conclusion:** A low vitamin D status is present in 57.6% of the study population in Duhok. This finding may have clinical implications due to the increased risk of future metabolic diseases.

**Duhok Med J 2016; 10 (1): 31-39.**

**Keywords:** Vitamin D, Apparently healthy population, Duhok governorate

Much interest has recently arisen in the function and metabolism of vitamin D. This is because it has been reported to be essential nutrient for maintaining good health and play an important role in the pathogenesis of various diseases<sup>1,2,3</sup>. Worldwide, the prevalence of vitamin D insufficiency is high and rising<sup>4,5</sup>. The third National Health and Nutrition Examination Survey (NHANES III) reported the prevalence of vitamin D deficiency in the USA to be

between 25% and 57% of adults<sup>6</sup>. In developing countries, the deficiencies of important nutrients such as vitamin D, iron and zinc are major public health problems and have significant adverse health impacts. For example the prevalence of vitamin D deficiency in patients with type 1 diabetes mellitus was 15% to 90.6%<sup>7,8</sup>. The main marker of vitamin D status is the metabolite 25(OH) D, which is synthesized in the liver<sup>9,10</sup>. Serum 25(OH) D concentrations are largely determined by

\* Professor of clinical Biochemistry; Department of Clinical Biochemistry, College of Medicine, University of Duhok, Duhok, Iraq.

\*\* Lecturer, Dept. of Clinical Biochemistry, College of Medicine, University of Duhok, Duhok, Iraq  
Correspondent author: Prof. Dhia J. Al-Timimi. EMail: altimimidj@yahoo.com

environmental factors, mainly through vitamin D intake and ultraviolet exposure. Measurement of serum 25(OH) D levels may be considered medically necessary in general population and might be used as a marker of metabolic bone disease with other bone disease detection markers. Little is known, however, about the level and the prevalence of vitamin D deficiency among the population of Duhok governorate. The present study was designed to determine vitamin D status among different age and sex groups.

## **METHODS**

### **Subjects and Study design**

This cross-sectional study was conducted at the Department of Chemistry and Clinical Biochemistry, College of Medicine, University of Duhok, Kurdistan Region, Iraq from May 2015 to January 2016. One thousand and two hundred seventy apparently healthy subjects were included in this study. Among these 24 were newborns babies and infants who were brought for vaccination at the vaccination unit of primary care centers in Duhok city. Fifty three samples from primary school children were obtained from previously collected samples<sup>11</sup>, while 85 samples were drawn from adolescents attending intermediate and secondary schools in different areas of Duhok governorate. Adults (n=1086) were recruited by personal request from the staff

and blood bank donors of Azadi Teaching Hospital and Duhok Blood Bank. The rest of the sample comprised 22 elderly people chosen from the relatives of patients attending Duhok Emergency Teaching Hospital.

The inclusion criteria were the absence of recent infections, chronic and endocrine diseases. Subjects on drug therapy including steroids, calcium or vitamin D supplementation were excluded from the study. Subjects with sunlight exposure less than 15 minutes in summer and 30 minutes in winter were also excluded from the study. Formal consent was obtained from the parents of children and adults after the nature of the study had been explained to them. The board of postgraduate committee of the Duhok University, medical branch approved the study protocol.

### **Data collection**

An especially-designed questionnaire was used to obtain information from the participants about age, sex, past medical history including (hypertension, diabetes mellitus, thyroid and parathyroid disease, liver and renal disease). Blood samples were collected for serum 25(OH) D and blood glucose measurement. The serum levels of 25(OH) D and glucose were measured by cobas 6000 using electrochemiluminescence immunoassay principle and glucose oxidase principle,

respectively. Serum 25(OH) D levels were defined as: Severe deficiency (<10 ng/ml), insufficiency (10-29.9 ng/ml), and sufficiency (30-150 ng/ml)<sup>12</sup>. Diagnosis of asymptomatic hyperglycemia based on World Health Organization criteria 2006<sup>13</sup>.

## RESULTS

The main characteristics of the study sample are presented in (Table 1). There was a significant difference in mean 25(OH) D levels between the age groups (Table 2) that showed 25(OH) D levels of 21.98, 25.20, 28.19, 31.32 and 38.31 ng/ml ( $p= 0.02$ ). There was a significant difference in mean 25(OH) D levels among adult males and females ( $p=$

0.001). There was also a significant difference in mean 25(OH) D levels among adolescent males and females ( $p= 0.01$ ). Overall, mean 25(OH) D levels were significantly lower in females ( $p= 0.001$ ) as compared to males (Table 3). Overall 731(57.6%) subjects were with low 25(OH) D (< 30 ng/ml), of these, 651(51.3%) subjects were vitamin D insufficient (10-29.9 ng/ml), while 80(6.3%) subjects had severe vitamin D deficiency (< 10 ng/ml), with a significant difference ( $p= 0.003$ ) among age groups (Table 4). Comparison of the present study results with that reported elsewhere is demonstrated in Table<sup>5</sup>.

**Table 1 Characteristics of the different Study Groups**

Characteristics	Infants	Children	Adolescents	Adults	Elderly
Study group n (%)	24(1.9)	53(4.2)	85(6.7)	1086(85.5)	22(1.7)
Age (years)	<1.0	2-12	13-19	20-60	>60
Male sex n (%)	13(54.2)	28(52.8)	28(32.9)	344(31.7)	9(40.9)
FSG>100 mg/dl n (%)	0.0	2(3.8)	2(2.4)	137(12.6)	5(22.7)
Pregnant women n (%)	0.0	0.0	0.0	101(13.6)	0.0

**Table 2 Mean Serum 25(OH) D (ng/ml) by Age Group**

Population	Number	Mean $\pm$ SD	Range
Infants	24	38.31 $\pm$ 15.28	16.0 - 70.0
Children	53	31.32 $\pm$ 12.44	9.8 - 63.0
Adolescents	85	21.98 $\pm$ 10.42	7.9 - 58.3
Adults	1087	28.19 $\pm$ 13.70	5.1 - 71.0
Elderly	22	25.20 $\pm$ 16.30	9.44 - 68.45
Total	1270	28.04 $\pm$ 13.26	5.1 - 71.0

## VITAMIN D STATUS AMONG APPARENTLY HEALTHY POPULATION

**Table 3 Mean Serum 25(OH) D (ng/ml) by Age Group and Gender**

	Males Number	Mean ± SD	Females Number	Mean ± SD	P value*
Infants	13	38.73±18.07	11	37.81±12.03	0.88
Children	28	32.68±11.31	25	29.86±13.85	0.42
Adolescents	28	26.39±13.67	57	20.17±8.27	0.01
Adults	344	33.10±19.8	742	19.63±7.70	0.001
Elderly	9	26.02±13.23	13	24.73±15.33	0.839
Total	422	32.64±18.63	848	20.28±8.09	0.001

**Table 4 Vitamin D Status by Age Groups**

Age Group	Number	Vitamin D status 25(OH) D (ng/ml)		
		<10 n (%)	≥10-29.9 n (%)	≥30-150 n (%)
Infants	24	0(0.0)	6(25.0)	18(75.0)
Children	53	1(1.8)	18(34.0)	34(64.2)
Adolescents	85	6(7.1)	55(64.7)	24(28.2)
Adults	1086	72(6.6)	560(51.6)	454(41.8)
Elderly	22	1 (4.6)	12(54.5)	9(40.9)
Total	1270	80(6.3)	651(51.3)	539 (42.4)
Chi squared test	P value	0.0003		

**Table 5 Vitamin D Status in Duhok Compared to Other Countries**

Country	Mean±SD	Vitamin D (ng/ml)	
		Deficient (%)	Insufficiency (%)
Duhok	28.04±13.26	6.3	51.3
Israel <sup>14</sup>	22.9±10.1	27	51
Turkey <sup>15</sup>	16.9±13.09	74.9	13.8
Saudi Arabia <sup>16</sup>	26.6±9.8	28.3	39.4
Kuwait <sup>17</sup>	13.3±6.5	58.8	24.5
Egypt <sup>18</sup>	32.2±7.6	23.7	13.6
Germany <sup>19</sup>	18±4.2	30.2	61.6

## DISCUSSION

There are no enough data about vitamin D status of age and sex groups in Duhok province, Kurdistan region, Iraq. Thus, vitamin D status was assessed in this cross-sectional study by measurement of serum 25 (OH) D levels. This study

revealed that 57.6% of the apparently healthy subjects living in Duhok have suboptimal serum vitamin D levels, and 6.3% are vitamin D deficient. The mean 25(OH) D level for the entire study population (28.04+13.26 ng/ml) was found to be in the range considered to be

insufficient (<30ng/ml). The insufficiency status in the present study was somewhat milder among infants and children when compared with that of older individuals. In our study population, mean 25(OH) D levels in females were significantly lower than in males. The results of this study are consistent with the findings reported by others, but, in contrast with other reported values<sup>14,15,16,17,18,19</sup>. This discrepancy of our results from other studies may be related to the cutoff point for identifying vitamin D status. Most of the studies selected serum 25 (OH) D levels less than 20 ng/ml, cutoff point for identifying vitamin D deficiency<sup>20,21</sup>, whereas in our study a cutoff point of < 10 ng/ml was used for identifying severe vitamin D deficiency. However, such a high prevalence of suboptimal vitamin D status in our population is especially noteworthy, because several factors are known to impact negatively on vitamin D status. Of these, nutrient status, malabsorption, drug therapy, dressing style and exposure to sunlight are the most marked negative effect on vitamin D level. In addition, low vitamin D status has been reported in patients with diabetes and during the course of pregnancy<sup>23,24</sup>. The present study showed a high number of subjects with asymptomatic hyperglycemia as well as pregnancy. However, the dietary intake of vitamin D was not determined, which is a

limitation of this study. A second limitation was the variation in sample size among the different age groups, i.e. the majority of the subjects were adults in comparison to infants, children, adolescents and elderly. Although low vitamin D status may be caused by a number of factors, including insufficient synthesis in the skin, due to limited sunlight exposure and inadequate intake or absorption of vitamin D, further studies are needed to determine if improving 25(OH) D levels from deficiency to sufficiency improves vitamin D status in general population and reduce the risk of metabolic diseases..

## REFERENCES

1. Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW, and Giovannucci EL: Plasma vitamin D metabolites and risk of colorectal cancer in women. *Cancer Epidemiol Biomarkers Prev* 2004; 13:1501–1508.
2. Ahonen MH, Tenkanen L, Teppo L, Hakama M, and Tuohimaa P: Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). *Cancer Causes Control* 2000; 11:847–852.
3. Cantorna MT, and Mahon BD: Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. *Exp Biol Med* 2004; 229:1136–1142,
4. Rucker D, Allan JA, Fick GH, and Hanley DA. Vitamin D insufficiency

- in a population of healthy western Canadians. *CMAJ* 2002; JUNE 11: 166 (12)
5. Abdelelah S, Jazar, Hamed R, Takruri, and Najwa A. Khuri-Bulos. Vitamin D Status in a Sample of Preschool Children Aged From 1 to 6 Years Visiting the Pediatrics Clinic at Jordan University Hospital. *J Med J* 2011; 45 (4):308- 316.
  6. Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, and Sahyoun NR: Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. *Bone* 2002, 30:771-777.
  7. Svoren BM, Volkening LK, Wood JR, and Laffel LM. Significant vitamin D deficiency in youth with type 1 diabetes mellitus. *J Pediatr.* 2009; 154(1): 132-4.
  8. Al-Agha AE and Ahmad IA. Association among Vitamin D Deficiency, Type 1 Diabetes Mellitus and Glycemic Control. *JDM* 2015; 6 (9): 1000594.
  9. Fraser WD, Milan AM. Vitamin D assays: past and present debates, difficulties, and developments. *Calcif Tissue Int.* 2013; 92:118-27.
  10. Institute of Medicine. 2011 Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Pr; 2011.
  11. Al-Timimi D j, and Salih S F. A study of blood cholesterol and related risk factors in primary school children of Duhok Governorate, Kurdistan Region, Iraq. *Duhok Med J* 2014; 8(2): 20-29.
  12. Ziaee A, Javadi A, Javadi M, Zohal M, and Aaghi A. Nutritional status assessment of minodar residence in Qazvin city, Iran: vitamin D deficiency in sunshine country a public health issue. *Glob J Health Sci* 2013; 5(1): 174-9.
  13. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of WHO/IDF consultation. Geneva, Switzerland: World Health Organization, 2006.
  14. Oren Y, Shapira Y, Agmon-Levin N, Kivity S, Zafrir Y, Altman A, Lerner A and Shoenfeld Y. Vitamin D Insufficiency in a Sunny Environment: A Demographic and Seasonal Analysis. *IMAJ* 2010; 12(12): 751-6.
  15. Hekimsoy Z, Dinç G, Kafesçiler IS, Onur E, Güvenç Y, Pala T, and Özmen BF. Vitamin D status among adults in the Aegean region of Turkey. *BMC Public Health* 2010; 10:782
  16. Naeem Z, AlMohaimed A, Sharaf FK, Ismail H, Shaukat F, and Inam B. Vitamin D status among population of Qassim Region, Saudi Arabia. *International Journal of Health Sciences, Qassim University,* 2011; 5(2): 116-24.
  17. Molla AM, Al Badawi M, Hammoud MS, Molla AM, Shukkur M, Thalib L and Eliwa M. Vitamin D status of mothers and their neonates in Kuwait. *Pediatrics International* 2005; 47: 649–652
  18. Tayeb IM, EL-Saghier EOA, Cheta S, Sabbah NA and Raafat N. Assessment of Vitamin D status among senior

- executive managers in large scale industries in the 10th of Ramadan city, Egypt. *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)* 2013; 12(6): 77-83
19. Rabenberg M, Nave CS, Busch MA, Rieckmann N, Hintzpeter B and Mensink GBM. Vitamin D status among adults in Germany, results from the German Health Interview and Examination Survey for Adults (DEGS1). *BMC Public Health* 2015; 15:641.
  20. Catherine M. Gordon, Kerrin C. DePeter, Henry A. Feldman, Estherann Grace, and Jean Emans. Prevalence of Vitamin D Deficiency among Healthy Adolescents. *Arch Pediatr Adolesc Med.* 2004; 158:531-537
  21. Tangpricha V, Pearce EN, Chen TC, and Holick MF. Vitamin D insufficiency among free-living healthy young adults. *Am J Med.* 2002; 112: 659-662.
  22. Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, and Sahyoun NR. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. *Bone.* 2002; 30:771-777.
  23. Al-Timimi DJ, and Ali AF. Serum vitamin D in diabetes mellitus type 2: relation to glycemic control. *J clin diagno res* 2013; 7:2686.
  24. Al-Timim DJ, Ferwerdin SH, and Narin A Mossa NA. Vitamin D status in pregnant and non-pregnant women in a Kurdistan Region, north Iraq 2013 *Duhok Med J;* 7(1):49-56.

## پوخته

ئاستی فیتامین د ل دەف تاکئن کومه لگه هی یین ساخله م ل پارێزگه ها دهوکی، هه ریمما کوردستانا عیراقی

**پێشهکی و ئارمانج:** کیمبون و نه به سییا فیتامین د دهیته هه ژمارتن ژ ئارێشین ساخله میی یین به رچاڤ سه رانسهری جیهانی. ئه ڤ ڤه کولینه هاته ئه نجامدان ژبو هه لسه نگاندا ئاستی فیتامین د دنموه کا تاکین کومه لگه هییدا یین ساخله م.

**رێکنین ڤه کولینی:** ئاستی فیتامین د هاته سنورکرن دخوینا ۱۲۷۰ که سین به سه رڤه ساخله م، دگه ل ژیین دناڤه را (کیمتر ژ ۱ سال تا پتر ژ ۶۰ سال). ژوانا یین نبوی و ڤرنیک (۲۴ که س)، زاروکین قوناغا سه ره تایی (۵۳ که س)، سنیل (۸۵ که س)، مه زن (۱۰۸۶ که س) ئو یین پیر (۲۲ که س). ریزا به ره لاقبونا کیمبون و نه به سییا فیتامین د هاته سنورکرن.

**ئه نجام:** ب شیوه کی به رچاڤ نه وه که ڤی هاته دیتن د ئاستی فیتامین د دا دناڤه به را ژیین جیاواز ( $P=0.02$ ), هه ره سا نه وه که ڤی ب شیوه کی به رچاڤ هاته دیتن د ئاستی فیتامین د دا دناڤه به را هه ردوو ره گه زاندا. ب گشتی ل دهف ۷۲۱ که سان (۰.۵۷.۶٪) ئاستی فیتامین د دناڤ خوینیدا یی کیمبو (کیمتر ژ 30 ng/ml) ژوانا ۶۵۱ که سان (۰.۵۱.۳٪) ئاستی فیتامین د پیجه ک یی کیمبو (10-29.9 ng/ml), به یی ل دهف ۸۰ که سان (۰.۶.۳٪) ئاستی فیتامین د گه له ک یی کیمبو (کیمتر ژ 10 ng/ml) دگه ل نه وه که ڤیه کا ب شیوه کی به رچاڤ دناڤه به را ژیین جیاوازدا ( $p=0.003$ ).

**دهرئه نجام:** کیمبونا ئاستی فیتامین د هاته دیتن ب ریزه یا (۰.۵۷.۶٪) ل دهف که سین ب خوه گرتی دڤی ڤه کولینیدا ل دهوکی. دبیت ئه ڤی دیتنی کارتیکنین کلینیکی هه بن ژ ئه گه ری به رزیونا مه ترسیین ئیشین میتابولزمی دپاشه روژی دا.

## الخلاصة

### حالة الفيتامين د لدى افراد المجتمع الاصحاء ظاهريا في محافظة دهوك اقليم كردستان العراق

**الخلفية والاهداف:** إن نقص وعدم كفاية فيتامين د من المشاكل الصحية الشائعة حول العالم. تم اجراء هذه الدراسة المقطعية في محافظة دهوك لغرض تقييم حالة الفيتامين د لدى عينة من افراد المجتمع الاصحاء ظاهريا.

**طرق البحث:** تم قياس مستوى فيتامين د  $25(OH) D$  في مصل الدم لـ ١٢٧٠ شخص من الاصحاء ظاهرياً، شملت العينة مختلف الاعمار وضمت حديثي الولادة والرضع (عدد ٢٤)، أطفال من المرحلة الابتدائية (عدد ٥٣)، المراهقين (عدد ٨٥)، البالغين (عدد ١٠٨٦) والمسنين (عدد ٢٢).

**النتائج:** اظهرت النتائج اختلافا في معدل مستويات الفيتامين د بين مجاميع الاعمار وكذلك بين الجنسين بمستوى احصائي معنوي. عموماً ٧٣١ (٥٧.٦%) شخص كان لديهم مستوى فيتامين د أقل من (30 ng/ml)، من هؤلاء ٦٥١ (٥١.٣%) شخص كان لديهم عدم كفاية (29.9-1٠ ng/ml)، بينما ٨٠ (٦.٣%) شخص كان لديهم نقص فيتامين د (أقل من 10 ng/ml).

**الاستنتاج:** أظهرت الدراسة ان حالة نقص الفيتامين د موجودة لدى ٥٧.٦% من الافراد المشمولين في هذه الدراسة في دهوك. قد يكون لهذا الاستنتاج آثار سريرية مهمة ويرجع ذلك إلى زيادة اختطارالاصابة بأمراض التمثيل الغذائي في المستقبل.

CAN PERIODONTAL THERAPY REDUCES THE SEVERITY OF ACTIVE  
RHEUMATOID ARTHRITIS?

HASHIM D. MOUSA, PhD\*

*Submitted 16 May 2016; accepted 30 June 2016*

---

**ABSTRACT**

**Background:** A significant association between periodontitis and Rheumatoid Arthritis (RA) has been reported.

**Aim:** This study was done to determine the effect of periodontal treatment on severity of RA. Patients and Methods: This study was done on 60 patients, age 30-60 years, who were randomly selected from patients attending Duhok Center for Rheumatic Diseases and Medical Rehabilitation. The patients were classified into two groups: Group 1: patients with diagnosis of RA and periodontal disease who received Non-Surgical Periodontal Treatment (NSPT) during the study and group 2: patients with diagnosis of RA and periodontal disease who were monitored during the study but did not receive periodontal treatment. At the initial visit, periodontal health status of the patients based on clinical attachment loss and probing pocket depth score, and disease activity score were determined. After six month, the periodontal status and severity of rheumatoid arthritis were rescored and reassessed for both groups following the same procedure.

**Results:** Initially, there were no significant difference in periodontal status and severity of RA for both groups. After 6 months period, there was significant difference in intra-group analysis for both groups regarding periodontal status and severity of RA but there was no significant difference in inter-group analysis of periodontal status and disease activity score.

**Conclusion:** There is no significant difference in improvement of severity of RA and periodontal disease in patients with RA treated with NSPT, compared to control cases with RA.

**Duhok Med J 2016; 10 (1): 40-48.**

**Keywords:** Periodontitis, Rheumatoid arthritis, Non-surgical periodontal treatment

---

**R**heumatoid arthritis (RA) is characterized by systemic inflammation of wrist and hand joints, leading to permanent deformity. RA and periodontitis share the same pathogenic and clinical features.<sup>1</sup>

Recent studies suggest association between periodontitis and RA.<sup>2-5</sup> In addition, two clinical trials studies suggested that management of periodontal disease could

have a significant effect on severity of RA.<sup>4</sup> Similarly, a significantly increased periodontal attachment loss was observed in RA patients compared to controls.<sup>5</sup>

Few studies have shown that periodontal management could induce a significant decrease in Disease Activity Scores (DAS28) and Erythrocyte Sedimentation Rate (ESR).<sup>6-9</sup> More studies are needed to determine whether full therapy of

---

\* Lecturer, Department of Periodontology, College of Dentistry, University of Duhok, Kurdistan Region, Iraq.  
Email: hashimdawood2007@yahoo.ca

periodontitis in RA patients leads to improvement of clinical outcomes. The goal of this study is to demonstrate the effect of periodontal therapy on the severity of RA.

## PATIENTS AND METHODS

This flow-up study was conducted during March 2013 to April 2015. The study population consist of 60 male and female patients, aged 30-60 years, who attended Duhok Center for Rheumatic Disease and Medical Rehabilitation. All patients were informed about the nature of the study and verbal consent was obtained from each one. The study protocol was approved by the ethical Committee of the General Directorate of Health in Duhok. All RA patients have already been diagnosed by rheumatologists according to revised American College of Rheumatology/ European League Against Rheumatism classification criteria.<sup>10</sup>

Patients were assigned into two groups: Group 1 were patients diagnosed with RA and Periodontal Disease (PD) who received Non-surgical Periodontal Treatment (NSPT) during the study, while Group 2 were patients diagnosed with RA and PD who were monitored during the study but did not receive periodontal treatment (they were treated after the end of the study). The two groups were followed up for 6 months. The Probing Pocket Depth (PPD), Clinical Attachment

Level (CAL), RA Disease Activity Score<sup>28</sup> (DAS28) were measured at baseline and six months later.

### Exclusion criteria

1. Systemic disease, e.g. diabetes, hypertension.
2. Smoking, pregnancy.
3. Antibiotic coverage for dental or medical reasons during the 3 months before the study.
4. Patients with RA without periodontal disease.

### Rheumatoid Arthritis Severity

#### Measurement

Disease activity was assessed using the Disease Activity Score derivative for 28 joints [DAS28].<sup>11</sup>

### Periodontal measurement

In the Dental Health Polyclinic, assessment of periodontal disease was done using disposable gloves and mask, disposable dental mirror and periodontal probe (William) probe. CAL was assessed by measuring the distance from cement-enamel junction (CEJ) to base of the pocket in millimeters. The PPD was assessed from gingival margin to base of the pocket.<sup>12</sup>

### Periodontal therapy (Scaling and Root planning)

For removal of supra-gingival and sub-gingival plaque and calculus, Scaling and Root Planning (SRP) were performed using both hand instruments and an

ultrasonic system, under local anesthetic if necessary (in case of pain or on patient's request).

**Statistical analysis**

Collection and analysis of data were done using SPSS version 23. Quantitative data were analyzed with independent or paired t-tests and categorical data with chi-square, McNemar-Bowker and Fisher's exact tests. A p-value less than 0.05 was considered significant.

**RESULTS**

The distribution of the baseline variables (age, gender, RA severity and periodontal status) of the study groups is shown in

Table 1. There was a significant difference in the age of the participant: the mean age of patients in case group and control was 51.77± 1.56 and 45.90 ± 1.83 respectively, p-value <0.018. There was no significant difference in gender distribution between the case and the control groups. In addition, there was no significant difference in periodontal status and severity of rheumatoid arthritis for both groups.

**Table 1: Baseline characteristics of the two study groups**

		Cases (n = 30)		Controls (n = 30)		P
		No. (%)	Mean ± SE	No. (%)	Mean ± SE	
Sex	Male	12 (40)		15 (50)		0.604*
	Female	18 (60)		15 (50)		
Age			51.77± 1.56		45.90 ± 1.83	0.018**
DAS at baseline			2.07 ± 0.15		1.89 ± 0.17	0.464**
Severity of periodontal disease at baseline	Mild	8 (26.7)		9 (30)		0.725*
	Moderate	15 (50)		12 (40)		
	Severe	7 (23.3)		9 (30)		

\* Based on Chi square test.

\*\* Based on independent t-test.

SE = standard error

Table 2 shows comparison in periodontal and RA parameters at baseline and after 6 months for the case group. There was a highly significant difference in periodontal

status and rheumatoid arthritis severity at baseline and after 6 months (p= 0.003 and < 0.001, respectively).

**Table 2: Comparison of the cases (n = 30) at baseline and after 6 months of periodontal treatment**

	At baseline		After 6 months		P
	No. (%)	Mean ± SE	No. (%)	Mean ± SE	
DAS		2.0 ± 0.15		1.0 ± 0.17	< 0.001*
Severity of periodontal disease	Mild	8 (26.7)	18 (60)		
	Moderate	15 (50)	9 (30)		0.003**
	Severe	7 (23.3)	3 (10)		

\* Based on paired t-test.

\*\* Based on McNemar-Bowker test.

SE = standard error.

Table 3 shows comparison in periodontal and RA parameters at baseline and after 6 months for the control group. Again there was a highly significant difference in

rheumatoid arthritis severity ( $p < 0.001$ ); the difference was also significant for the periodontal status ( $p = 0.014$ ).

**Table 3: Comparison of the controls (n = 30) at baseline and after 6 months**

	At baseline		After 6 months		P
	No. (%)	Mean ± SE	No. (%)	Mean ± SE	
DAS		1.87 ± 0.17		1.0 ± 0.19	< 0.001*
Severity of periodontal disease	Mild	9 (30)	19 (63.3)		
	Moderate	12 (40)	9 (30)		0.014**
	Severe	9 (30)	2 (6.7)		

\* Based on paired t-test.

\*\* Based on McNemar-Bowker test.

SE = standard error.

Table 4 presents the differences in periodontal and RA parameters after six months for the case and the control groups.

There was no significant difference in improvement between the two groups.

**Table 4: Comparison of the two study groups after six months**

	Cases (n = 30)		Controls (n = 30)		P
	No. (%)	Mean ± SE	No. (%)	Mean ± SE	
DAS after 6 months		1.00 ± 0.17		1.00 ± 0.19	1.0*
Severity of disease after 6 month	Mild	18 (60.0)	19 (63.3)		
	Moderate	9 (30.0)	9 (30.0)		1.0**
	Severe	3 (10.0)	2 (6.7)		

\* Based on independent t-test.

\*\* Based on Fisher's exact test.

SE = standard error.

## **DISCUSSION**

An association between RA and PD has been suggested since 1820, when the management by extraction was the most commonly executed. Epidemiological studies found that the prevalence of PD and RA is the same: about 5% of the population greater than 50 years old of age are affected. PD and RA are chronic diseases that may be influenced by immunologic, genetic and environmental factors, resulting in destruction of bone and tissue during periods of outbreaks of periodontal disease.<sup>13</sup> Patients with RA can have greater difficulties with dental hygiene due to limitations in the movements of the hands and pain in the temporomandibular joint.<sup>14</sup>

The pathobiology of rheumatoid arthritis and periodontal disease is the same; both are chronic inflammatory diseases, with releasing of cytokines, production of other inflammatory cell products and activation of complement.<sup>15,16</sup>

In the present study, lack of significant deference between cases and controls may be due to small sample size and equal number of patients. There is a significant difference in age between two groups, which may be because it often occurs later in life or family history increase the rate of happing of RA.

Intra-group analysis of case group at baseline and after six month showed a

highly significant difference in Disease Activity Score for severity of the RA. The severity of PD significantly decreased after six months, thus systemic inflammatory products decreased by periodontal treatment and this agree with other studies done.<sup>17,18</sup> The improvement in RA after periodontal treatment could be related to decrease in these markers. Other explanation is that removing of periodontal pathogens by periodontal treatment could decrease exposure of the joints to bacteria and their toxins, leading to improved RA conditions.<sup>19</sup>

In Table 3, intra-group analysis of the control group at baseline and after six month showed a high significant difference in disease activity score of the rheumatoid arthritis and severity of periodontal diseases significantly decreased after six months, which may be due to taking their drugs, or after oral examination, they become more aware about their oral hygiene.

In Table 4, inter-group analysis of the case and the control groups at baseline and after six month showed no significant difference in disease activity score of the RA and severity of PD.

## **CONCLUSION**

There was no significant difference in improvement of severity of rheumatoid arthritis and periodontal diseases in patients with rheumatoid arthritis, so

control of periodontal infection and inflammation by means of scaling and root planning or taking drugs of rheumatoid arthritis in patients with periodontal disease and rheumatoid arthritis might contribute to a reduction in signs and symptoms of active RA.

### RECOMMENDATION

Larger studies are needed to explore the effect of non-surgical periodontal therapy on clinical indicators of RA, using more rigorous clinical outcome and biochemical measures as well as giving attention to confounding factors of co-morbidity.

### REFERENCES

1. Mercado FB ,Marshall RI, Bartold PM. Inter-relationships between rheumatoid arthritis and periodontal disease. A review. *J Clin Periodontol*; 2003. 30:761–772
2. Ramamurthy NS, Greenwald RA, Celiker MY, Shi EY. Experimental arthritis in rats induces biomarkers of periodontitis which are ameliorated by gene therapy with tissue inhibitor of matrix metalloproteinases. *J Periodontol*; 2005.76: 229–33.
3. Ogrendik M D; Siranus Kokino, MD; Ferda Ozdemir, MD; Philip S. Bird, BSc, MSc, PhD; Stephen Hamlet, BSc, MSc. Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis. *MedGenMed*; 2005.7(2): 2.
4. Riberio J, Anna leao,Arthur Bnoveas. Periodontal infection as a possible severity factor for rheumatoid arthritis. *J Clin Periodontol*; 2005.32: 412–416
5. Pischon N, Pischon T, Kröger J, Gülmez E, Kleber BM, Bernimoulin JP et al. Association among rheumatoid arthritis, oral hygiene, and periodontitis. *J Periodontol*; 2008. 79(6): 979–86.
6. Juliana Ribeiro,Anna leao,Arthur Bnoveas. Periodontal infection as a possible severity factor for rheumatoid arthritis. *J Clin Periodontol* ; 2005.32: 412–416.
7. Ortiz P, Bissada NF, Palomo L, Han YW, Al-Zahrani MS, Panneerselvam A, Askari A et al. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. *J Periodontol*; 2009. 80: 535–540.
8. Al-Katma MK, Bissada NF, Bordeaux JM, Sue J, Askari AD. Control of periodontal infection reduces the severity of active rheumatoid arthritis. *J Clin Rheumatol*; 2007. 13:134–137.
9. Pinho Mde N, Oliveira RD, Novaes AB Jr, Voltarelli JC. Relationship between periodontitis and rheumatoid arthritis and the effect of non-surgical periodontal treatment. *Braz Dent J*; 2009. 20: 355–364.
10. Aletaha D ,Neogi T, Silman A, Funovits J , Felson TD, Bingham III CO et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. *Ann Rheum Dis*; 2010. 69(9): 1580-8.

11. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. *Clin Exp Rheumatol*; 2005. 23 (5 Suppl 39): S93-9
12. Loe, H, Brown. Early –onset periodontitis in adolescent and young adult. *J Periodontal*; 1991. 62:608-616.
13. El-Shinnawi U, Soory M. Associations between periodontitis and systemic inflammatory diseases: response to treatment. *Recent Pat Endocr Metab Immune Drug Discov*; 2013.7(3): 169-88.
14. Persson GR. Rheumatoid arthritis and periodontitis – inflammatory and infectious connections. Review of the literature. *J Oral Microbiol*; 2012. 4.
15. Petty RE , Southwood RT, Manners P International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 *J Rheumatol*; 2004.31: 390-392.
16. Smolik I. Robinson D, El-Gabalawy HS. periodontitis and rheumatoid arthritis: epidemiologic, clinical, and immunologic associations. *Compend Contin Educ Dent*; 2009 30:188-190
17. D'Aiuto F, Nibali L, Parkar M, Suvan J, Tonetti MS. Short-term effects of intensive periodontal therapy on serum inflammatory markers and cholesterol. *J Dent Res*; 2005 84:269–273.
18. Erciyas K, Sezer U, Ustün K, Pehlivan Y, Kisacik B, Senyurt SZ et al Effects of periodontal therapy on disease activity and systemic inflammation in rheumatoid arthritis patients. *Oral Diseases*; 2013.19(4): 394–400.
19. Simelyte E, Simelyte E, Rimpiläinen M, Lehtonen L, Zhang X, Toivanen P. Bacterial cell wall induced arthritis: chemical composition and tissue distribution of four *Lactobacillus* strains. *Infect Immun*; 2000. 68:3535.

## پوخته

## کارتیکرنا چاره‌سه‌رکرن پدی ل سەر دژواریا ئیشین گه‌ها

**ئارمانج:** په‌یوه‌ندیا مه‌عه‌وی دناقبه‌را ئیشیت پدی و ئیشیت گه‌ها هاته ده‌ست نیشان کرن. ئارمانج ژفی فه‌کولینی دیارکرن کارتیکرنا چاره‌سه‌ریا پدی ل سەر کیمکرنا دژواریا ئیشیت گه‌ها.

**رێکێن فه‌کولینی:** فه‌کولینه‌کا چاقدیری کری ل سەر (٦٠) نه‌خوشا هاته کرن ئه‌قیت ژیی وان دناقبه‌را (٦٠-٣٠) سالی دا ئه‌وین هاتینه ژینگرتن بشیوه‌کی گوتره‌یی ل نه‌خوشخانا گه‌هان ل ده‌وکی و نه‌خوش هاتنه دابه‌شکرن بو دوو گروپا.

گروپی ئیکی: ئه‌و نه‌خوشین ئیشین پدی و ئیشین گه‌ها هه‌ین و چاره‌سه‌ریا ئیشین پدی وه‌رگرتین د ده‌می فه‌کولینی دا.

گروپی دوویی: ئه‌و نه‌خوشین ئیشین پدی و ئیشین گه‌ها هه‌ین وچ چاره‌سه‌ریا ئیشین پدی وه‌رنه‌گرتینه د ده‌می فه‌کولینی دا.

**ئه‌نجام:** ده‌ستپیکێ چ جیاوازیین دیار دناقبه‌را ئیشین پدی و دژواریا ئیشین گه‌هان نه‌بو. پشتی شه‌ش هه‌یفا جیاوازی دناقبه‌را گروپاندا هه‌بو، دناقبه‌را گروپی ئیکی و گروپی دوویی بو ئیشیت پدی و ئیشین گه‌هان.

**ده‌رئه‌نجام:** ده‌ستپیکێ چ جیاوازیین دیار دناقبه‌را ئیشین پدی و دژواریا ئیشین گه‌هان نه‌بو. پشتی شه‌ش هه‌یفا جیاوازی دناقبه‌را پروپاندا هه‌بو.

## الخلاصة

### تأثير علاج امراض اللثة على شدة التهاب المفاصل

**الهدف:** علاقة معنوية بين التهاب اللثة و التهاب المفاصل تم طرحها. الهدف من الدراسة لايجاد مدى تأثير علاج امراض اللثة على التقليل من شدة التهاب المفاصل.

**طريقة البحث:** دراسة تتابعية اجريت على ٦٠ مريض الذين اعمارهم تتراوح بين ال(٣٠-٦٠) سنة و الذين اختيروا عشوائيا من المرضى الذين يراجعون مركز الروماتيزم والتهاب المفاصل في دهوك . تم تصنيف المرضى الى مجموعتين المجموعة الاولى: المرضى الذين لديهم التهاب المفاصل و التهاب اللثة والذين استلموا علاج امراض اللثة خلال الدراسة. المجموعة الثانية: المرضى الذين لديهم التهاب المفاصل و التهاب اللثة والذين لا يستلمون اي علاج للثة خلال الدراسة. في البداية صحة اللثة و الانسجة الداعمة يعتمد على قياس جيوب اللثة و قياس مدى فقدان الانسجة الداعمة و قياس شدة المرض بعد ستة اشهر لمعرفة تأثير علاج اللثة على شدة المرض.

**النتائج:** في البداية لم يلاحظ اي فرق معنوي بين اللثة و شدة المرض. بعد ستة اشهر هناك فرق معنوي ملحوظ داخل المجاميع للمجموعتين الاولى والثانية بالنسبة لحالة اللثة و شدة التهاب المفاصل .

**الاستنتاجات:** في البداية لم يلاحظ اي فرق معنوي بين اللثة و شدة المرض. بعد ستة اشهر هناك فرق معنوي ملحوظ داخل المجاميع .

**VITAMIN D STATUS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME****SHEREEN A. IBRAHIM, MBChB, MSc, PhD\****Submitted 1 February 2016; accepted 30 June 2016***ABSTRACT**

**Background:** Polycystic ovary syndrome (PCOS) is a common endocrinopathy affecting women in their reproductive age characterized by anovulation. This heterogeneous disorder is usually accompanied by hormonal and metabolic disturbances mainly FSH-LH imbalance, insulin resistance, dyslipidemia and hirsutism. A variety of previous studies emphasized on the evaluation of dihydroxy vitamin D 25(OH)D in sera of PCOS patients. It is concluded that PCOS patients are more likely to have vitamin D deficiency and or insufficiency. The aim of the present study is to evaluate the role of vitamin D in PCOS pathogenesis and its association with metabolic disturbances.

**Methods:** This case control study involved forty clinically diagnosed PCOS patients according to Rotterdam criteria with twenty apparently healthy women as a control group. Physical examination was done as well as case history was taken by a questionnaire. Laboratory examinations were performed by automated method using Cobas 6000 analyzer.

**Results:** Total serum vitamin D levels showed a highly significantly statistically decrease in PCOS women compared to control ( $p < 0.005$ ). Among patients, 75% were considered deficient, 15% insufficient and 10% with normal levels respectively. Moreover, there was a significant correlation between vitamin D deficiency and body mass index (BMI).

**Conclusion:** Vitamin D deficiency may have a role in the pathogenesis of PCOS through initiating metabolic disturbances mainly insulin resistance and increased BMI which may have an influence on the ovarian functions.

**Duhok Med J 2016; 10 (1): 49-57.**

**Keywords:** Polycystic ovary syndrome, vitamin D and lipid profile.

**P**olycystic ovary syndrome (PCOS) is a common endocrinopathy affecting around 6-10% of women in their reproductive age characterized by anovulation. This heterogeneous disorder is usually accompanied by hormonal and metabolic disturbances mainly FSH-LH imbalance, insulin resistance, dyslipidemia and hirsutism.<sup>1,2,3</sup> Until 2003, there was no concise and universally accepted clinical definition for PCOS, but The Rotterdam

ESHRE/ ASRM- sponsored PCOS consensus workshop group managed to establish a set of criteria enabling clinicians to diagnose PCOS in a precise manner.<sup>4,5</sup> It was concluded that no single diagnostic criterion was sufficient for clinical diagnosis of PCOS, therefore, two out of three criteria have to be exist; chronic anovulation, clinical and/or biochemical hyperandrogenism and polycystic ovaries.<sup>6</sup>

\* PhD, Lecturer, Dept. of Physiology, College of Medicine, University of Duhok.  
Correspondent author: Shereen A. Ibrahim, email: shereen.abdulla@yahoo.com

However, vitamin D traditionally plays an important role in bone metabolism as well as calcium-phosphorus homeostasis.<sup>7</sup> Moreover, recently new functions have been revealed such as its crucial role in mediating immune cells functions.<sup>8</sup> Reduced vitamin D levels have been linked with a variety of conditions mainly cardiovascular diseases, diabetes, metabolic diseases and cancer.<sup>9,10</sup> Even though the variety of research have been conducted regarding the association of PCOS with various conditions, negligible studies have focused on the role of vitamin D and its contribution to the pathogenesis of PCOS. The aim of this study is to evaluate the role of vitamin D and its possible association with variable manifestations in women having PCOS.

#### **METHODS:**

This case control study was conducted at Department of Physiology, College of Medicine, University of Duhok from November 2015 to February 2016 . Participants involved forty clinically diagnosed PCOS patients according to Rotterdam criteria (oligo- and/or anovulation or clinical and/or biochemical hyperandrogenism or polycystic ovaries on ultrasound) with twenty apparently healthy women as a control group. Following clinical diagnosis, physical examination was done including height, weight and body mass index as well as

case history was taken by a questionnaire. Five milliliters of venous blood were collected from each participant for laboratory investigations.

Lipid profile including total serum cholesterol (Tch), triglyceride (TG), high density lipoprotein (HDL) were measured manually (BioLab, France) whereas low density lipoprotein (LDL) and very low density lipoprotein (VLDL) were calculated using Friedewald formula. Total serum vitamin D levels were assayed by automated method using Cobas 6000 (Roche Diagnostics, USA). Hormonal assays including follicular stimulating hormone (FSH) and luteinizing hormone (LH) were performed using enzyme immunoassay technique (Biomerieux manufacturer, France).

Statistical analysis was done using SPSS version 18 (Chicago, USA). All variables were expressed as mean  $\pm$  standard deviation (SD) and the independent t-test used to determine the statistical significance of difference in mean between two groups. p values of 0.05 or less were considered statistically significant.

#### **RESULTS:**

The mean age of participants in this study (both patients and controls) was 29 years. PCOS patients who were clinically diagnosed had infertility of about 3.34 years. Body mass index (BMI) was statistically significantly higher in PCOS

patients (28.14 vs. 22.9) compared to control ( $p= 0.005$ ). Follicular stimulating hormone (FSH) of PCOS group was significantly lower compared to control ( $p=0.04$ ) whereas luteinizing hormone (LH) was significantly higher in patients vs. control ( $p= 0.01$ ) (Table 1).

**Table 1: Basic characteristics of PCOS patients and control subjects**

Parameters	PCOS	Control	P value
Body Mass Index (BMI)	28.14 ± 3.12	22.9 ± 2.05	0.005
Duration of infertility (years)	3.34 ± 2.57	NA	NA
Age (years)	29.1 ± 4.71	29.7 ± 3.88	0.91
FSH	6.31 ± 2.44	10.59 ± 2.63	0.04
LH	13.23 ± 2.18	5.84 ± 1.95	0.01

Fasting blood glucose levels of PCOS patients was significantly higher compared to control ( $p= 0.001$ ). Concerning lipid profile, total serum cholesterol and low density lipoprotein were significantly higher ( $p = 0.001$ ) in PCOS patients compared to control. Furthermore, high density lipoprotein (HDL) was significantly lower in PCOS compared to control subjects ( $p=0.005$ ). However, both triglyceride and VLDL did not show significant differences between study groups (Table 2).

**Table 2: Lipid profile and D 25(OH)D among study groups.**

Parameters	PCOS (N = 40)	Control (N = 20)	p value
Fasting Glucose	111.7 ± 2.65	92.3 ± 3.75	0.001
Total Cholesterol	170.12 ± 4.52	136.8 ± 3.03	0.001
Triglyceride	94.2 ± 4.02	92.7 ± 3.53	0.77
HDL	38.57 ± 1.16	47.11 ± 0.92	0.005
LDL	108.7 ± 4.68	71.9 ± 3.16	0.001
VLDL	18.7 ± 0.88	17.6 ± 0.67	0.32
Total 25 hydroxy vitamin D (ng / ml)	16.25 ± 2.31	43.2 ± 1.16	< 0.005

Total serum 25(OH)D levels showed a highly statistically significant decrease in PCOS women compared to control ( $p < 0.005$ ) (table 3). Among patients, 75% were considered deficient, 15% insufficient and 10% with normal levels respectively. 90% of control subjects had normal vitamin D levels with 10% of insufficient (Table 4).

**Table 3: Number and percentage of deficient and insufficient patients and controls.**

Parameters	Deficiency (< 20 ng/ml)	Insufficiency (20-30 ng/ml)	Normal levels (30-100 ng/ml)
PCOS patients (No. = 40)	30 (75 %)	6 (15%)	4 (10%)
Controls (No. = 20)	0 (0 %)	2 (10 %)	18 (90%)

Pearson's correlation coefficient between vitamin D and body mass index (BMI) displayed a significant negative correlation ( $p=0.05$ ) with a negligible and non significant values with HDL, FSH and LH respectively.

**Table 4: Pearson's correlation coefficient between variables.**

Parameters	r value	p value
Vitamin D - BMI	- 0.254	0.05
Vitamin D - HDL	- 0.16	0.1
Vitamin D - FSH	- 0.08	0.31
Vitamin D - LH	- 0.05	0.38

**DISCUSSION:**

This study aimed to demonstrate the association between vitamin D deficiency and PCOS pathogenesis as well as the possible mechanisms underlying that. PCOS women had significantly increased BMI ( $p=0.005$ ) which was significantly correlated with vitamin D deficiency (table 5). This is indicated in previous literature concluding that this may be due to existence of obesity and excess androgen levels which subsequently resulting in insulin resistance.<sup>11,12,13</sup> Metabolic and endocrine disturbances in PCOS are well expressed in our study represented by elevated fasting glucose and low HDL levels (Table 2) as well as hormonal disturbances including disturbances in FSH and LH values (Table 1). Previous

studies indicated that altered FSH/LH ratio in PCOS patients have adverse effects on ovulation represented by failure in maturation of ovum during menstrual cycle and subsequently unovulation.<sup>14,15</sup> In addition, present results are in concordance with previous literature indicating that borderline hyperglycemia, hyperinsulinemia and hyperlipidemia may be regarded as the main inducer of insulin resistance in PCOS women.<sup>16,17</sup>

This study showed a highly statistically significant decrease in total 1,25 hydroxyvitamin D levels in PCOS women compared to control ( $p<0.005$ ) as well as the majority of patients (75%) were considered to have hypovitaminosis D. Although the exact mechanisms of vitamin D deficiency in PCOS are not well understood, these results are supported by previous studies concluding that polymorphisms in vitamin D receptor (VDR) gene and deficiency in VDR expression on target cells might be associated with metabolic and endocrine disturbances in PCOS.<sup>18,19</sup> Moreover, studies suggested that there is association between vitamin D and insulin resistance. Vitamin D potentiates insulin action by stimulating insulin receptors expression and thereby enhancing insulin responsiveness for glucose.<sup>20,21</sup> Furthermore, transcription of insulin gene is activated by 1,25 (OH) D2.<sup>22,23</sup> Vitamin

D regulates both intracellular and extracellular calcium that is important in insulin-mediated intracellular processes in insulin responsive tissues such as adipose tissues.<sup>24,25,26</sup>

Although absence of androgen measurement could be one of the possible limitations of the present study, this is managed by diagnosing study participants according to Rotterdam criteria based on the presence or absence of hirsutism. Moreover, the sample size of the present study may be low for such a common women health problem. Despite the researcher's attempts for including more participants, the study was conducted based on availability of participants. In conclusion, this study suggest that vitamin D deficiency may have a role in the pathogenesis of PCOS through initiating metabolic disturbances mainly insulin resistance and increased BMI which may have an influence on the ovarian functions. Therefore, its recommended that vitamin D should be prescribed to PCOS patients having vitamin D deficiency as an ancillary treatment to improve metabolic disturbances mainly insulin resistance. Future studies should pay further attention to the relationship between vitamin D and metabolic disturbances to clarify the association between insulin resistance and hypovitaminosis D.

## REFERENCES:

1. Richardson MR. Current Perspectives in Polycystic Ovary Syndrome. *Am Fam Physician*. 2003; 68(4): 697704.
2. Gulekli B, Turhan NO, Senoz S et al. Endocrinological, ultrasonographic and clinical findings in adolescent and adult polycystic ovary patients: a comparative study. *Gynecol Endocrinol* 1993;7:273–277.
3. Azziz R, Woods S, Reyna R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab* 2004;89:2745–2749.
4. Sheehan MT. Polycystic Ovarian Syndrome: Diagnosis and Management. *Clin Med Res*. 2004, 2 (1):13–27.
5. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. *Hum Reprod Update*. 2003;9(6):505-514.
6. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril*. 2004, 81(1):19-25.
7. Ehrmann, D. Polycystic ovary syndrome. *The New Eng J of Med*. 2005; 352:1223–1277.
8. Grandmunn M and Verson-Hoyneck V. Vitamin D- roles in women's reproductive health. *Reproductive Biology and Endocrinology*. 2011; 9: 146.

9. Holik MF. Vitamin D deficiency. *N Engl J Med.* 2007; 357 (3):266-281.
10. Alpert PT and Shaikh U. The effects of vitamin D deficiency and insufficiency on the endocrine and paracrine systems. *Bio Res Nurs.* 2007; 2:117-129.
11. Hahn, S. Haselhorst, U, Tan, S et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. *Exp Clin Endocrinol and Diabetes.* 2006; 114: 577–583.
12. H, R. Li, R. Brereton, H, et al. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. *Metabolism: Clinical and Experimental.* 2011;60:1475–1481.
13. Wehr E, Pilz P, N. Schweighofer et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. *European Journal of Endocrinology.* 2009; 161: 575–582.
14. R. Yildizhan, M. Kurdoglu, E. Adali et al. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. *Archives of Gynecology and Obstetrics.* 2009;280:559–563.
15. Trummer O, Giuliani A, H.-J. Gruber et al. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. *European Journal of Endocrinology.* 2011; 164: 741–749.
16. Wehr E, Pieber T, and Obermayer B. Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: a pilot study. *Journal of Endocrinological Investigation.* 2011; 34: 757–763.
17. Y. Krul, C. Snackey, Y. Louwers et al. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. *European Journal of Endocrinology.* 2013; 6: 853–865.
18. H. Darwish and H. F. DeLuca. Vitamin D-regulated gene expression. *Critical Reviews in Eukaryotic Gene Expression.* 1993; 3:89–116.
19. C. Potera. Diet and nutrition: vitamin D regulates MS gene. *Environmental Health Perspectives.* 2009; 117:190-196.
20. T. Mahmoudi. Genetic variation in the vitamin D receptor and polycystic ovary syndrome risk. *Fertility and Sterility* 2009; 92: 1381–1383.
21. B. Maestro, S. Molero, S. Bajo, et al. Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D3. *Cell Biochemistry and Function,* 2002; 3: 227–232.
22. Thompson RL, Spedding S and Bucklet JD. Vitamin D in the etiology and management of polycystic ovary syndrome. *Clin Endocrinol.* 2012; 77: 343-350.
23. Teegarden D and Donkin S. Vitamin D: emerging new roles in insulin sensitivity. *Nutr Res Rev.* 2009; 22: 82-92.

24. Heaney RP. Vitamin D in health and disease. *Clin J Am soc Nephrol*. 2008; 5:1535-41.
25. Lopez FR, Chedraui P and Fernandez AM. Vitamin D and aging; beyond calcium and bone metabolism. *Maturitas*. 2011; 69:27-36
26. Rashidi B, Haghollahi F, Shariat M and Zayerii F. The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. *Taiwan J Obstet Gynecol*. 2009; 48(2): 142-147.

## پوختہ

### فیتامین دی ل جہم نہ ساخین کیسبونا ہیگلدانئ

**پیشہ کی و نارمانج:** کیسبونا ہیگلکہ دانئ ئیکہ ژنہ خوشییین بہرہ لاق ل جہم ژنا و تا نوکہ ئہ گہرین وی ددیار نینن، ژنا نہ ساخ ہئی نہ خوشییی دەورا وی یا ہہ یقانہ گپرو دبیت و ہیگ دروست نا چیبیت. نارمانج ژئی قہ کولینی دیارکرنا رولی فیتامین دی یہ دیارکرنا کاریگہ ریا وی لسہر کاری ہیگلکہ دانئ.

**ریکین قہ کولینی:** ئە قہ کولینہ ہاتہ ئە نجامدان ل کولپڑا پزیشکی بہ شئی فسیولوجی و پشکدار ہاتنہ دابہ ش کرن لسہر دوو گروپا: گروپی ئیکی نہ ساخ و ژمارا وان ۴۰ کہس بون و گروپی دووی ژنئین نورمال بون و ژمارا وان ۲۰ کہس بون. تاقیکرنئین لابوری یین پیدئی ہاتنہ ئە نجامدان و ہرہوسا پیژانینئین کلینیکی بریکا فورمہ کا تایبہ ت ہاتنہ وەرگرتن.

**ئہ نجام:** ئە نجامین قہ کولینی دیارکرنا کو خوینا نہ ساخین کیسبونا ہیگلکہ دانئ کیمیا فیتامین دی ہنہ و ئە قہ چہ ندہ کاریگہ ریا کا نہرئینی لسہر کاری ہیگلدانئ دکہ ت.

**دہرئہ نجام:** کیمبونا فیتامین دی کاریگہ ریا کا خراب لسہر کاری ہیگلدانئ ہہ یہ و دبیتہ فاکتہ رہ کی سہرہ کی ژبو کارکرنا وی بشیوہ کی نہ نورمال.

## الخلاصة

### تقييم دور الفيتامين دي لدى النساء المصابات بمتلازمة تكيس المبايض

**خلفية وأهداف البحث:** متلازمة تكيس المبايض هو خلل افرازي أيضا غير معروف السبب يتميز بعدم الاباضة و زيادة في مستوى الاندروجين في الدم و احيانا تترافق مع اعراض اخرى مثل خلل في افراز الانسولين. الهدف من هذه الدراسة هو تحديد دور الفيتامين دي لدى النساء المصابات بمتلازمة تكيس المبايض.

**طرق البحث:** تضمنت هذه الدراسة ستون مشاركات و قد تم تقسيمهن الى مجموعتين, المجموعة الاولى تألفت من أربعون مريضا مشخصا كلينيكيًا بمتلازمة تكيس المبايض اما المجموعة الثانية تضمنت عشرون اشخاصا اصحاء كمجموعة ضابطة. تم اجراء جميع التحليلات المختبرية في مختبر الفسلجة بكلية الطب و الحصول على المعلومات الاكلينيكية الاضافية حول حالات المرضى من خلال أستبيان. تم تحليل المعلومات و اجراء الاحصاء الطبي باستعمال البرامج المختصة.

**النتائج:** أظهرت نتائج الدراسة وجود نقصان ملحوظ في مستوى الفيتامين دي في دم المرضى مقارنة بالمجموعة الضابطة.

**الاستنتاج:** تلخصت الدراسة بأن نقص الفيتامين دي في دم المرضى المصابين بمتلازمة تكيس المبايض من المرجح ان يكون لها دورا فعالا و تأثيرا مباشرا على وظائف المبايض. لذلك ينصح بأعطاء الفيتامين دي كجزء من العلاج للمرضى الواتي عندهن نقص بالفيتامين المذكور.

**ACNE VULGARIS: THE PREVALENCE, SEVERITY AND THE ASSOCIATED FACTORS AMONG SECONDARY SCHOOL STUDENTS IN A DISTRICT OF KURDISTAN REGION /IRAQ**

**KAMIL R. F. CHALKY, MBChB\***  
**SAMIM A. AL-DABBAGH, MBChB, DTM&H, D.Phil, FFPH\*\***  
**ZEYAD S. AL-DABBAGH, MBChB, FCABMS, FJMC\*\*\***

*Submitted 1 February 2016; accepted 30 June 2016*

---

**ABSTRACT**

**Background and objectives:** Acne vulgaris is a common dermatological disorder among secondary school students. It is frequently complained by students in our locality without being properly studied. This study aimed to measure the prevalence and severity of acne vulgaris and factors affecting them among secondary school students in a district of Kurdistan Region, Iraq.

**Methods:** A cross sectional design was performed. A multistage random sample of 575 secondary school students of both genders selected from 6988 students in Amedi district/ Duhok Governorate. All Students were clinically examined and interviewed for data collection regarding socio- demographic variables of age, gender, ethnicity, residence and family income. Also information was collected regarding parental history of acne, self excoriative behavior and make up use among females. Their nutritional status was measured by the body mass index. The severity of acne was assessed by using Global Acne Grading system. Data were collected and analyzed by using the statistical package for social sciences (SPSS version 22).

**Results:** The results revealed prevalence rates of 71.7% and 87.8% by self-reporting and by clinical examination respectively. The mild, moderate and severe forms were found respectively in 90.8%, 9% and 0.2% of students diagnosed with acne vulgaris. Papules and comedones were the most prominent acne lesions. No statistically significant associations were detected between prevalence or severity of acne vulgaris and socio demographic factors of age, gender, ethnicity, residence and body mass index. Family history of acne vulgaris was significantly associated with severity ( $p < 0.05$ ) but not with the prevalence ( $p > 0.5$ ).

**Conclusions:** The study demonstrated a high prevalence of acne vulgaris with substantial genetic role in the severity of the disease.

**Duhok Med J 2016; 10 (1): 58-68.**

**Keywords:** Acne Vulgaris, Prevalence, Severity. Kurdistan region

---

**A**cne vulgaris (AV) is a common dermatological health problem among secondary school students with greatest frequency at the ages of 15-18 in both sexes.<sup>1-3</sup> A prevalence rate of 70-80%

has been reported, with a wide variation in different countries.<sup>4-8</sup> The disease is mainly encountered on the face, chest and back. Factors like excessive sebum excretion, hormonal stimulation, poral

---

\*Specialist in Community medicine, Duhok Directorate General of Health, Kurdistan Region, Iraq

\*\*Professor and Chairman ,Family and Community medicine department, College of Medicine, University of Duhok , Kurdistan Region, Iraq

\*\*\*Lecturer, Dermatology Section, College of Medicine, University of Duhok, Kurdistan Region, Iraq  
Correspondence to Samim A Al-Dabbagh, samimaldabbagh@yahoo.com, Mobile+964-750-4161406

occlusion and bacterial colonization play a role in etiology. Also several other factors have been incriminated in the etiology and severity of the disease like age, gender, ethnicity, nutritional status and family history.<sup>1-3</sup>

### **SUBJECTS AND METHODS**

A cross sectional study was conducted on a random sample of secondary school students in Amedi district during the period from January to April, 2015. Amedi district is one of the seven districts comprising Duhok governorate in Kurdistan Region, Iraq. Two ethnic groups share living in the area Kurds who are the majority and Assyrians Christians as a minority. After obtaining a formal approval from the scientific committee of the Kurdistan Board for Medical specializations, a multistage random sampling method was used for obtaining a sample size of 575 students. In the first stage 12 secondary schools were selected at random out of 25 present in Amedi District with total number of (6988) students. In the second stage each school was stratified into 6 strata, three for males and three for females of 10<sup>th</sup>, 11<sup>th</sup> and 12<sup>th</sup> classes, and a systematic random sampling

method was used to take equal percentages of students from each stratum and 615 students were recruited for the study.

Each selected student was then seen in a private room by one of the researchers who has a 10 years practice in dermatology. A questionnaire was filled up regarding socio demographic characteristics of age, gender, ethnicity, residence, family income. Moreover data were also collected regarding make up use among females, self excoriative behavior and parental history of AV. After that each student was examined for dominant types of acne lesions (comedones, papules, pustules, nodules or no lesion) in all six locations of body (forehead, right cheek, left cheek, nose, chin, chest /upper back). The severity of AV was measured using Global Acne Grading System (GAGS). The six locations were first graded according to severity (4 for nodules, 3 for pustules, 2 for papules, 1 for comedones and zero for no lesion). The severity of AV was then calculated as the sum of multiplying the location factor by the grade of its dominant lesion of all six locations as follow<sup>9</sup>:

Type of acne lesion and its grade	Location of Acne lesion							
		Forehead*2F	Right cheek*2F	Left cheek *2F	Nose*1F	Chin*1F	Chest and upper back*3F	Total
	Comedones (G=1)							
	Papules (G=2)							
	Pustules (G=3)							
	Nodules (G=4)							
<b>Grand Total</b>								
<b>F: Location Factor, G: Grade of acne lesion, Local Score = F*G, Total Score =Sum of local sores . Mild acne =1-18, Moderate acne 19-30, Severe acne =31-38, Very severe acne =39 and more</b>								

Weight and height were measured for estimation of body mass index which was classified into three categories according to WHO growth reference chart for 5-19 years.<sup>10</sup> Obese or overweight (>one SD), normal weight (1SD to -2SD) and thinness or severe thinness (<-2SD). Family income was divided into 3 categories: good (owning a house, car and have constant salary), sufficient (having one of the three) and insufficient (having none of the three). Statistical package for social sciences (SPSS, version 22) was used for data entry and analysis. P value at  $\leq 0.05$  was considered statistically significant. Chi-square ( $\chi^2$ ) test was used for comparing proportions of different characteristics. Non parametric tests like Mann-whitney

and Kruskal Wallis tests were used for comparing continuous variables of different categories.

## RESULTS

A total of 575 students completed the survey successfully with a mean age  $\pm$  SD of 17.27  $\pm$ 1.08 years. The sample comprised 304 (52.9%) females and 271(47.1%) males. Table 1 shows that the prevalence of AV was 87.8%; with 86% for males and 89.5% for females. Table 1 also shows that the self reporting prevalence was significantly lower than actual one estimated by clinical examination.

**Table 1: The prevalence of AV and Reliability of self-reporting by gender**

	No.	Prevalence of AV by Examiners %	Prevalence of AV by student's self-reporting %	Total agreement %	Kappa	P value
Males	271	86.0	67.5	77.1	0.39	<0.001
Females	304	89.5	75.3	83.2	0.44	<0.001
All	575	87.8	71.7	80.3	0.42	<0.001

Table 2 shows the six prone areas for AV. Forehead area was less times free of acne lesions especially in males. Papules were more frequently dominant in all acne prone areas except the nose in which the comedones were more frequently observed

**Table 2. Frequency distribution according to dominant acne lesions in six acne prone areas of the body**

	Dominat type of acne lesion					
	Clear N (%)	Comedones N (%)	Papule N (%)	Pustules N (%)	Nodule N (%)	Total N (%)
<b>Forehead</b>						
All	188 (37.2)	85 (16.8)	225( 44.6)	6 (1.2)	1(0.2)	505(100)
M	104 (44.6)	31(13.3)	94( 40.3)	3(1.3)	1(0.4)	233(100)
F	84 (30.9)	54(19.9)	131(48.2)	3(1.1)	0(0)	272(100)
<b>Right cheek</b>						
All	255(50.5)	52(10.3)	184(36.4)	11(2.2)	3(0.6)	505(100)
M	110(47.2)	30(12.9)	83(35.6)	8(3.4)	2(0.9)	233(100)
F	145(53.3)	22(8.1)	101(37.1)	3(1.1)	1(0.4)	272(100)
<b>Left cheek</b>						
All	303(60.0)	36(7.1)	152(30.1)	10(2.0)	4(0.8)	505(100)
M	132(56.7)	21(9.0)	71(30.5)	7(3.0)	2(0.9)	233(100)
F	171(62.9)	15(5.5)	81(29.8)	3(1.1)	2(0.7)	272(100)
<b>Chin</b>						
All	288(57.0)	50(9.9)	156(30.9)	9(1.8)	2(0.4)	505(100)
M	144(61.8)	14(6.0)	67(28.8)	6(2.6)	2(0.9)	233(100)
F	144(52.9)	36(13.2)	89(32.7)	3(1.1)	0(0.0)	272(100)
<b>Nose</b>						
All	243(48.1)	234(46.3)	26(5.1)	1(0.2)	1(0.2)	505(100)
M	120(51.5)	96(41.2)	15(6.4)	1(0.4)	1(0.4)	233(100)
F	123(45.2)	138(50.7)	11(4.0)	0(0.0)	0(0.0)	272(100)
<b>Chest / upper back</b>						
All	303(60.0)	3(0.6)	189(37.4)	7(1.4)	3(0.6)	505(100)
M	146(62.7)	2(0.9)	78(33.5)	4(1.7)	3(1.3)	233(100)
F	157(57.7)	1(0.4)	111(40.8)	3(1.1)	0(0.0)	272(100)

Table 3. Shows that age, gender, ethnicity, residence, family income, BMI and make up usage had no significant association with the prevalence of AV .

---



---

**ACNE VULGARIS: THE PREVALENCE, SEVERITY AND THE ASSOCIATED FACTORS**

---



---

**Table 3: Prevalence of acne vulgaris by socio-demographic variables**

	N	%	P value
<b>Age Group</b>			
16	175	83.4	0.1
17	167	89.2	
18-19	233	90.4	
<b>Total</b>	<b>575</b>	<b>87.8</b>	
<b>Gender</b>			
Male	271	85.6	0.1
Female	304	89.8	
<b>Total</b>	<b>575</b>	<b>87.8</b>	
<b>Ethnicity</b>			
Kurdish	505	88.3	0.3
Assyrian	70	84.3	
<b>Total</b>	<b>575</b>	<b>87.8</b>	
<b>Residence</b>			
Urban	298	86.6	0.3
Rural	276	89.1	
<b>Total</b>	<b>574</b>	<b>87.8</b>	
<b>Family Income</b>			
Not sufficient	71	94.4	0.2
Sufficient	472	86.9	
Good	32	87.5	
<b>Total</b>	<b>575</b>	<b>87.8</b>	
<b>BMI</b>			
Normal	340	88.2	0.3
Overweight a/ obese	92	90.2	
Thin /severe thinness	134	84.3	
<b>Total</b>	<b>566</b>	<b>87.6</b>	
<b>Females using make up</b>			
YES	185	90.7	0.4
No	86	86.3	
<b>Total</b>	<b>304</b>	<b>89.1</b>	

Table 4 reveals that family history of AV has no significant effect on the prevalence of the disease among siblings. However, the association was higher when both parents and/or mothers had history of AV, but also did not reach a statistical significance. Similar non significant association was found with history of AV among sisters and/or brothers of students.

**Table 4: Association between family history and prevalence of acne vulgaris**

		N	Acne prevalence		P value
			NO.	%	
<b>Parental history of acne vulgaris</b>	<b>Father</b>	113	97	85.8	0.3
	<b>Mother</b>	93	86	92.5	
	<b>Both parents</b>	47	43	91.5	
	<b>None of them</b>	322	279	86.6	
	<b>Total</b>	<b>575</b>	<b>505</b>	<b>87.8</b>	
<b>Sisters and/or brothers with acne vulgaris</b>	<b>One or more</b>	429	383	89.3	0.06
	<b>No one</b>	146	122	83.6	
	<b>Total</b>	<b>575</b>	<b>505</b>	<b>87.8</b>	

Table 5 shows no significant association between the severity of AV and each one of the variables of age, gender, ethnicity, residence, family income, BMI and make up use by female students.

**Table 5: The association between severity of acne vulgaris with variables; age, gender, ethnicity, residence, family income, BMI and make use by females.**

	N	% mild	% moderate	P value
<b>Age Group</b>				
16	145	25.2	3.6	0.2
17	149	28.0	1.6	
18-19	210	37.7	4.0	
Total	504	90.9	9.1	
<b>Gender</b>				
Male	231	41.1	4.8	0.4
Female	273	49.8	4.4	
Total	504	90.9	9.1	
<b>Ethnicity</b>				
Kurdish	445	81.0	7.3	0.09
Assyrian	59	9.9	1.8	
Total	504	90.9	9.1	
<b>Residence</b>				
Urban	257	45.9	5.2	0.5
Rural	246	44.9	4.0	
Total	503	90.9	9.1	
<b>Family income</b>				
Not sufficient	67	11.5	1.8	0.5
Sufficient	410	74.1	6.9	
Good	28	5.0	0.6	
Total	505	90.5	9.3	
<b>BMI</b>				
Normal	385	69.9	6.8	0.6
Over weight and Obese	91	16.1	2.0	
Thinness and Severe thinness	26	4.8	0.4	
Total	502	90.8	9.2	
<b>make up use by females</b>				
Yes	185	63.0	6.8	0.2
No	80	28.7	1.5	
Total	265	91.7	8.3	

Table 6 reveals a significant association between the severity of AV and family history of the disease. A significantly higher scores of mean rank of AV severity scores were encountered when the affected students had parental history of AV of both parents and/or mother compared to those with no parental history and/or father history of AV(P=0.04). Similarly,

## ACNE VULGARIS: THE PREVALENCE, SEVERITY AND THE ASSOCIATED FACTORS

students who had sisters and/or brothers with AV experienced significantly more severe forms of the disease compared to those with no such history ( $p < 0.001$ ).

Finally the study found that the overall prevalence of self excoriative behavior was 64.7%.

**Table 6: severity of acne vulgaris association with family history of acne vulgaris**

		N	Mean Ranks of Acne severity scores	P value
<b>Parental history of acne vulgaris</b>	<b>None of them</b>	<b>319</b>	<b>270.8</b>	<b>0.04</b>
	<b>Father</b>	<b>113</b>	<b>291.6</b>	
	<b>Mother</b>	<b>93</b>	<b>313.8</b>	
	<b>Both Parents</b>	<b>47</b>	<b>326.2</b>	
	<b>Total</b>	<b>572</b>		
<b>Sisters and /or brothers with acne vulgaris</b>	<b>Yes</b>	<b>429</b>	<b>245.4</b>	<b>&lt;0.001</b>
	<b>No</b>	<b>146</b>	<b>302.5</b>	
	<b>Total</b>	<b>575</b>		

### DISCUSSION

Secondary school students are the most vulnerable ages for the disease and easily accessible. Despite that, however, this might limit generalizability of the findings as the disease might start earlier and clears at older ages<sup>1-3</sup>. The GAGS scale was selected for measuring the severity of AV as it is simple and quick method.<sup>9</sup>

The study showed an overall prevalence of 87.8%. Similarly, other studies reported high prevalence rates in Iran<sup>4</sup> (85.9%), Nigeria<sup>5</sup> (90.7%), and Brazil<sup>6</sup> (96.0%). However, much lower rates were reported in China<sup>7</sup> (38.0%) and Cameroon<sup>8</sup> (60.0%). This might be due to ethnic variation, using different diagnostic criteria or including younger age group.

In this study students underestimated their acne status in comparison to clinical examination. This finding was against that

reported in a similar study in Norway,<sup>11</sup> where students had overestimated their acne status. This might be due to dissimilarities of psychosocial environment between the two populations. Female students in this study expressed better agreement than male students. This might be explained by the fact that the female are more linked with beauty and appearance and are more sensitive to changes in their body image than males. It was noted that papules and then comedones were the dominant acne. This is beneficial to health authorities to arrange for treatment modality which depends on the type of the lesion.<sup>1,12</sup>

Clinically more disfigured forms of acne scars were observed in about 3% of patients. This is an essential health problem due to the special treatment needed; with no guarantee of cure.<sup>13</sup> In

addition a high prevalence of self excoriative behavior (64.7%) was reported; which worsen the lesions and increases the probability of acne scars.

The study found no significant differences in the acne prevalence between males and females. Similar finding was observed in a study in Iran<sup>4</sup>, however, a study in Greece found higher acne prevalence in females in ages of 11-14 years and in males in ages of 14-16 years.<sup>14</sup> In addition to that a study in Lithuania demonstrated a higher acne prevalence among female at ages 10-12 years which might be explained by earlier female maturation.<sup>15</sup>

The current study revealed no significant difference in the acne prevalence between the two ethnic groups of Kurds and Assyrians, which might be due to small number of the latter. Studies around the world found significant differences among different ethnic groups.<sup>16,17</sup>

The study found that previous history of AV among parents, sisters and/ or brothers had no significant effect on the acne prevalence among students. Contradictory results were reported in other studies; which might be due to variations in targeted ages and sample biases.<sup>6</sup>

A total of 90.7%, 9.1% and 0.2% were described as having mild, moderate and severe acne respectively. Similar findings were observed by other studies in different

parts of the world such as in Iran<sup>4</sup>, Nigeria<sup>5</sup>, and Brazil<sup>6</sup>.

In this study parental history of AV was significantly associated with the severity of the disease and the association remains significant with maternal history. This is consistent with the results of another study; indicating the role of mother's genetics in causing more severe forms of acne.<sup>6</sup> Similar significant association was found with sisters and/or brothers. This might be due to different types of genes from parents with variable ability to transmit to the next generation. On the other hand no significant association was found between the severity of AV and age group, gender, ethnicity, place of residence, nutritional status and using of makeup.

In conclusion AV is a highly prevalent skin disorder among the studied population with substantial genetic role in transmitting severe forms of acne vulgaris.

## REFERENCES

1. James WD, Berger TG, Elston DM. Andrews' diseases of the skin. 11th ed. Philadelphia, PA: Elsevier/Sounders, 2011
2. Garg VK, Sardana K. Comprehensive text book of dermatology. Delhi: Pawaninder P.Vij, 2010.
3. Williams H C, Dellavalle R P, Garner S. Acne Vulgaris. The Lancet 2012, 379(9813): 361-372.

4. Noorbala MT, Mozaffaray B, Noorbala M. Prevalence of acne and its impact on the quality of life in high school-aged adolescents in Yazd. *Journal of Pakistan Association of Dermatologists* 2013; 23(2): 168-172
5. Yahya H. Acne vulgaris in Nigerian adolescents-prevalence, severity, beliefs, perceptions and practices. *Int J Dermatol* 2009; 48(5): 498-505
6. Bagatin E, Timpano DL, Guadanhim LR, Dose S, Nogueira VM, Terzian LR, et al. Acne vulgaris: Prevalence and clinical forms in adolescents from Sao Paulo, Brazil. *An Bras Dermatol* 2014; 89(3): 428-435.
7. Shen Y, Wang T, Zhou C, Wang X, Ding X, Tian S, et al. Prevalence of acne vulgaris in Chinese adolescents and adults. *Acta Derm Venereol* 2012; 92(1): 40-44.
8. Mbuagbaw J, Abongwa C, Ozoh G, Blacket K. The prevalence of acne vulgaris in secondary school students in Yaoundé, Cameroon. *Int J Dermatol* 2006 [cited 2015 Feb 16]; 5(2).
9. Adityan B, Kumari R, Thappa DM. Scoring system in acne vulgaris. *Indian J Dermatol Venereol Leprol* 2009; 75 (3): 323-6.
10. WHO. Growth references for the ages 5-19 years. Geneva: WHO, 2015.
11. Halverson JA, Olesen AB, Thoresin M, Holm J, Bjertness E, Dalgard, F. Comparison of self-reported skin complaints with objective skin signs among adolescents. *Acta Derm Venereol* 2008; 88(6): 573-77.
12. Suzanne CS, Brenda GB, Janice LH, Kerry HC, editors. *Brunners and Suddath's Text book of Medical Surgical Nursing* 12<sup>th</sup> ed. Philadelphia: Williams and Wilkins, 2010.
13. Anatonella T, Maria PD, Kenneth RB, editors. *Acne Scars Classification and Treatment* 1<sup>st</sup> ed. New York: Taylors and Francis, 2010.
14. Tasoula E, Gregoriou S, Chalikias E, Lazarou D, Rigopoulos D, Katsambas A. The impact of acne vulgaris on quality of life and psychic health in young adolescents in Greece. Results of population survey. *An Bras Dermatol* 2012; 87(6): 862-869.
15. Karciauskiene J, Valiukeviciene S, Gollnik H, Stang A. The prevalence and risk factors of adolescent acne among schoolchildren in Lithuania: a cross-sectional study. *J Eur Acad Dermatol Venereol* 2013; 28 (6): 733-736.
16. Freyer EA, Rebaza RM, Sami DA, Lozada CP. The prevalence of facial acne in Peruvian adolescents and its relation to their ethnicity. *J adolesc health* 1998; 22(6): 480-4
17. Perkins AC, Cheng CE, Hillebrand GG, Miyamoto K, Kimball AB. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, continental Indian and African American women. *J Eur Acad Dermatol Venereol* 2011; 25(9):1054-60.

## پوخته

## زیپکیت گه نجاتیی: ریژه یا به ربه لاقیا و توندیا وی و هوکارین په یه وه نندیدار

**زهمینه و نامانج:** زیپکیت گه نجاتیی دهردهکی پیستی یی به لاقه دنافا خویندکارین قوناغا نامادهیی دا یا کو زوربه یا جاران خویندکارل کومه لگه ها مه ل بهر دنالن بیی کو نه وچه نده بباشی هاتبیته لیکولینکرن. نامانجا فی فیه کولینی دهرئخستنا به ربه لاقیا زیپکیت گه نجاتیی و توندیا وی و هوکارین په یه وه نندیدار دنافا خویندکارین نامادهیی دا دنافا یه ک زکرتین هریم کوردستانا عراقی.

**ریک:** نه ف فیه کولینه بشیوی پانه برهیی هاته دارشتن، نمونه کا هرهمه کی یا پیکهاتی ژ ۵۷۵ خویندکاران هاته هلبزرتن ژنافا ۶۹۸۸ خویندکارین نامادهیی بیین سه ر ب که رتی نامیدی پاریزگه هادهوکی فه. چاچی که فتن دگه ل هه می خویندکارا هاته کرن و پشکنین نفا جهی بو هاتنه کرن بو تومارکرنا پیژانینن جفاکی و دیموگرافی وه ک زی، ره گه ز، نفش، داهاتی خیزانی، میژویا پرسکیت گه نجاتیی ل دهف دایبابا، رهفتارا تیقلکرنا بیستی و بکارئینانا میکایژی ژلای خویندکارین کچ فه. باری خوراکیی خویندکاران هاته هه لسه نگاندن ب ریا نیشاده ری بارمتا له شی. پاشان پشکنین بو هه میان هاته کرن بو هه لسه نگاندا توندیا زیپکیت گه نجاتیی برییا بکارئینانا سیسته ما جیهانی یا پولینکرنا زیپکیت گه نجاتیی دا بیین هاتنه کومکرن وشروفه کرن ب ریا به سته یا نامارا یا زانستین جفاکی.

**نه نجام:** ل دیف نه نجامین فی لیکولینی به ربه لاقیا زیپکیت گه نجاتیی ب ریژه یا ۷۱.۷٪ و ۸۷.۸٪ لگوره ی دیتنا خویندکاران و پشکنینا نوژداری لیدف ئیک هاته ده ستنیشانکرن. ل نه فا دوماهی خویابو کو ۹۰.۸٪ ژ خویندکارین زیپکه هه یین ب سفکاتی توشببون ۹٪ ب نافنجی و بتنی ۰.۲٪ ژ وانا ب گرانی توشی فی نه خوشیی ببون. زوربه یا حاله تین پرسکین گه نجاتیی ژ جورئ پاپبول یان زیوان بو. چ په یه وه نندیه کا به رچا ف دناقبه را به ربه لاقیا زیپکیت گه نجاتیی و توندیا وی دگه ل هوکارین کومه لایه تی و دیموگرافی دا نه بون وه ک زی، ره گه ز، نفش، خوجهی و نیشانده ری بارمتا له شی. هه بونا میژویا خیزانی یا پرسکیت گه نجاتیی په یه وه نندیه کا به رچا ف هه بو دگه ل توندیا پرسکیت گه نجاتیی ( $p < 0.5$ ) به ل نه دگه به ربه لاقیا وی ( $p > 0.5$ ).

**دهره نجام:** فی لیکولینی دیارکر کو ریژه یه کا زور یا خویندکارا توشی نه خوشیا پرسکیت گه نجاتیی بوینه و رولی بوماوهیی د توندیا پرسکیت گه نجاتیی دا یا خویایه.

## الخلاصة

### حب الشباب: معدل الانتشار والشدة والعوامل المقترنة بهما

**الخلفية والاهداف:** حب الشباب عبارة عن اعتلال جلدي شائع بين طلاب المرحلة الاعدادية والذي كثيرا ما يعاني منه الطلاب في مجتمعنا دون ان يدرس بشكل وافي. كان الهدف من هذه الدراسة احتساب معدل انتشار حب الشباب وشدة والعوامل التي تؤثر عليهما بين طلاب المرحلة الاعدادية في قاطع ضمن اقليم كردستان العراق.

**طرق البحث:** في هذه الدراسة التي اعتمد فيها التصميم المقطعي. تم اختيار عينة عشوائية مؤلفة من ٥٧٥ طالبا من كلا الجنسين من بين ٦٩٨٨ طالبا في قاطع العمادية، محافظة دهوك. وقد تم مقابلة جميع الطلاب وفحصهم سريريا لغرض جمع البيانات المتعلقة بالخصائص الاجتماعية والديموغرافية مثل العمر، الجنس، العرق، دخل العائلة، التاريخ الابوي لحب الشباب، سلوك سلخ الجلد الذاتي، واستعمال المكياج من قبل الطالبات. تم قياس الحالة التغذوية للطلاب عن طريق احتساب مؤشر كتلة الجسم. وتم أيضاً تحديد شدة حب الشباب بالاعتماد على مقياس النظام العالمي لتصنيف حب الشباب وفي النهاية تم جمع البيانات و تحليلها باستعمال برنامج الحزمة الاحصائية للعلوم الاجتماعية.

**النتائج:** أظهرت الدراسة بان معدل انتشار حب الشباب بين الطلاب كان ٧١.٧% و ٨٧.٨% اعتمادا على الابلاغ الذاتي والفحص السريري على التوالي. تبين من الاخير بان ٩٠.٨% من حالات حب الشباب كانت من النوع البسيط، ٩% من النوع المتوسط بينما ٠.٢% فقط من الطلاب وصفت حالتهم بالشديدة. ابرز اصابات حب الشباب كانت من النوع الحبيبي والزؤاني.

لم يجد علاقة ملحوظة بين معدل انتشار حب الشباب او شدته والعوامل الاجتماعية و الديموغرافية مثل العمر، الجنس، العرق، السكن ومؤشر كتلة الجسم. التاريخ العائلي لحب الشباب كانت ذا علاقة ملحوظة مع شدة حب الشباب ( $p < 0.5$ ) وليس بمعدل انتشارها ( $p > 0.5$ ).

**الاستنتاجات:** أظهرت الدراسة معدلاً عالياً لانتشار حب الشباب مع وجود دور ضمني (أساسي) للوراثة في شدة حب الشباب.

## SPECTRUM OF BONE MARROW PATHOLOGY AT HEVI PEDIATRIC HOSPITAL: SIX YEARS EXPERIENCE

ADNAN A. AL-DOSKI, M.B.Ch.B., F.I.B.M.S\*

*Submitted 14 March 2016; accepted 30 June 2016*

### ABSTRACT

**Background:** Hematological disorders are relatively frequent in children. The spectrum of hematological disorders in children is broad, ranging from very frequent conditions like iron deficiency anemia to relatively rare congenital disorders. Bone marrow examination is one of the common and relatively non- dangerous invasive procedures done regularly in pediatric units. The objective of the study is to determine the spectrum of hematological disorders at Hevi pediatric teaching hospital in Duhok province, Kurdistan, Iraq.

**Methods:** The study was a retrospective one. All children who underwent bone marrow examination reported by the hematology department, at Hevi hospital over a period of six years from 2009-2014, were reviewed and re-examined. The clinical data, clinical examination and the indication for the marrow test on the request form as well as the marrow end result were all recorded and analyzed to know the relative frequencies.

**Results:** A total 814 cases of bone marrow examination results were considered from patients the age ranged from 20 days to 15 years. The median age of the cases was 4 years and male to female ratio (M:F) was 1.1:1. Out of the 569 de novo patients, 455 (80%) were non-malignant, while the remaining 114 (20%) patients were of malignant hematological disorders. The most common non-malignant hematological disorder was peripheral consumption of platelets (idiopathic thrombocytopenia purpura ITP) accounting for 28.4%, followed by megaloblastic anemia (12.8%), hypersplenism (12.1%), aplastic anemia (4.4%), marrow erythroid hyperplasia (4.2%), storage disorders (2.8%), while in 148 (32.5%) cases there were no pathological marrow disorder detected. Among the malignant hematological disorders, ALL constituted (70%), while AML cases were (21%), less common cases included mature B-cell leukemia (Burkitt's Lymphoma/leukemia) (4.4%) and mixed lineage acute leukemia (1.7%). Inadequate or diluted samples were encountered in 45 cases (5.5%), while in 200 (24%) cases bone marrow done for follow up and 188 (94%) of them were of known cases of acute leukemia.

**Conclusion:** The most common non-malignant hematological disorders in the pediatric Hevi hospital are peripheral consumption of platelet (ITP). The most common amongst the malignant hematological disorders is ALL followed by AML.

**Duhok Med J 2016; 10 (1): 69-80.**

**Keywords:** ...bon marrow aspiration and biopsy, bon marrow pathology, a plastic anemia

**H**ematological disorders are relatively frequent in children. Unlike adults the spectrum of hematological disorders in children is broad, ranging from very frequent conditions like iron deficiency anemia to relatively rare congenital disorders like Fanconi's anemia, thrombocytopenia with absent radius (TAR syndrome) and Blackfan Diamond syndrome. Similarly the spectrum of

\* Lecturer, Department of Pathology, College of Medicine, University of Duhok, Duhok, Iraq.  
dr\_adnananwar@uod.ac

hematological disorders is somewhat different in the developing world than the industrial countries<sup>1</sup>.

Bone marrow examination is one of the common and relatively safe invasive procedures done regularly in pediatric units. Though an invasive process, it can be performed without any problems, even in the presence of severe thrombocytopenia with slight or no danger of bleeding.

The cellular elements of the blood produced by bone marrow; include whole formed blood cells (platelets, red cells and leucocytes). While a lot of information can be gathered by testing the peripheral blood itself, it is sometimes necessary to examine the source of the blood cells in the bone marrow to find more about the nature of hematopoiesis; this is done essentially by bone marrow study (aspiration and biopsy)<sup>2</sup>.

Bone marrow aspiration and trephine biopsy are vital to prepare the marrow sample. The aspirate yields bone marrow which can be examined under a microscope by a hematopathologist and sometime used to perform more requested tests including flow cytometry, cytogenetic and molecular studies.

Examination of bone marrow is helpful in the diagnosis of both hematological and some non-hematological disorders. Malignant hematological diagnosis,

staging, and therapeutic monitoring are essential indications of the marrow study. Also, estimation of peripheral blood cytopenia, thrombocytosis, leukocytosis, different types of anemia can be done<sup>3</sup>; this is also an important tool in the diagnosis of some non-hematological disorders like storage diseases, leishmaniasis, metastatic carcinoma, pyrexia of unknown origin, and disseminated infection in immunocompromised hosts<sup>4</sup>.

### **MATERIAL AND METHODS**

In this retrospective study all children who underwent bone marrow examination reported by the hematology department, Hevi pediatric teaching hospital, Duhok-Kurdistan region - Iraq over a period of six years from 2009-2014, were reviewed and re-examined. The clinical data including age, gender, clinical examination records and the indication for the marrow test on the request form as well as the marrow end result were all documented.

Bone marrow examination results were also recorded. Data was analyzed to know the relative frequencies in our pediatric patients.

Inclusion criteria:

All cases coming for bone marrow examination. Indications were unexplained anemia, cytopenia (mono-di and pancytopenia), fever, organomegaly,

lymphadenopathy, and /or bleeding manifestations.

Insufficient or dry tap samples were excluded from the study.

The study was approved by ethical committee.

at the College of Medicine – University of Duhok (Kurdistan region).

## RESULTS

A total of 814 cases that had undergone bone marrow examination were reviewed. The age of patients ranged from 20 days to 15 years. Inadequate or diluted samples were 45 (5.5%) and were excluded from the study, follow up cases was 200 (24.5%), leaving a total of 569 (70%) cases that were de novo cases. The median age of the latter group was 4 years and included 306 (52.8 %) males and 263 (47.2%) females. The male to female ratio (M:F) was 1.1:1 of the de novo cases, 455 (80%) patients were found to have non-

malignant conditions (table 1), while the remaining 114 (20%) patients were having malignant hematological disorders (table 2).


As seen in (table 1) peripheral consumption of the platelets (idiopathic thrombocytopenia purpura ITP) was the most common, accounting for 28.4% amongst the non-malignant group. Megaloblastic anemia ranked as the second most frequent non-malignant condition 12.8%. Hypersplenism leading to consumption of two or more blood elements was presumed to be the diagnosis in another 12.1%. Other important diagnoses were less frequent and included aplastic anemia in 4.4% (this was mostly non-severe as shown in table 2), marrow erythroid hyperplasia in 4.2%, storage disorders in 2.8%; other cases were sporadic as shown in table I. In 148 (32.5%) cases there were no significant marrow pathology disorder made.

**Table 1- Variety of non-malignant hematological disorders**

Disorders	No. of cases	%	Median age (years)	Male	Female
No significant marrow pathology	148	32.5	4.3	80	68
Peripheral consumption of platelets (ITP)	129	28.4	3.5	73	56
Megaloblastic anemia	58	12.8	1	26	32
Peripheral consumption of blood elements	55	12.1	5	30	25
Aplastic anemia	20	4.4	7	10	10
Marrow erythroid hyperplasia	19	4.2	5	11	8
Iron deficiency anemia	7	1.5	2.2	4	3
Guacher disease	7	1.5	3.8	5	2
Niemann-Pick_disease	6	1.3	1.4	3	3
Visceral leishmaniasis	2	0.4	8;16 months	0	2

**SPECTRUM OF BONE MARROW PATHOLOGY AT HEVI PEDIATRIC**

Disorders	No. of cases	%	Median age (years)	Male	Female
Pure red cell aplasia (PRCA)	1	0.22	6 months	0	1
Chediak-Higashi syndrome	1	0.22	3	1	0
Absent megakaryocytes	1	0.22	18 months	1	0
TAR syndrome	1	0.22	3 months	1	0
<b>Total</b>	<b>455</b>			<b>245</b>	<b>210</b>




**Figure (1) Variety of non malignant hematological disorder**

**Table 2- Classification of disease severity in aplastic anemia (AA), classified according to Hoffbrand et al**

Prognostic classification of aplastic anemia		No	%
Non- severe	AA	16	85 %
Severe	AA	3	15 %
Very-severe	AA	1	5 %

**Prognostic classification of aplastic anemia**




**Figure (2) Classification of disease severity in aplastic anemia**

During the period of the study a total of 114 malignant hematological disorders were diagnosed by bone marrow examination (table 3), the most common (70%) were acute lymphoblastic leukemia (ALL), the second frequency was acute

myeloid leukemia (AML), less common were mature B-cell leukemia (Burkitt Lymphoma/leukemia) and mixed lineage acute leukemia, other malignant cases were sporadic as shown in (table 3)

**Table 3 - Variety of hematological and non-hematological malignant disorders**

Disease	No. of cases	%	Median age (years)	Male	Female
Acute lymphoblastic leukemia B-type	70	61.3	4.5	36	34
Acute lymphoblastic leukemia T-type	10	8.8	7	5	5
Acute myeloid leukemia	24	21.1	4	11	13
Mature B-cell ALL (Burkitt leukemia)	5	4.4	7.5	4	1
Mixed lineage acute leukemia	2	1.7	5	0	2
Chronic myeloid leukemia	1	0.9	6	1	
Small solid tumor ( neuroblastoma)	1	0.9	4		1
B.M. with secondary malignancy	1	0.9	7		1
<b>Total</b>	<b>114</b>	<b>100</b>		<b>57</b>	<b>57</b>



**Figure (3): Frequency of hematological malignant disorder**

The follow up subgroup included 200 cases out of which 94% were follow up case of acute leukemia. The bone marrows were in complete remission in about three quarter of the cases, while they were in relapse state in 9%, while other bone marrow states are outlined in table 4.

**Table 4 - Variety of followed known cases of hematological and non-hematological malignancy.**

Followed cases of leukemia and malignant	No. of cases	%
Complete remission	151	75.5
Failure of remission or partial remission	19	9.5
Relapsed	18	9
Cases non-hematological follow up	12	6
<b>Total</b>	<b>200</b>	
No of cases followed by two times BME	31	
No of cases followed by three or more times BME	18	

**DISCUSSION**

The spectrum of hematological disorders in children is very broad and bone marrow examination may offer a definitive diagnosis in a good number of cases. It is a relatively harmless and straightforward procedure in experienced hands. Infection, extreme bleeding or embolism was seldom reported complications during or after bone marrow examination<sup>2</sup>.

The two important nutritional anemias in namely: megaloblastic and iron deficiency anemia constitute about 9.3% of non-malignant diagnoses in this study, which is lower in relationship to other studies where its frequencies ranged from as low as 24% to as high as 68%<sup>5</sup>; the cause of this lower frequency is that the majority of these nutritional anemias can diagnosed based on peripheral blood counts and film and supplementary serum/red cell testing rather than bone marrow, like iron study, serum vitamin B12 and folate estimation and thereafter can be confirmed by response to appropriate by therapy.

It was noted that the most frequent causes of referral to the hospital for marrow examination in the above subgroup of patients were anemia, pallor, or failure to thrive, which are common problems in developing countries much less frequent cause of referral in the latter category is blood counts abnormalities as cytopenia (pancytopenia, dicytopenia) or macrocytic anemia. It is quite unlikely that megaloblastic anemia presents with thrombocytopenia or leucopenia only<sup>6</sup>. Determination the causes of megaloblastic anemia could not be ascertained because of the retrospective nature of the current study, but it is well known that folate deficit is more frequent in children, while B12 deficiency is more frequent in adults, the usual presentation age of megaloblastic anemia in the industrial world is in early life<sup>5</sup>. While it can occur at any age in developing countries like ours, in this study megaloblastic anemia occurred in earlier age and median age of

one year. Amongst other nutritional anemias was iron deficiency accounting for only 1% of bone marrow diagnoses which is unlike the study Fazlur Rahim et al<sup>7</sup> from Iran, where anemia of iron deficiency cause accounted for 5% of bone marrow diagnoses. This percentage is lower than expected as an expected 60-80% of the world residents are affected by iron deficiency anemia<sup>8</sup>. The likely reason is as we stated earlier, is that iron deficiency is generally diagnosed by non-invasive investigations without the need for bone marrow.

Idiopathic thrombocytopenia purpura (ITP) was the most frequent bone marrow diagnosis found in this study and accounted a third of the non-malignant cases. Mucocutaneous bleeding in pediatrics is mostly caused by ITP<sup>9</sup>. Its incidence on testing bone marrow varies from 32% to 48%<sup>5</sup> in different studies. ITP incidence in the current study is higher than 4.62 % reported by AL-Ghazaly<sup>10</sup> and the 9.43% by Fazlur Raheem et al<sup>7</sup> from Yemen and Iran respectively. The cause of this high incidence of ITP is likely due to the practice of referring almost all cases of thrombocytopenia for bone marrow examination even if they do not show any atypical features, despite the American Society of Hematology (ASH) recommendations are stated that BM examination should be restricted to those

with the atypical features. A study of Hevi pediatric hospital in 2011, bone marrow examination in isolated childhood thrombocytopenia without any atypical features, did not show any to be leukemias or aplastic anemia<sup>11</sup> thus questioning the need for a bone marrow aspiration in children with suspected idiopathic thrombocytopenic purpura<sup>12</sup>. Physician and parental concern about the possibility of a diagnosis of leukemia frequently underlies the justification for the performance of this procedure. The limitations of the current study includes: data being collected retrospectively, drug history could not be ascertained from the records of every case and the lack of availability of immunological tests related to ITP.

Aplastic anemia (AA) was the third most common found in the study and constituted 4.4% of the cases. In this study, AA was seen to affect equally both males and females and the median age was 7 years because the most frequent cause of hypoplastic marrow was Inherited AA (Fanconi anemia) which is recessively inherited and clinically usually presents between the ages of 3-10 years<sup>13</sup>, while the remaining cases were due to chemotherapy induced marrow suppression in known cases of malignancy managed in Hevi pediatric hospital. Pallor (anemia), failure to thrive, mucocutaneous hemorrhage,

dysmorphism, and skeletal abnormality like polydactyl and small face and eyes were the cause of child's parents or family doctors seeking medical attention, in cases thereafter diagnosed as Fanconi Anemia. The latter diagnosis was generally presumptive in our practice, since chromosomal breakage studies were not available.

Aplastic anemia epidemiologically has an unusual geographical distribution compared to that of acute leukemias, with higher frequency in the developing world than in the industrial countries<sup>1,14</sup>. Its exact prevalence in Iraq is unknown due to lack of dependable population based studies. European studies have implicated certain drugs in the etiology of marrow failure. Unexpectedly, drugs play little role in etiology of the disease in Thailand, where it is mostly idiopathic<sup>15</sup>. Prognosis of AA is directly correlated to the decrease in peripheral blood cell counts, mainly the neutrophil amount:  $<200\text{GRA}/\mu\text{L}$  and platelets  $<20,000/\mu\text{L}$  defines very severe aplastic anemia. Repeated bacterial sepsis or fungal infections resulting from refractory neutropenia are common causes of death<sup>16</sup>.

Malignant hematological disorders in this study were 114 cases (14.8%), and acute lymphoblastic leukemia (ALL) constituted the majority (70%) followed by AML in 21% while the rest were cases of

lymphoma and one case each of chronic myeloid leukemia and neuroblastoma. The high incidence of ALL in children in this study is similar to that reported from other developing countries like Kenya and Pakistan<sup>17,18</sup>.

Follow up bone marrow constituted 24.5% of all bone marrows performed during the study period. The cause of such large number of cases is due to the fact that Hevi pediatric teaching hospital is the only oncology center in the province

About 22% of the requested marrow examinations turned out to be normal marrows with well represented marrow elements and the clinical diagnoses were not hematological, therefore some time marrow examination had been done to exclude other causes of anemia, fever and especially in cases of pyrexia of unknown origin.

We found 13 cases of metabolic storage disorders; 7 cases of Gaucher's disease and 6 cases of Niemann-Pick disease. These rare disorders which are autosomal recessive disorders tend to be more likely to occur in populations with high consanguinity rates, as it is the case in Duhok where consanguineous marriages constitute 27% of all marriages<sup>19</sup>.

Among parasitic afflictions that maybe diagnosed by marrow examination, two cases of Leishmaniasis were diagnosed during the study period, a finding shared

by earlier studies from Yemen and Iran (Fuzlar et al<sup>7</sup> and AL-Ghazaly<sup>9</sup>). The latter studies also reported malaria, which we did not find in the current study, most likely to earlier successful mosquito eradication programs.

Marrow erythroid hyperplasia constituted 19 (4.2%) cases in the study due to high frequency of inherited hemolytic anemia that can influence the marrow's capacity to produce an enough number of blood cell types and liberate them into the circulation<sup>20</sup>.

## CONCLUSIONS

Bone marrow examination is an essential step in verifying the diagnosis of many hematological disorders. The most common disorder among the non-malignant hematological conditions was peripheral consumption of platelets (ITP) in this study. The second most common condition was megaloblastic anemia while iron deficiency anemia was the least common disorder. Aplastic anemia ranked as the third most serious nonmalignant disorder found in this study. The most common amongst the malignant hematological disorders is ALL followed by AML.

## REFERENCES

1. Neal S. Young, Janis L. Abkowitz, Lucio L. New Insights into the Pathophysiology of Acquired

Cytopenias. *Hematology*, 2000; 18 - 38.

2. Omal IK, Sumer H, Tufan A, Shorbagi A. Bone marrow embolism after marrow aspiration and biopsy. *Am J Haematol*. 2005; 78(2):158.
3. Fend F, Tzankov A, Buik K. Modern techniques for the diagnostic evaluation of the trephine bone marrow biopsy: Methodological aspects and applications. *Prog Histochem Cytochem* 2008; 42: 203 – 52.
4. Bain BJ, Clark DM, Wilkins BS. The normal bone marrow. In Bain BJ, Clark DM & Wilkins BS editors. *Bone marrow Pathology* 4th Ed. Singapore, Wiley- black well, 2010:1- 51.
5. Ng SC, Kuperan P, Chan GL. Megaloblastic anemia- a review from University Hospital, Kuala Lumpur. *Ann Acad Med Sing*. 1988;17:261.
6. Mohammad AJ. Thrombocytopenia in children. *J Postgr Med Inst* 2004;18(3) 353-8.
7. Rahim F, Ahmad I, Islam S, Hussain M, Khattak TAK, Bano Q. Spectrum of hematological disorders in children observed in 424 consecutive bone marrow aspirations/biopsies. *Pakistan Journal of Medical Sciences* 2005; 21(4): 433-436.
8. Zlotkin SH. Current Issues for the Prevention and Treatment of Iron Deficiency Anemia. *Indian Pediatrics j*. 2002; 39: 125-129.
9. Mohammad AJ. Thrombocytopenia in children. *J Postgrad Med Inst* 2004; 18:353-8

10. Al-Ghazaly J, Al-Selwi AH, Abdullah M, Al-Jahafi AK, Al-Dubai W, Al-Hashdi A. Pattern of haematological diseases diagnosed by bone marrow examination in Yemen. A developing country experience. *Clin Lab Haematol* 2006; 28: 376-81
11. Abdulrehman A, Khalid NA. Bone marrow examination in isolated childhood thrombocytopenia. *Pak Paed J* 2011; 35(4): 209-12.
12. Buchanan G. Childhood acute idiopathic thrombocytopenic purpura: how many tests and how much treatment required? *J Pediatr* 1985; 106(6): 928-30.
13. Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. *Blood* 1994; 84:1650-
14. Issaragrisil S, Leaverton PE, Chansung K, Thamprasit T, Porapakham Y, Young NS The Aplastic Anemia Study Group: The incidence of aplastic anaemia in Thailand. *Am J Hematol* 1999; 61: 164 -8.
15. Issaragrisil S, Chansung K, Kanfman DW, et al. Aplastic anemia in rural Thailand: its association with grain farming and pesticide exposure. *Am J Public Health* 1997; 87: 1551.
16. Chongli Y, Xiaobo Z. Incidence survey of aplastic anemia in China. *Chin Med Sci J* 1991; 6: 203 -07.
17. SG Kibria, MDU Islam, ASMJ Chowdhury, MY Ali, et al .Faridpur Med. Coll. J. 2010; 5(1): 11-13.
18. Githang'A JN, Dave P. Bone marrow examination at a paediatric hospital in Kenya. *East Afr Med J.* 2000;78:37-9.
19. Al-Allawi NA, Al Doski AA. Frequency of haemoglobinopathies at premarital health screening in Dohuk, Iraq: implication for a regional prevention programme, *EMHJ* 2010, 16(4), 381-385.
20. Momani A, Khasawneh R, Abed R..Spectrum of Bone Marrow aspiration test results at Prince Rashid Hospital/ Jordan; A 3 Year Experience. *Int J Biol Med Res.* 2012; 3(2): 1648-1650

## پوخته

## جورین نه خوشییین مهژیی ههستی ل نه خوشخانا هیفی یا زاروکان: دیفچوونا ۶ سالا

**پیشهکی و ئارمانج:** تیکچوونین خوینی زورن ل دهف زاروکان، جورین فان تیکچوونین خوینی بهررههن ژ جورئ بهرلهلاف وه کیموونا خوینی ژ کیماتیا ئاسنی بو جورین کهلهکین کیم ئهفین ئهگهرین تیکچوونا زکماکی. تیسنا مهژیی ههستی ئیک تیسین زوره و کیم مهترسه دهیته کرن ل بهکهیین زاروکان بشیوهکی بهردهوام. ئارمانجا فی فهکولینی ئهوه بو نیشانکرنا جورین درست ژ تیکچوونین خوینی ل نه خوشخانا هیفی فیژکرنی یا زاروکان، ل پاریزکهها دهوکی، کوردستانا عراقی.

**رینگین فهکولینی:** ئهف فهکولینه یا دیف چوونی بو، دیف چوونا ۸۱۴ کهیسین دیفیکرا ئهفین تیسنا مهژیی ههستی بو هاتیه کرن و نفیسین ل بهشی نه خوشییین خوینی ل نه خوشخانا هیفی دهمی ۶ سالا ژ ۲۰۰۹-۲۰۱۴. ههمی پیژانین فان نه خوشا و ئهگهری چیکرنا ئهفی تیسینی و ئهجامی تیسینی هاتینه نفیسین.

**ئهجام:** کوژمی ۸۱۴ کهیسین تیسنا مهژیی ههستی بو هاتیه کرن ئهجامین وان هاتینه وهرکرتن ژیی وان ژ ۲۰ روژی تاکو ۱۵ سال بوون و نافنجیا سالیان وان ۴ سالیه و ریژا نیر بو می 1:1.1. ئهفین ژیکرتی ۴۵۵ (٪۸۰) نه خوش ئهجامین وان تیکچوونا خوینی نه پهنجهشیری بو و ئهفین مایین ۱۱۴ (٪۲۰) نه خوش ئهجامی تیکچوونا وان خوینی پهنجهشیری بوون.

پیتریا تیکچوونا خوینی نه یا پهنجهشیری ئهوژی کیمبوونا پلیتین خوینی بریکا شکاندنا دهرفه می مهژی ههستی یا بی ئهگهر (٪۲۸.۴)، کیمبوونا خوینی Megaloblastic anemia (٪۱۲.۸)، پیچبوونا تهپکین خوینی ژ ئهگهری مهزنبوونا تحیلی (٪۱۲.۱)، کیمبوونا خوینی Aplastic anemia (٪۴.۴)، کیمخوونا یا زکماکی ژ ئهگهری شگانندی تهپکین خوینی (٪۴.۲)، تیکچوونا کومکرنی (٪۲.۸)، و (٪۳۲.۵) ۱۴۸ کهیس چ ئهگهر نه بوون و نه هاتنه دهست نیشانکرن.

ناف تیکچوونین خوینی یین پهنجهشیری جورئ ALL (٪۷۰)، جورئ AML (٪۲۱)، بشتی وان جورا لیوکیمیا گههشتی B (لیوکیمیا و لیمفوما Burkitt) (٪۴.۴)، و لیوکیمیا لهز جورئ تیکههه (٪۱.۷). ئهف کهیسین سامپلین وان کیم و رون ۴۵ (٪۵.۵) بوون، ئو ۲۰۰ (٪۲۴) کهیسا تیسنا مهژی ههستی بو هاته کرن ژ بهر دیفچوونا نه خوشییین وان یین گهفن ئهفین بهری نوکه هاتینه دهست نیشانکرن و (٪۹۴) ژوان پهنجهشیرا لیوکیمیا لهز بوون.

**دهرئهجام:** تیسنا مهژیی ههستی ئیک ژ ریکین گرنه بو دهست نیشانکرنا گهلهک نه خوشییین خوینی. پیترین تیکچوونا خوینی نه یا پهنجهشیری لقی فهکولینی ئهوه کیمبوونا پلیتین خوینی بریکا شکاندنا دهرفه می مهژی ههستی. یا دووی کیمبوونا خوینا کیم خوارنا ئهوژی کیمبوونا خوینی جورئ Megaloblastic anemia و کیمبوونا خوینی ژ ئهگهری کیمبوونا ئاسنی کیمتر بوو. بشتی وان یا سی تیکچوونا نه پهنجهشیری ئهوژی کیمبوونا خوینی ژ Aplastic anemia. ئو ژ تیکچوونین پهنجهشیری یا ههمی پتر جورئ ALL پاش جورئ AML.

## الخلاصة

طيف من أمراض نخاع العظم في مستشفى هيفي لاطفال: تجربة ٦ سنوات

**الخلفية وأهداف البحث:** الاضطرابات الدموية متكررة نسبياً في الاطفال. وطيف الاضطرابات الدموية في الاطفال واسع تتكون من الحالات الشائعة مثل فقر الدم الحديدي الى حالات النادرة من الاضطرابات الخلقية. ويعتبر فحص نخاع العظم من إحدى الفحوصات الشائعة وليست خطيرة نسبياً من حيث التعامل تجرى بشكل متكرر في مختبرات مستشفيات الاطفال. والهدف من الدراسة هو لتحديد الاطيف الدقيقة للاضطرابات الدموية في مستشفى هيفي التعليمي للاطفال في محافظة دهوك، كردستان العراق.

**طرق البحث:** تعتبر من الدراسة الاستيعابية. راجعنا ٨١٤ حالات متتالية من تقارير فحوصات نخاع العظم التي أجريت من قبلي في وحدة أمراض الدم مختبر مستشفى هيفي لاطفال للسنوات ٢٠٠٩-٢٠١٤. وتدون لكل حالة المعلومات السريرية منها الفحص السريري للمريض و الهدف من اجراء الفحص مع نتيجة تقرير الفحص.

**النتائج:** مجموع نتائج فحوصات نخاع العظم ٨١٤ حالة، العمر تتراوح بين ٢٠ يوم الى ١٥ سنة والمعدل العمري كانت ٤ سنوات ونسبة الذكور الى الاناث هو ١.١ : ١. ونتائج ٤٥٥ (٨٠%) مريض من الحالات المختارة كانت ليست سرطانية، بينما ١١٤ (٢٠%) مريض اضطراباتهم الدموية كانت سرطانية. وأكثر الحالات الغير السرطانية هو فرولية نقص أقرص الدم المجهولة السبب وكانت (٢٨.٤%)، فقر الدم الضخم الارومات (١٢.٨%)، نقص الخلايا الدم الناتج من فرط نشاط الطحال (١٢.١%)، فقر الدم من عدم التنسج (٤.٤%)، فقر الدم الانحلالي الخلقى (٤.٢%)، اضطرابات التخزين (٢.٨%) ونتائج ١٤٨ (٣٢.٥%) حالة كانت طبيعية ولم تكن هناك اي اضطراب دموي في نخاع العظم. وبالنسبة لحالات السرطانية نوع ALL (٧٠%)، AML (٢١%) وأقل حالات المسجلة كانت ليوكيميا حادة من نوع B الناضج (٤.٤%) وليوكيميا حادة مختلطة النسب (١.٧%)

والنماذج القليلة والغير كافية للدراسة كانت ٤٥ (٥.٥%)، بينما ٢٠٠ (٢٤%) حالة أجريت الفحص من أجل متابعة حالاتهم المرضية المشخصة و ١٨٨ (٩٤%) من الحالات المشخصة كانت ليوكيميا الحادة.

**الاستنتاجات:** تعتبر فحص نخاع العظم من الخطوات المهمة لتوصيح تشخيص معظم حالات الاضطرابات الدموية. ومعظم حالات الغير السرطانية كانت فرولية نقص أقرص الدم المجهولة السبب و ثاني حالات شيوعاً من فقر الدم التغذية كانت فقر الدم الضخم الارومات ونقص فقر الدم الحديدي من الاسباب القليلة والاخير فقر الدم من عدم التنسج من الحالات المهمة الغير السرطانية. وأما بالنسبة لحالات اضطرابات الدم السرطانية هو ALL ثم تأتي AML.

**ZINC DEFICIENCY AMONG WOMEN DURING CHILD BEARING AGE**

**KAJEEN R. HUSSEN, MSc\***  
**DHIA J. AL-TIMIMI, M Phil, PhD\*\***

*Submitted 16 March 2016; accepted 22 May 2016*

**ABSTRACT**

**Background:** Zinc deficiency appears to be an important public health problem throughout the world. The objective was to assess zinc status among randomly selected women of child bearing age.

**Methods:** Women of child bearing age (15-45 years) from 3 urban and 3 rural areas in Duhok governorate, Kurdistan region were included in the study. Collection of data was carried out during the period from August 2015 until the end of January 2016. Serum zinc level and zinc status was determined.

**Results:** Overall 121 (30.3%) women were zinc deficient ( $\leq 70\mu\text{g/dl}$ ). Of these, 51 (12.8%) had severe zinc deficiency ( $< 50\mu\text{g/dl}$ ) and 70 (17.5%) had marginal zinc deficiency ( $50-70\mu\text{g/dl}$ ). Mean serum zinc level was significantly lower in women of older age group, pregnant and those with  $> 6$  number of children.

**Conclusion:** Moderate Zinc deficiency was found among women during child bearing age with a high prevalence in older age group, married, pregnant and those with  $> 6$  number of children.

**Duhok Med J 2016; 10 (1): 81-89.**

**Keywords:** Serum Zinc, Child bearing age women.

**Z**inc is a trace metal required in modest amounts to maintain health and optimal physiological functions. It plays an important role in growth and reproduction<sup>1</sup>. Approximately 300 enzymes are known to require zinc for their activities. Zinc is required for DNA synthesis, cell division and protein synthesis<sup>2</sup>. Zinc deficiency therefore results in adverse consequences on the body, although severe deficiency is now considered rare, mild to moderate zinc deficiency may be relatively common

throughout the world<sup>3,4</sup>, and appears to be an important public health problem in many developing countries, including Iraq<sup>5</sup>.

To date, attempts to assess zinc status in vulnerable groups to zinc depletion and low plasma zinc concentration have been few<sup>6,7</sup>. Therefore, this preliminary study aimed to assess zinc status as hypothesized in the most vulnerable sector of our population i.e. the women of child bearing age and to ascertain the relationship between zinc and some other factors

\* Department of Chemistry and Clinical Biochemistry, College of Medicine, University of Duhok, Duhok, Iraq.

\*\* To whom Correspondence should be addressed Email: altimidj@yahoo.com.

which could be relevant in the low status of zinc in women, such as age, marital status, parity, pregnancy status, residency and socioeconomic status.

## **METHODS**

### **Design**

This cross-sectional study included 400 apparently healthy females of child bearing age province of Duhok Governorate, Kurdistan region Iraq. Selection of the participants was done through simple random sampling method. They were chosen from the relatives of patients attending Health Care Centers in villages (Zaweta, Mangesh and Batofa) and in Duhok city center (Malta, Bahdenan and Tanahe). Characteristics among females included age, socioeconomic, educational and marital status. Height, weight and blood pressure recorded by using standard methods. Data on the number of house hold and number of rooms of the house, crowding index is an indicator for socioeconomic status was calculated by dividing the number of household by the number of rooms.

### **Measures**

Blood samples were collected after overnight fasting for 12-14 hours for later measurement of serum zinc level. Serum zinc was analyzed by flame atomic absorption spectrophotometer (Perkin Elmer) using a standard procedure.

Women Zinc deficiency was defined as “concordant” by age if they were no more than 45 years apart, by pregnancy if either pregnant or non-pregnant by self report, by parity if they self-reported as the number of children one or more, and by area if they were no far from the defined urban or rural areas. Women with serum zinc level 50-70  $\mu\text{g/dl}$  considered with marginal zinc deficiency, and severe zinc deficiency for levels  $< 50 \mu\text{g/dl}$ .

Ethical clearance for the study was taken from the General Directorate of Health in Duhok Governorate. Informed consent was obtained from the respondents after explaining the objective of the study.

### **STATISTICAL ANALYSIS**

All data were analyzed using the Statistical Package for Social Sciences SPSS. Unpaired students t-test was calculated to assess differences in serum zinc among study groups. Significance of association between various variable was assessed using chi-square test.

## **RESULTS**

The General characteristics of the study females have been described in Table 1. The mean of age was 26.6( $\pm 6.8$ ) years, height 159.6( $\pm 5.9$ )cm, weight 57.2( $\pm 9.7$ )kg and mean BMI was 22.3( $\pm 3.0$ ). The mean serum zinc level was 86.1( $\pm 21.4$ ), it was higher for urban women compared to rural women, but the difference was not significant. Higher

percentages (75.0) of women were married. Mean age at marriage was 20.2 years. of the 300 married women 126(42.0%) were pregnant. 79(19.8%) of women were belong to good families and 263(65.0%) were belong to medium and 58(14.5%) were belong to poor families. About 232(58.0%) of females were illiterate. No statistically significant difference was found using a P value of <0.05 for general characteristics in rural and urban women.

The sample population was distributed in different age groups as <20, 20-30, 31-40 and >40 years and their zinc levels analyzed. It was found that mean zinc level

was higher in age group (<20) as compared to other age groups(20-30 and 31-40) then starts decreasing significantly up to 40 years(Fig.1).




Fig 1 Comparison of mean serum Zinc level among women of different age groups.

Table 1 Main characteristic of women of childbearing age.

Characteristic	All (n=400) Mean±SD	Rural (n=181)* Mean±SD	Urban (n=219) Mean±SD	p-value
Age(years)	26.6±6.8	26.2±7.0	26.2±7.0	0.2
Height(cm)	159.6±5.9	159.4±6.1	159.4±6.1	0.5
Weight(kg)	57.2±9.7	57.1±9.9	57.1±9.9	0.7
BMI(kg/m <sup>2</sup> )	22.3±3.0	22.3±3.0	22.3±3.0	0.9
Systolic blood pressure (mmHg)	112.4±14.4	112.7±13.2	112.7±13.2	0.6
Diastolic blood pressure (mmHg)	75.8±9.9	76.1±9.5	76.1±9.5	0.8
S. Zinc	86.1±21.4	87.1±21.03	84.9±21.9	0.3
Family size	7.5±3.9	7.3±4.0	7.7±3.8	0.4
	n(%)	n(%)	n(%)	
Married	300(75.0%)	138(76.2%)	162(74.0%)	
unmarried	100(25.0%)	43(23.8%)	57(26.0%)	
Marriage age	300			
Pregnant women	126(42.0%)	55(39.9%)	71(43.8%)	
Non pregnant	174(58.0%)	83(60.1%)	91(56.2%)	
Literate	168(42.0%)	70(38.7%)	98(44.7%)	
Illiterate	232(58.0%)	111(61.3%)	121(55.3%)	
Family size				
SES:				
Good	79(19.8%)	23(12.7%)	56(25.6%)	
Medium	263(65.0%)	121(66.9%)	142(64.8%)	
poor	58(14.5%)	37(20.45)	21(9.6%)	

\* Rural women Vs. Urban women

## ZINC DEFICIENCY AMONG WOMEN DURING CHILD BEARING AGE

Of the four hundred women, 121(30.2%) were zinc deficient. Severe zinc deficiency <50 µg/dl was found in 51(12.7%) women. Out of 51 women with severe zinc deficiency, 33(64.7%) were pregnant (Table 2).

**Table 2 Frequency of zinc deficiency in women of childbearing age**

Serum zinc (ug/dl)	Overall (n=400) n (%)	Pregnant (n=126) n (%)	non-pregnant (n=174) n (%)
<50	51(12.7)	33(64.7)	18(35.2)
50-70	70(17.5)	27(38.5)	22(31.4)
>70	279(69.7)	66(23.6)	134(48.0)

The mean and SD of serum zinc level in pregnant and non-pregnant women is demonstrated in Table 3. Statistically significant difference was found in the mean value of serum zinc in second (unadjusted OR (95% CI) 5.86(2.65-12.9), P<0.0001) and third trimester (unadjusted OR (95% CI) 3.05(1.53-6.09), p=0.001) when compared with the non-pregnant women.

**Table 3 Frequency and mean+SD serum Zinc level in pregnant and non-pregnant women**

	n	Mean±SD	Serum zinc <70n(%)	level (ug/dl)>70	Unadjusted OR(95%CI)	p-value
Non-pregnant	(174)	89.9±21.0	40(23.0%)	134(77.0%)		
Pregnant	(126)					
1 <sup>st</sup> trimester	(49)	82.6±23.2	18(36.7%)	31(63.3%)	1.94(0.98-3.83)	0.05
2 <sup>nd</sup> trimester	(33)	71.5±21.8	21(63.6%)	12(36.4%)	5.86(2.65-12.9)	<0.0001
3 <sup>rd</sup> trimester	(44)	78.8±26.1	21(47.7%)	23(52.3%)	3.05(1.53-6.09)	0.001

The mean serum zinc level with respect to parity is demonstrated in Table 4. Significantly higher level of serum zinc was found (p=0.03) in women having no children versus women with ≥6 number of children.

**Table 4 Association between serum Zinc levels and number of children**

(Children) n	(mothers) N	Mean±SD	Serum zinc ≤70 n (%)	level (ug/dl) >70 n (%)	Unadjusted OR(95%CI)	p-value
0	78	92.9±23.7	32(41.0%)	46(59.0%)		
1-2	102	85.7±21.9	33(32.4%)	69(67.6%)	1.45(0.78-2.68)	0.23
3-5	92	86.3±22.3	32(34.8%)	60(65.2%)	1.30(0.69-2.43)	0.40
≥6	28	78.6±21.2	5(17.0%)	23(82.1%)	3.20(1.10-9.30)	0.03

The association between serum zinc level and the different variables were analyzed (Table 5). A significance association has been found in married and un- married women (P=0.02).

**Table 5 Association between different variables with serum Zinc levels among rural and urban women**

Variables	S. Zinc $\leq 70\mu\text{g/dl}$ n (%)	S. Zinc $>70\mu\text{g/dl}$ n (%)	Unadjusted OR(95%CI)	P-value
<b>Age:</b>				
<20 yrs.	22(32.4%)	46(67.6%)	1.12(0.64-1.97)	0.67
$\geq 20$ yrs.	99(29.8%)	233(70.2%)		
<b>Married</b>	100(33.3%)	200(66.7%)	1.88(1.09-3.22)	0.02
<b>Un-married</b>	21(21.0%)	79(79.0%)		
<b>Age at marriage:</b>				
<17 yrs.	20(32.2%)	42(67.8%)	0.94(0.51-1.70)	0.84
$\geq 17$ yrs.	80(33.6%)	158(66.4%)		
<b>Children:</b>				
Yes	68(30.6%)	154(69.4%)	0.63(0.37-1.08)	0.09
No	32(41.0%)	46(59.0%)		
<b>BMI:</b>				
<23 kg/m <sup>2</sup>	71(31.3%)	156(68.7%)	1.11(0.72-1.72)	0.60
$\geq 23$ kg/m <sup>2</sup>	50(28.9%)	123(71.1%)		
<b>Literate</b>	51(30.4%)	117(69.6%)	1.00(0.65-1.55)	0.96
<b>Illiterate</b>	70(30.2%)	162(69.8%)		
<b>Urban</b>	60(27.4%)	159(72.6%)	0.74(0.48-1.13)	0.17
<b>Rural</b>	61(33.7%)	120(66.3%)		

## DISCUSSION

Zinc deficiency appears to be an important public health problem in many developing countries, including Iraq<sup>9, 10</sup>. In our sample of women included, the overall prevalence of zinc deficiency was 30.2%, of whom 12.7% women were severe zinc deficient. It is therefore, such a high prevalence of low zinc status in the women during child bearing age is especially noteworthy because several factors are known to impact negatively on zinc status. Of these, can be insufficient intake of dietary zinc and physiological stress by pregnancy<sup>11,12</sup>. Mild to moderate zinc deficiency is common in several developing countries, because the commonly consumed staple food have low zinc contents and are rich in phytates. The phytate contents of cereal proteins is

known to decrease the availability of zinc, thus the prevalence of zinc deficiency is likely to be high in a population consuming large quantities of cereal proteins. Therefore, the zinc status in population reported here appears to be associated, at least in part, with low intakes of poorly available dietary zinc<sup>13</sup>. But in fact, we noticed that this low zinc status ( $<70 \mu\text{g/dl}$ ) is highly associated with course of pregnancy in women. Zinc deficiency appears to be highly prevalent in the pregnant women 60/126(47.6%) compared to 40/176(23.0%) non-pregnant. Similar decline in serum zinc levels during pregnancy is reported by others<sup>14</sup>, Considering the differences in risk factors across countries, rural women during child bearing age have significantly lower mean serum zinc levels compared to urban

women<sup>15</sup>. But, in our study, the mean serum zinc level was nearly similar in rural and urban women, which confirmed the data presented are likely to be a representative of the general population actual data, although, zinc bioavailability based on zinc intake and availability factor (percentage of available dietary zinc) has not been determined, which is a limitation of this study. However, it is likely that the changes in serum zinc level were caused solely by other factors. i.e. a vast majority of females studied were married with an age >20 years, multi parity, illiterate, medium-poor socioeconomic status and in the second and third trimesters of pregnancy, all these factors may collectively affected serum zinc level and zinc status in women during child bearing age.

In conclusion, a low zinc status is present in 30.2% of women during child bearing age. This finding suggests that greater priority should be given to the correction of abnormal zinc status in susceptible women.

## REFERENCES

1. Frassinetti S, Bronzetti GL, Caltavuturo L, Cini M and Della C. The role of zinc in life: a review. *Journal of environmental pathology, toxicology and oncology*. 2006; 25(3).
2. Prasad AS and Shankar AH. Zinc and immune function: the biological basis of altered resistance to infection. *The American journal of clinical nutrition*. 1998; 68(2): 447S-63S.
3. Al-Timimi DJ and Al-Rubaii AY. Current status of zinc in healthy and sick elderly. *Journal Fac Med Baghdad*. 2001; 43(1):73-6.
4. Prasad A S. Discovery of human zinc deficiency: 50 years later. *Journal of Trace Elements in Medicine and Biology*. 2012; 26(2):66-69.
5. Al-Timimi DJ. Marginal zinc deficiency: a significant but unrecognized public health problem in Iraq. *Duhok Med J*. 2009; 3(1):1-3.
6. Al-Timimi DJ, Sulieman DM, Hussein KR. Zinc status in type 2 diabetic patients: relation to the progression of diabetic nephropathy. *Journal of clinical and diagnostic research*. 2014; 8(11):4-6.
7. Al-Timimi DJ, Mahmud HM, Mohammed DA, Ahmed IH. Serum zinc and metabolic health status in siblings of patients with type 2 diabetes mellitus *Journal of clinical and diagnostic research*. 2015; 9(12): 5-8
8. Al-Timimi DJ, Al-Sharbatti SS, Al-Najjar F. Zinc deficiency among a healthy population in Baghdad, Iraq. *Saudi Med J* .2005; 26(11):1777-781.
9. Al-Timimi DJ and Mahmoud H. Evaluation of zinc status among patients with diabetes mellitus. *Duhok Medical j*. 2011.5(2):1-10.
10. Al-Timimi DJ and Al-Bakir MM. Evaluation of zinc status in patients

- with metabolic syndrome. JABHS, 2009; 10(3): 23-28.
11. Al-Timimi DJ, Al-Omari W, Clor MM. Zinc in pregnancy; relation to course and outcome. Journal Fac Med Baghdad.1998; 40(2):143–48.
  12. Shah D and Sachdev HPS. Effect of gestational zinc deficiency on pregnancy outcomes: summary of observation studies and zinc supplementation trials. British Journal of nutrition.2001; 85(S2): S101-S108.
  13. Shah D and Sachdev HPS. Zinc deficiency in pregnancy and fetal outcome. Nutrition review. 2006; 64(1): 15-30.
  14. Seshadri, Subadra. .Prevalence of micronutrient deficiency particularly of iron, zinc and folic acid in pregnant women in South East Asia. British Journal of Nutrition.2001; 85(S2): S87-92.
  15. Bodnar LM and Wisner KL. Nutrition and depression: implications for improving mental health among childbearing-aged women. Biological psychiatry.2005; 58(9):679-85.

## پوختہ

## کیمبوونا توخمی توتیایی ل دهف نافرہ تان دماوی ژیی ئینانا زاروکاندا

**پاشین و نارمانج:** کیمبوونا توخمی توتیایی دنافلہ شی مروقی ئیکہ ژ ناریشہ یین ساخلہ میی یین ہرہ بہ ربہ لاق و گرنگ ل سہ رانسہ ری جیہانی. مہرہم ژ نجامدانا فی فہ کولینی ئوہ داکو ناستی توخمی توتیایی د ماوی ژیی ئینانا زاروکاندا بہیتہ پیغان ل دهف وان نافرہ تان یین کو ب شیوہ یہ کی ہرہ مہ کی ل باژیری دھوکی بؤ فی فہ کولینی ہاتینہ ہلبژارتن.

**کہرہ ستہ:** ژبؤ نجامدانا فی فہ کولینی، نمونہ یین ہرہ مہ کی ژ ۴۰۰ نافرہ تان ہاتنہ وەرگرتن کو ژیی وان دناقہہ را ۱۵-۴۵ سالان دابوو. ژ سہرجمی فان نافرہ تان، ۲۱۹ (۵۴.۷٪) ٹاکنجیئ باژیری بوون و ۱۸۱ (۴۵.۳٪) ٹاکنجیئ گوندان بوون. ئہف نمونہ دماوی دناقہہ را ہیفہ تہ باخا سالا ۲۰۱۵ ہتا دوماہیا کانوینا ئیککی یا سالا ۲۰۱۶ ہاتنہ کومکرن و ل دویفدا ناستی توخمی توتیایی ل دهف وان ہاتہ پیغان.

**ئہ نجام:** ژ سہرجمی ۴۰۰ نافرہ تین نمونہ ژئ ہاتینہ وەرگرتن، ۱۲۱ (۳۰.۳٪) نافرہ تان ناریشہ یا کیمیا توخمی توتیایی ہببو ب تیکراییی (۷۰ مگگ/دل)، ۵۱ (۱۲.۸٪) نافرہ تان ناریشہ یا کیمیا توتیایی یا توند ہببو ب تیکراییی (۵۰ مگگ/دل)، ہر ديسان ۷۰ (۱۷.۵٪) نافرہ تان ژئ ناریشہ یا کیمیا توتیایی یا پەراویزی ہببو ب تیکراییی (۷۰-۵۰ مگگ/دل). تیکراییی ناستی توخمی توتیایی ل ب شیوہ یہ کی بہرچاڈ ل دهف نافرہ تین ژیی وان مہزن، خیزاندار، دووگیان و ٹاکنجیئ گوندان بلندتریوو.

**دہرئہ نجام:** پشتی نجامدانا فی فہ کولینی، نجامان ہوسا بؤمہ دا دیارکرن کو کیمیا توخمی توتیایی یا نافنجی ل دهف نافرہ تان ہببو د ماوی ژیی ئینانا زاروکاندا و ئہف ناریشہ ل دهف نافرہ تین دووگیان پتر یا بہ ربہ لاق بوو.

## الخلاصة

### نقص الخارصين لدى النساء خلال سن الانجاب

**الخلفية والاهداف:** يبدو أن نقص الخارصين تكون مشكلة صحية عامة ومهمة في جميع أنحاء العالم، والهدف من هذه الدراسة هو تقييم حالة الخارصين بين النساء في سن الانجاب.

**طرق البحث:** شملت الدراسة ٤٠٠ امرأة وكانت أعمارهن ما بين ١٥-٤٥ عاماً، منهم ٢١٩ (٥٤.٧%) من المناطق الحضرية، و ١٨١ (٤٥.٣%) من المناطق الريفية. جمع البيانات كانت خلال الفترة ما بين آب ٢٠١٥ وحتى نهاية كانون الأول ٢٠١٦، وتم تحديد مستوى الخارصين في مصل الدم.

**النتائج:** كانت ١٢١ (٣٠.٠%) من النساء تعاني من نقص الخارصين ( $\leq 70$  مايكروكرام/ديسيلتر)، منهم ٥١ (١٢.٨%) لديهم نقص شديد في الخارصين ( $\leq 50$  مايكروكرام/ديسيلتر) و ٧٠ (١٧.٥%) من النساء لديهم نقص هامشي في الخارصين ( $50-70$  مايكروكرام/ديسيلتر).

**الاستنتاج:** أظهرت الدراسة نقص معدل الخارصين بين النساء خلال سن الانجاب مع انتشار عالية في النساء الحوامل.

**IS FINE NEEDLE ASPIRATION CYTOLOGY A VALID DIAGNOSTIC TOOL IN NODULAR GOITER?**

**HAYDER HUSSEIN IBRAHIM FRCSED\***  
**MOWAFAQ M. BAHADIN FRCS, CABS\*\***

*Submitted 10 April 2016; accepted 17 June 2016*

---

**ABSTRACT**

**Background:** Fine needle aspiration cytology (FNAC) is commonly used tests for diagnosis of thyroid nodules. Is available procedure and provides specific diagnosis rapidly with minimal complications.

**Aim:** To assess the validity of FNAC in the evaluation of thyroid nodules performed at our institution and to compare our results with other studies elsewhere.

**Patients and methods:** This study was conducted on 51 consecutive patients who underwent FNAC for diagnosis during the period from Feb 2012-Feb 2015. The final histopathological diagnosis was considered the gold standard.

**Results:** The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of FNAC for the diagnosis of neoplastic thyroid nodules were 84.6%, 97.3%, 94.1%, 91.6%, 94.8% respectively. Papillary carcinoma was the common type in neoplastic group (53.8%).

**Conclusion:** Our study suggest that FNAC is a sensitive , specific and accurate initial diagnostic test for the preoperative evaluation of patients with thyroid nodules. Our results are comparable with current published articles and the clinician should be encouraged to use FNAC as the initial modality in assessment of thyroid nodules.

**Duhok Med J 2016; 10 (1): 90-98.**

**Keywords:** Thyroid nodule, Fine needle aspiration cytology, Accuracy.

---

**N**odular goiter remains a problem of enormous magnitude all over the world. The problem in clinical practice is to distinguish reliably the few malignant tumors from the many harmless nodules. Thyroid nodules have a reported prevalence of 4–7% of adult population and fewer than 5% of adult thyroid nodules are malignant<sup>1</sup>

There are a variety of tests giving anatomical and functional information (as isotope scan and ultrasound) about the

thyroid gland but fine needle aspiration cytology (FNAC) gives direct morphological information and has supplanted most other tests for preoperative evaluation of thyroid nodules. Histological examination of the removed thyroid swelling is the most accurate way to determine the pathology.

FNAC is established as a first line diagnostic test for assessment of nodular goiter and give a significant increase in the diagnosis of malignant lesion of

---

\* Ass. Professor in general surgery, medical school, Duhok medical faculty, Duhok university IRAQ

\*\* Ass. Professor in general surgery, medical school, Duhok medical faculty, Duhok university IRAQ

Correspondence author Dr. Hayder H Ibrahim Email hayder1950@yahoo.com

thyroid<sup>2,3</sup>. FNAC is therefore used as the key investigation in combination with imaging investigations in many recognized centers to diagnose or exclude malignancy in nodular goiter. Several studies have reported a high degree of specificity, sensitivity, positive and negative predictive values of FNAC for thyroid lesion<sup>3,4</sup>.

FNAC is, however, not without limitations; accuracy is lower in suspicious cytology and in follicular neoplasms. The main aim of FNAC is to identify nodules that require surgery and those benign nodules that can be observed clinically and decrease the overall thyroidectomy rate in patients with benign diseases.

This study is aimed at determining the diagnostic accuracy of FNAC of thyroid nodules performed at our institution and to compare our results with other studies elsewhere.

#### **MATERIALS AND METHODS**

A cross sectional study was conducted on fifty one patients with goiter (multiple and solitary thyroid nodules) during the period Feb.2012–Feb.2015 in Duhok private hospitals. All patients underwent complete history taking, physical examination, otolaryngeal assessment, hormonal assay (serum T3, T4 and TSH), ultrasound examination and chest x-ray. Isotope thyroid scan was not performed because it is not available. Patients showing either

solitary or multiple nodules were included in the study. Informed consent was obtained from all participants included in the study. FNAC was performed on all solitary nodules and dominant nodules of multinodular goiter. Fine needle aspiration was done by pathologist using a 22- or 23-gauge needle attached to a 20 cc air tight disposable syringe without Ultrasound guide. Samples were smeared onto glass slides and fixed in 95% methanol, along with one or two air-dried smears for May Grunwald Giemsa (MGG) stain. In cystic lesions, after aspiration of fluids, the lesion was again aspirated. The fluid was centrifuged and smears are made from sediment. Wet-fixed smears were stained with Hematoxylin and Eosin and Papanicolaou stains, while air-dried smears were stained with MGG stain.

Type of surgical operation performed depend on the pathology of the gland and surgical specimen was sent for histopathology in all operated cases. The main outcome measures were to correlate the preoperative diagnostic workup with FNAC along the clinical findings with that of postoperative pathological findings.

Inclusion criteria include those patients presenting with thyroid swelling who underwent FNAC, thyroid surgery and histopathological examination. Exclusion criteria was those patients having FNAC

done but did not had thyroid surgery and patients with unsatisfactory aspirate.

The sensitivity, specificity, diagnostic accuracy, positive and negative predictive values of FNAC in diagnosing thyroid lesions relative to the final histological diagnoses were analyzed by SPSS software, according to the following equation:

$$\text{Sensitivity} = \frac{\text{True positive}}{\text{True positive} + \text{False negative}}$$

$$\text{Specificity} = \frac{\text{True negative}}{\text{True negative} + \text{False positive}}$$

$$\text{Positive predictive value} = \frac{\text{True positive}}{\text{True positive} + \text{False positive}}$$

$$\text{Negative predictive value} = \frac{\text{True negative}}{\text{True negative} + \text{False negative}}$$

$$\text{Diagnostic accuracy} = \frac{\text{True positive} + \text{True negative}}{\text{Total number of patients}}$$

Statistical analysis was done using SPSS software.

**RESULTS**

This study consist of 51 cases, there were 44 females and 7 males F/M 6.3/1. Age range was 19–70 years, mean age and standard deviation was 44.8 ± 15.43.

All patients presented with swelling in the front of the neck (100%), other complaint was pain in the neck (3.9%), pressure effect mainly shortness of breath (13.7%). Multinodular goiter in (70.5%) and solitary nodule in (29.4%) as in Table 1.

**Table 1 Study Sample by Demographic and Clinical Characteristics**

Characteristic	Total Cases		
	No.	%	
Age	< 20 year	2	3.9%
	20 - 30	9	17.6%
	31 - 40	13	25.4%
	41 - 50	14	27.4%
	> 50	13	25.4%
Sex	Male	7	13.7%
	Female	44	86.2%
Presenting complaint	Swelling	51	100%
	Pain	2	3.9%
	Pressure effect	7	13.7%
Duration	1 – 5 months	15	29.4%
	6 – 12 months	20	39.2%
	> 1 year	16	31.3%
Site of swelling	Right lobe	8	15.6%
	Left lobe	7	13.7%
	Both lobes	36	70.5%

FNAC was categorized into neoplastic and non-neoplastic groups (no intermediate group recorded in current study) and results were compared with the corresponding histopathological diagnosis shown in Table 2. We identified one false positive result from neoplastic group and two false negative results from benign group as in Table 3 and histopathological diagnosis was shown in Table 4.

**Table 2 Type of Lesion by FNAC and Histopathology**

Type of lesion	FNAC	Histopathology
Non-neoplastic	Solitary nodular goiter	5
	Multinodular goiter	24
	Hashimoto,s thyroiditis	9
Neoplastic	Follicular adenoma	3
	Follicular carcinoma	0
	Papillary carcinoma	8
	Medullary carcinoma	0
	Anaplastic carcinoma	1
		1
<b>Total</b>	<b>51</b>	<b>51</b>

**Table 3 False FNAC Yield by Histopathological Diagnosis**

False Results	No.	FNAC Yield	Histopathological Diagnosis
False positive	1	Follicular adenoma	Hashimoto,s thyroiditis
False negative	1	Nodular goiter	Papillary carcinoma
	1	Nodular goiter	Follicular adenoma

**Table 4 Study Sample by Histopathological Diagnosis**

Hisopathological Diagnosis	Number (%)
Multinodular goiter	24 (47)
Solitary nodular goiter	5 (9.8)
Hashimoto,s thyroiditis	9 (17.6)
Follicular adenoma	3 (5.8)
Follicular carcinoma	1 (1.9)
Papillary carcinoma	7 (13.7)
Medullary carcinoma	1 (1.9)
Anaplastic carcinoma	1 (1.9)

Analysis of the FNAC results obtained were compared with the histological findings in order to rule out malignancy. The analysis yielded a sensitivity of 84.6%, specificity 97.3%, positive predictive value of 91.6%, negative predictive value of 94.8% and test accuracy of 94.1% as in Table 5.

**Table 5 Validity of FNAC Test**

Specificity	97.3%
Sensitivity	84.6%
Positive Predictive Value	91.6%
Negative Predictive Value	94.8%
Accuracy	94.1%

## DISCUSSION

Early diagnosis of thyroid cancer still maintains its importance for higher life

expectancy due to the low malignant potential of thyroid nodule.

FNAC of the thyroid gland has radically changed the management of patients with thyroid disease. It is an efficient method of differentiating benign from malignant thyroid nodules and is widely accepted as the most specific diagnostic test in the preoperative assessment of thyroid nodules<sup>5,6,7</sup>.

In the present study, the age of patients ranged from 19-70 years with mean of 44.8 years and majority of patients were in their 4<sup>th</sup> decade (27.4%). Females were more affected than males (F/M 6.3 :1) Our results were in agreement with other studies<sup>8,9,10,11,12</sup>. The commonest lesion was non-neoplastic condition and comprised 74.5% while neoplastic lesion 25.4%. Out of the neoplastic lesions, papillary neoplasms were the commonest 53.8% (seven out of thirteen patients) which is similar to other studies<sup>8,10</sup>. The sensitivity and specificity for FNAC in published series range between 65-98% for sensitivity and 73-100% for specificity<sup>13,14,15,16</sup>. In our study, the analysis of the data revealed sensitivity of 84.6% and specificity of 97.3%, which translates into a test accuracy of 94.1%. The results of our study are comparable with the published data from different parts of the world. Kumar et al. in their study on 89 patients with enlarged thyroid

gland reported a sensitivity of 77%, specificity of 100%, and test accuracy of 97.7%<sup>16,17</sup>. Similarly, a study conducted by Nggada et al. in a teaching hospital in Nigeria reported a sensitivity of 88.9%, specificity of 96.1%, and test accuracy of 94.2%<sup>7</sup>. The wide range of values for sensitivity and specificity reported by different studies may be attributed to differences in number of cases and the included diagnostic categories. Some authors categorize follicular lesions as histopathologically benign, while others categorize these lesions as malignant<sup>13,14</sup>. In our study, we evaluated the follicular lesions in the neoplastic category. Factors that may reduce the validity of FNAC include, inexperience of the cytopathologist, inadequate sampling and difficulties of differentiation of benign and malignant follicular lesions. Inadequate sampling often results from calcified nodules or nodules with cystic degeneration in larger areas. US guided sampling reduces the error in diagnostic test rates in such conditions<sup>13,18,19</sup>.

Most common lesions that contribute to false-positive results, as in our study, are nodular lesion. The false positive rate in neoplastic group amounted 8.3%. In general, it may be difficult to establish a cytologic differentiation between follicular hyperplastic nodules which are diagnosed as suspicious for malignancy or some of

the follicular adenomas and well differentiated follicular carcinomas. It is reported that such conditions may lead to false-positive results<sup>20,21</sup>.

The false negative rate (FNR) is defined as the percentage of patients with benign cytology in whom neoplastic lesions are later confirmed after thyroidectomy. The false negative FNAC results may occur because of sampling error or misinterpretation of cytology and are of great concern because they indicate the potential to miss a malignant lesion<sup>22</sup>. However, it is difficult to calculate the true frequency of false negative results, because only a small percentage of patients with benign cytological findings undergo surgery. In the present study, false negative FNA has occurred in two out of thirty seven (5.4%) patients with benign diagnosis. This is consistent with reports in the literature that suggest a false negative rate of 2 - 7%<sup>23,24</sup>.

Limitation of our study was small sample size, inconclusive (intermediate) group was not detected in our study which might be due to small sample size as well as the FNAC were performed without ultrasound guide.

In conclusion our study suggest that FNAC is a sensitive, specific and accurate initial diagnostic test for the preoperative evaluation of patients with thyroid nodules. Our results are comparable with

current published articles and the clinician should be encouraged to use FNAC as the initial modality in assessment of thyroid nodules.

#### Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper

#### REFERENCES

1. Guido M. Sclabas, Gregg A. Staerkel, Suzanne E. Shapiro, et al. Fine Needle aspiration of thyroid & correlation with histopathology in a contemporary series of 240 patients. *Am J Surgery* 2003; 186: 702-10
2. Orell RS, Sterrett GF, Walfars MN, Whitaker D. *Manual and atlas of fine needle aspiration cytology*, 3rd ed. U.K, London: Elsevier Publication; 1996. p. 110
3. Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. *Cancer* 2007;111:508-11
4. Serna de la Saravia C, Cuellar F, Saravio Day E, Harach HR. Accuracy of aspiration cytology in thyroid cancer: A study in 1 institution. *Acta Cytol* 2006;50:384-6.
5. Haruna A. Nggada, Alhaji B. Musa, Bata M. Gali, Mustapha I A. Khalil: Fine Needle Aspiration Cytology Of Thyroid Nodule(S): A Nigerian Tertiary Hospital Experience. *The Internet Journal of Cardio-vascular Research* 2006; 5(1): 1.
6. Tabaqchali M A, Hanson J M, Johnson S J, Wadehra V, Lennard T W, Proud G. Thyroid aspiration cytology in Newcastle: a six year cytology/histology correlation study. *Ann R Coll Surg Engl* 2000;82(3): 149-55
7. Nggada H A, Khalil M I A. Fine Needle Aspiration Cytology (FNAC) Technique as a diagnostic tool of tumours in the UMTH, Nigeria. *Highland Medical Research Journal* 2003; 1(3): 28-30.10.
8. Gupta M, Gupta S, Gupta VB. Correlation of fine needle aspiration cytology with histopathology in the diagnosis of solitary thyroid nodule. *J Thyroid Res.* 2010;18:37-40
9. Alam M, Qureshi H, Jan QA. Accuracy of FNAC as a diagnostic modality in the management of solitary thyroid nodule. *J Med Sci.* 2010;18:94-61
10. Dorairagen N and Jayashree N. Solitary nodule of the thyroid and role of fine needle aspiration cytology in diagnosis. *J Indian Med Assoc*, 1996; 94: 50-61
11. R. Bakhos, S. M. Selvaggi, S. Dejong, et al., "Fine-needle aspiration of the thyroid: rate and causes of cytohistopathologic discordance," *Diagnostic Cytopathology*, vol. 23, no. 4, pp. 233-237, 2000.
12. J. L. Morgan, J. W. Serpell, and M. S. P. Cheng, "Fine-needle aspiration cytology of thyroid nodules: how useful is it?" *ANZ Journal of Surgery*, 2003 vol. 73, no. 7, pp. 480-483.

13. Pandey P, Dixit A, Mahajan NC. Fine-needle aspiration of thyroid: A cytohistologic correlation with clinical evaluation of discordant cases. *Thyroid Res. Pract* 2010;9:32-9
14. Bagga PK, Mahajan NC. Fine-needle aspiration cytology of thyroid swellings: How useful and accurate is it? *Indian J Cancer* 2010;47:437-42
15. Haberal AN, Toru S, Ozen O, Arat Z, Bilezikçi B. Diagnostic pitfalls in the evaluation of fine needle aspiration cytology of the thyroid: Correlation with histopathology in 260 cases. *Cytopathology* 2009;20:103-8.
16. Amrikachi M, Ramzy I, Rubinfeld S, Wheeler TM. Accuracy of fine-needle aspiration of thyroid. *Arch Pathol Lab Med* 2001;125:484-8.
17. Kumar S, Aqil S, Dahar A. Role of fine needle aspiration cytology in thyroid diseases. *J Surg Pak* 2008;13:22-5.
18. Ali SZ. Thyroid cytopathology: Bethesda and beyond. *Acta Cytol* 2011;55:4-12
19. Borget I, Vielh P, Leboulleux S, Allyn M, Iacobelli S, Schlumberger M, et al. Assessment of the cost of fine-needle aspiration cytology as a diagnostic tool in patients with thyroid nodules. *Am J Clin Pathol* 2008;129:763-71
20. Esmaili HA, Taghipour H. Fine-needle aspiration in the diagnosis of thyroid disease: An appraisal in our institution. *ISRN Pathology* [Internet]. 2012 Jun [cited 2012 Aug 2]; 912728:[about 4 p.]
21. Dündar E, Paşaoğlu Ö, Kebapçı M, Bildirici K. Retrospective evaluation of fine needle aspiration biopsy of the thyroid. *Türkiye Klinikleri J Med Sci* 2002; 22:14-7
22. Hall TL, Layfield LJ, Philippe A, Rosenthal DL. Source of diagnostic error in the fine needle aspiration of the thyroid. *Cancer* 1989;63:718-25.
23. Layfield LJ, Reichman A, Bottles K, Giuliano A. Clinical determinants for the management of thyroid nodules by fine needle aspiration cytology. *Arch Otolaryngol Head Neck Surgery* 1992;118:717-21
24. Liel Y, Ariad S, Barchana M. Long term follow up of patients with initially benign thyroid fine needle aspiration. *Thyroid* 2001;11:775-8

## پوخته

ئه‌ری وەرگرتنا نمونین شانیهی بده‌رزیکێ ریکه‌کا باشه بو ده‌ستنیشانکرنا په‌ریزاده‌یا گریکی؟

**پیشه‌کی:** وەرگرتنا نمونین شانیهی بده‌رزیکێ ئیکه ژ ریکین مشه کو ده‌یته بکارینان بو ده‌ستنیشانکرنا گریگین گلاندا تایروید. ئه‌ری ئه‌ڤ ریکه ده‌ستنیشانکرنا کا دروست دده‌ت بله‌ز و بکیمترین ئالوزی؟

**ئارمانج:** دیارکرنا بکیرهاتنا ریکا وەرگرتنا نمونین شانیهی بده‌رزیکێ بو هه‌لسه‌نگاندنا گریگین تایرویدئ لده‌ف مه‌ و به‌راوه‌ردکرنا دگه‌ل فه‌کولینین جیهانی.

**ریگین فه‌کولینی:** ئه‌ڤ فه‌کولینه هاته ئه‌نجامدان لسه‌ر ۵۱ نه‌ساخا کو تاقیکرنا وەرگرتنا نمونین شانیهی بده‌رزیکێ بو هاتییه کرن ژبو ده‌ستنیشانکرنا هه‌ر ژ شواتا ۲۰۱۲ ئه‌ه تا شواتا ۲۰۱۵ ئه‌ه و ئه‌نجام ده‌هاتنه به‌راوه‌ردکرنا دگه‌ل تاقیکرنا نه‌سیجی وه‌ک ستانده‌رد.

**ئه‌نجام:** فه‌کولینی دیارکر کو ریکا هه‌ستداری و ریکا تاییه‌تمه‌ندی و ریکا دروستیا گشتی یا ریکا وەرگرتنا نمونین شانیهی بو ده‌ستنیشانکرنا گریگین په‌نجه‌شیری بقی شیوه‌ی بوو: ۸۴.۶٪ ، ۹۷.۲٪ و ۹۴.۱٪ لدویف ئیک.

**ده‌رئه‌نجام:** وەرگرتنا نمونین شانیهی بده‌رزیکێ ریکه‌کا هه‌ستداری و تاییه‌تمه‌ندی و گه‌له‌ک دروسته بو ده‌ستنیشانکرنا وه‌لسه‌نگاندنا ده‌ستپیکێ به‌ری نشته‌رگه‌ری بو گریگین گلاندا تایروید. ئه‌نجامین فه‌کولینی دبه‌راوردن دگه‌ل فه‌کولینین نوی بین به‌لافکری و نوژدارین مه‌ دشین فی ریکی بکاربینن بو هه‌لسه‌نگاندنا ده‌ستپیک.

## الخلاصة

### هل الرشف الابري الدقيق أداة تشخيصية صحيحة لأنسجة عقد الغدة الدرقية؟

**الهدف:** تقييم دورالتشخيص بواسطة الرشف الابري الدقيق لأنسجه عقد الغدة الدرقية ومقارنتها مع نتائج الفحص النسيجي للغده بعد إجراء العملية الجراحية.

**الطريقة:** هذه الدراسة شملت ٥١ حالة مرضية ( ٤٤ من الاناث و ٧ من الذكور) يعانون من عقد الغدة الدرقية خلال الفترة من شباط ٢٠١٢ لغاية شباط ٢٠١٥. لكل مريض تم اخذ عينة الرشف الابري على شرائح زجاجية ومعالجتها بمادة الهيماتوكسلين والايوسين ودراسة النتائج ومقارنتها بالزرع النسيجي لنفس المريض.

**النتائج:** أظهرت الدراسة ان الرشف الابري الدقيق ذو فاعلية كبيرة في تشخيص الاورام الخبيثة للغدة الدرقية وكانت نسبة حساسية الفحص ٨٤.٦% وخصوصية في التشخيص ٩٧.٣% والدقة التشخيصية ٩٤.١%.

**الاستنتاج:** اعتماداً على نتائج هذه الدراسة تبين أن فحص الرشف الابري الدقيق لعقد الغدة الدرقية هو حساس ومتخصص وذا دقة تشخيصية عالية في حالات أورام الغدة الدرقية السرطانية ومقاربة لدراسات أخرى مماثلة ومن المفضل استخدامها لتقييم حالات عقد الغدة الدرقية.

## EVALUATION OF SERUM ZINC LEVEL IN LIVER CIRRHOSIS PATIENTS IN DUHOK GOVERNORATE

BAYAR AHMED QASIM MRCP(UK), FKBMS, SCE Endo/Diabetes(UK)\*

AZAD SALIH FIBMS\*\*

MALAVAN HABEEB FIBMS\*\*\*

REZVAN F. ABDULJABBAR MSc, PhD\*\*\*\*

*Submitted ... 2016; accepted .... 2016*

### ABSTRACT

**Background:** In chronic liver disease, cirrhosis is a consequence that is whereby fibrous scar replaces normal hepatic tissue which leads to progressive loss of liver function. It is mostly caused by alcohol consumption and viral hepatitis B or C. Low serum zinc level is prevalent in liver cirrhosis and appears to be due to decreased oral intake especially intake of animal products, increase in cytokines or hormones responsible for zinc breakdown, increases zinc loss from kidneys and decreased gastrointestinal absorption secondary to congestion caused by portal hypertension.

**Aim of study:** To measure serum zinc level in liver cirrhosis in Duhok Governorate.

**Methods:** This case control study was conducted on a population of 70 randomly selected sample of patients with liver cirrhosis from 1st of January 2015 to 30th of December 2015, who come for follow up in the center of Gastrointestinal and Hepatic Disease, Duhok governorate, Iraq and those who admitted in the medical ward at Azadi General Teaching Hospital and 70 of matched healthy individuals as control group. Patients were interviewed, examined, and their blood samples taken for zinc level and assessment of Child–Pugh score was done for them.

**Results:** The mean zinc level in cases group was 73.11µg/dl versus 81.24 in control group ( P = 0.006). The number of participants, who were low for zinc level was 29 (41.4%) versus 14 (20%) in cases and control groups respectively (P = 0.006). As severity of liver cirrhosis increased, the zinc level decreased, it was 2 (14.3%) in class A, versus 19 (43.2%) in class B, versus 8 (66.7%) in class C of Child-Pugh score, the P value was significant at 0.024.

**Conclusion:** Hypozincemia is very common in patients with liver cirrhosis in Duhok. A routine measurement of serum zinc level in these patients is essential in the management, which will decrease the progression of liver cirrhosis.

**Duhok Med J 2016; 10 (1): 1-9.**

**Keywords:** liver cirrhosis, Zinc.

**C**irrhosis is a long term liver damage in which the healthy liver tissue replaced by fibrosis and this leads to liver failure.. The most common causes behind cirrhosis are alcoholism and hepatitis B or C. The distribution of liver cirrhosis shows

variations among genders, ethnic groups and geographical areas<sup>1</sup>. Majority of patients remain asymptomatic until they decompensate when disease is advanced. The clinical features of decompensated liver disease are accumulation of fluid in

\*Department of Medicine, college of medicine, University of Duhok; Azadi Teaching Hospital, Duhok; Iraq.

\*\*Oncology department, Azadi Teaching Hospital, Duhok; Iraq.

Corresponding author: Bayar Ahmed Qasim. Email: Bayarsabc@gmail.com

the abdominal cavity, bacterial infection of peritoneum, encephalopathy due to liver cirrhosis and bleeding from varices secondary to portal hypertension. The clinical examination may show different findings that needs hepatic or gastrointestinal evaluation to identify the underlying cause<sup>2</sup>.

The zinc, is a metallic element in group twelve of the periodic table (Zn, also called spelter) and its atomic number is 30<sup>3</sup>.

Zinc is important for maturity of immune system. As its essential for function of almost 300 enzymes of human body<sup>4</sup>. Zinc has important role against scar formation in liver tissue. It prevents cellular damage caused by oxidative stress. It is estimated that two billion people in the developing countries suffer from zinc deficiency like people living in Iran, whom their main diet is rice<sup>5</sup>. While zinc status studied in Iraqi population showed that the prevalence of severe zinc deficiency among the studied sample was 2.7%, and mild to moderate zinc deficiency was 55.7% of the study sample<sup>6</sup>. The daily required zinc for women is 8 mg/day and for men is 11 mg/day. Zinc is abundant in foods based on red meats, such as beef, lamb and liver<sup>3</sup>.

The low serum zinc level found in patient with liver cirrhosis appears because of effects of loss appetite and low intake of

animal protein, increase in cytokines or hormones responsible for zinc breakdown, increases zinc loss from kidneys and decreased gastrointestinal absorption secondary to congestion caused by portal hypertension<sup>5</sup>.

The protein produced by liver decreased in cases of liver cirrhosis. The metallothionein (MT) is a protein formed by liver have an important role in zinc metabolism, when oxidants process occur zinc released by this protein, the released zinc is essential in prevention of liver damage (cirrhosis). so any defects in synthesis of this protein will lead to zinc<sup>5</sup>.

It has been suggested that some of the clinical features of liver cirrhosis, such as testicular atrophy, loss of body hair, night blindness, poor wound healing, poor appetite, decreased taste and smell acuity, susceptibility to infections, enhanced sensitivity to drugs, and decreased neurocognitive performances, may be related to zinc deficiency<sup>4</sup>.

The patients with liver cirrhosis need regular checkup of serum zinc level in order to reduce the worsening of the disease. In some cases zinc therapy improve clinical outcome of these patients. In addition zink therapy corrects the reduced serum zinc level and decreases blood ammonia concentration by activating muscle glutaminsynthetase, resulting in decreasing incidence of

encephalopathy in patients with liver cirrhosis<sup>7</sup>.

### PATIENTS AND METHODS:

The population of this case-control study consisted of a total 70 randomly selected patients diagnosed with liver cirrhosis from 1<sup>st</sup> January 2015 to 30<sup>th</sup> December 2015, who came for follow up in the center of gastrointestinal and hepatic disease and those who were admitted in the medical ward at Azadi General Teaching Hospital and 70 of healthy individuals as control group. The patients were interviewed and examined, and their blood samples taken for zinc level and assessment of Child–Pugh score as shown in table 1<sup>8</sup>.

**Table (1) Child Pugh Score**

Measure	1 point	2 points	3 points
Total bilirubin, $\mu\text{mol/l}$ (mg/dl)	<34 (<2)	34-50 (2-3)	>50 (>3)
Serum albumin, g/dl	>3.5	2.8-3.5	<2.8
PT INR	<1.7	1.71-2.30	> 2.30
Ascites	None	Mild	Moderate to Severe
Hepatic encephalopathy	None	Grade I-II (or suppressed with medication)	Grade III-IV (or refractory)
Points	Class	One year survival	Two year survival
5-6	A	100%	85%
7-9	B	81%	57%
10-15	C	45%	35%

Inclusion criteria include patients already diagnosed with liver cirrhosis. This includes clinical finding (when liver span

is less than 8 cm with ascites and spleen enlargement), biochemical tests (prothrombin time more than 12 seconds and serum albumin less than 3.5g/dl), radiologically (increased echo pattern of liver, liver shrinkage to less than 8cm, diameter of portal vein more 1.3cm and size of spleen more than 13cm longitudinally) and previous histopathological report (diffuse fibrosis, obliteration of central vein and regenerating nodules)<sup>4</sup>.

Meanwhile, patients who were on zinc supplementation therapy, or those on hormonal therapy or cancer chemotherapy were excluded from the study. Further exclusion criteria were pregnancy, acute or chronic diarrhoea, or patients with autoimmune or immunodeficiency disorder (CD4+ count <200 and granulocytopenia <500/mm<sup>3</sup>)<sup>4</sup>.

Fasting serum zinc level were measured by Flame Atomic Absorption Spectrophotometry, Pye Unicam 2900. The reference ranges of serum zinc level were (73-127  $\mu\text{g/dl}$  for male, 70-114  $\mu\text{g/dl}$  for females)<sup>9</sup>.

Patients' informed consents were taken. Appropriate communication about the study was undertaken with the patients/carers.<sup>4</sup>

Venous blood samples were drawn and used for determination of serum zinc level (Flame Atomic Absorption

## EVALUATION OF SERUM ZINC LEVEL IN LIVER CIRRHOSIS PATIENTS

Spectrophotometry, Pye Unicam 2900) according to the data published by Pye Unicam Ltd.(reference Pye WPJ. Unicam atomic absorption data book. 2nd ed. Pye Unicam Ltd; 1976

A specially-designed questionnaire was used to obtain information from participants. Information include gender, age, weight. Data on personal health including history of chronic illnesses and any other drugs patient currently receiving it. All participants underwent a routine medical history & physical examination as clinically relevant.

All data were analyzed using the Statistical Package for Social Science (SPSS v21, Chicago, IL); paired student t- test was calculated to assess differences in serum analyte among groups. Significance of association between various risk factors was assessed using Chi-square test. Level of statistical significance was set at < 0.05.

### RESULTS

The age of majority of cases was  $\geq 60$  years (47.1%), while the age of majority of control group was between 30-40 years (50%) as shown in table 2.

**Table (2) Age distribution of study participants**

	20-30		30-40		40-50		50-60		$\geq 60$		Total
	vr		vr		vr	No.	vr	No.	No.		
Cases	2		2		15		18		33		70
	(2.9)		(2.9)		(21.4)		(25.7)		(47.1)		(100)
Controls	0	(0)	35		14		7	(10)	14		70
			(50)		(20)		(20)		(20)		(100)

Females constituted 51.4% (N=) of the patients, while number of males and females were equal in control group as shown in table 3.

**Table (3) Gender distribution of study participants**

	Male No. (%)	Female No. (%)	Total
Cases	34 (48.6)	36 (51.4)	70 (100)
Controls	35 (50)	35 (50)	70 (100)

The mean of zinc level in cases group was 73.11  $\mu\text{g}/\text{dl}$  versus 81.24 in control group and the P = 0.006 (Standard deviation in cases group 20.947 versus 12.702  $\mu\text{g}/\text{dl}$  in control group) as shown in table 4.

**Table (4) Difference between cases and control regarding zinc measurement**

	Zinc measure		
	Mean (microgm/dl)	Standard deviation (microgram/dl)	P value*
Cases	73.11	20.947	0.006**
Controls	81.24	12.702	

\* Statistical test used: independent t-test

\*\* the difference is statistically significant

The number of participants, who were low for zinc level was 29(41.4%) versus 14 (20%) in both cases and control groups respectively (P=0.006) as shown in table 5.

**Table (5) Difference between cases and control regarding zinc level**

	Zinc Level		
	Normal No. (%)	Low No. (%)	P value*
Cases	41 (58.6)	29 (41.4)	0.006**
Controls	56 (80)	14 (20)	

\* Statistical test used: Chi squared test

\*\* the difference is statistically significant

The difference in zinc level according to age and gender of participants, statistically were not significant as shown in table 6 and 7.

**Table (6) Difference in zinc level according to age of participants**

Zinc Level			
Age groups (years)	Normal No. (%)	Low No. (%)	P valu*
20-30	2	0	Not significant**
30-40	30	7	
40-50	16	13	
50-60	19	6	
60 and more	30	17	

\* Statistical test used: Chi squared test

\*\* the difference is statistically not significant

**Table (7) Difference in zinc level according to gender of participants**

Zinc Level			
Gender	Normal No. (%)	Low No. (%)	P value*
Male	51 (73.9)	18 (26.1)	Not significant**
Female	46 (64.8)	25 (35.2)	

\* Statistical test used: Chi squared test

\*\* the difference is statistically not significant

As severity of liver cirrhosis increased depending on Child Pugh score, the zinc level decreased; 2 (14.3%) in class A, versus 19 (43.2%) in class B, versus 8 (66.7%) in class C, (P = 0.024;table 8).


**Table (8) Difference in zinc level according to child Pugh score of patients**

Zinc Level			
Child Pugh Score	Normal No. (%)	Low No. (%)	P value*
A	12 (85.7)	2 (14.3)	0.024 **
B	25 (56.8)	19 (43.2)	
C	4 (33.3)	8 (66.7)	

\* Statistical test used: Chi squared test

\*\* The difference is statistically significant

HBV constitute the majority of cases 39(27.9%) of liver cirrhosis followed by cryptogenic 19(13.6%) as shown in figure 1.



**Figure (1) Causes of Liver Cirrhosis**

Diabetes Mellitus (DM) was the most prevalent co morbidity among liver cirrhosis cases and was diagnosed in 18 (12.9%) patients followed by asthma 4 (2.9%) as shown in table 9.

**Table (9) Co-morbidities**

	Number	%
None	46	32.9
DM	18	12.9
Hypertension	2	1.4
Asthma	4	2.9
Total	70	100

**DISCUSSION:**

Elements in blood have important role in diagnosis and prognosis of many diseases<sup>10</sup>. Many studies done before and show strong relation between zinc deficiency and liver cirrhosis.

Pramoolsinsap et al. found that patients with chronic active hepatitis, hepatocellular carcinoma and liver cirrhosis have zinc deficiency<sup>11</sup>. In et al. have found Chinese patients with liver cirrhosis were suffering from zinc deficiency<sup>12</sup>. Zinc level is correlated with eating habit of each community. The developing countries suffer from zinc deficiency more such as people living in Iran, whom their main diet is rice<sup>13</sup>. The phytate and fiber, which present in cereals, are responsible for decreasing zinc absorption<sup>14</sup>. Malnutrition is prevalent in patients with liver cirrhosis secondary to hepatitis B and C, so measuring zinc level may be a good indicator of nutritional status in these patients<sup>15</sup>. Some studies found difference in zinc levels in human. Lopez et al. found that zinc level is higher in men than in women<sup>16</sup>.

In the this study, as there is no significant difference between cases and controls regarding gender and age, the biases in interpretation of zinc level will decrease.

The results of our study showed the main cause of liver cirrhosis is viral hepatitis(HBV), which comprise the majority of cases of liver cirrhosis followed by cryptogenic type. There was significant difference between cases and control group regarding zinc status. These results are keeping with similar other studies (10, 11). The results of are of more

importance as there is role of zinc supplementation in treatment of viral hepatitis. Yuasa et al. found that Zinc replacement prevent replication of hepatitis C virus that is why zinc may play a important role in the development of future plans for treating intractable chronic hepatitis C<sup>17</sup>. Himoto et al. did a study on role of polaprezinc (complex of zinc and L-carnosine) on inflammation and fibrosis in patients with HCV. They found that polaprezinc have an anti-inflammatory effect on the liver in patients with chronic liver disease caused by HCV this by reducing iron level<sup>18</sup>.

in the current study we found that zinc deficiency correlated with liver cirrhosis<sup>19</sup> and indicators of liver failure like total bilirubin, albumin, and cholesterol<sup>11</sup>. Low zinc is more common in liver cirrhosis secondary to alcohol consumption<sup>20-25</sup>. Indeed; the low level is more prevalent if the underlying cause of cirrhosis is alcohol in comparison with other causes<sup>26</sup>. Hepatic encephalopathy is related to low zinc level in liver cirrhosis<sup>27,28</sup>. Accordingly, zinc therapy improves psychometric performances in hepatic encephalopathy<sup>29</sup>. On the other hand, some data show no benefit of treatment of zinc deficiency in comparison to standard treatment<sup>30,31</sup>. Despite these mixed results, treatment of zinc deficiency is recommended for patients suffering from hepatic

encephalopathy who are reluctant to usual therapy<sup>32,33</sup>.

In conclusion, hypozincemia is very common in patients suffering from liver cirrhosis. A regular evaluation of serum zinc in patients with liver cirrhosis will play a key role in management of such patients and will prevent worsening of the underlying disease. We need more studies to evaluate the exact role of zinc replacement on clinical, pathological response of patients with cirrhosis in Duhok.

## REFERENCES

1. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-Hepatic vascular Disorders (PHD). *Eur Respir J*. 2004; 24(5): 861-80.
2. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. *Am Fam Physician*. 2006; 74(5): 756-62.
3. Prasad AS. Zinc in human health: effect of zinc on immune cells. *Mol Med*. 2008; 14(5-6): 353-7.
4. Soomro AA, Devrajani BR, Shaikh K, Shah SZA, Devrajani T, Bibi I. Serum zinc level in patients with liver cirrhosis. *Pak J Med Sci*. 2009; 25(6): 986-91.
5. Atia F, Sultana N, Ahmed S, Ferdousi S, Sultana R, Atiquzzaman M. A Study of Serum Zinc level in Cirrhosis of Liver. *Bangladesh Journal of Medical Biochemistry*. 2013; 5(2): 44-7.
6. Dhia J. Al-Timimi, Shatha S. Al-Sharbatti, Farouk Al-Najjar. Zinc deficiency among a healthy population in Baghdad, Iraq. *Saudi Med J* 2005; Vol. 26 (11).
7. Mohammad Abbasi N, Sahar Hasani M, Mohammad Amin P, Seyed Reza M, Mohammad Reza Z. Evaluation of Zinc Plasma Level in Iranian Cirrhotic Patients due to Hepatitis B and Hepatitis C. *Hepatitis Monthly*. 2016; 2010 (Volume 10, Issue 1, Winter): 62-4.
8. Peng Y, Qi X, Guo X. Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies. *Medicine (Baltimore)*. 2016; 95(8): e2877.
9. Shameer, Shameer P PPV, Kaviarasan P K. Serum zinc level in vitiligo: A case control study. 2005.
10. Cesur S, Cebeci SA, Kavas GO, Aksaray S, Tezeren D. Serum copper and zinc concentrations in patients with chronic hepatitis B. *J Infect*. 2005; 51(1): 38-40.
11. Pramoolsinsap C, Promvanit N, Komindr S, Lerdverasirikul P, Srianujata S. Serum trace metals in chronic viral hepatitis and hepatocellular carcinoma in Thailand. *J Gastroenterol*. 1994; 29(5): 610-5.
12. Lin CC, Huang JF, Tsai LY, Huang YL. Selenium, iron, copper, and zinc levels and copper-to-zinc ratios in serum of patients at different stages of viral hepatic diseases. *Biol Trace Elem Res*. 2006;109 (1): 15-24.

13. Hambidge KM, Krebs NF. Zinc deficiency: a special challenge. *J Nutr.* 2007; 137 (4): 1101-5.
14. Prasad AS. Discovery of human zinc deficiency and studies in an experimental human model. *Am J Clin Nutr.* 1991;53(2): 403-12.
15. Carvalho L, Parise ER. Evaluation of nutritional status of nonhospitalized patients with liver cirrhosis. *Arq Gastroenterol.* 2006; 43(4): 269-74.
16. Lopes PA, Santos MC, Vicente L, Rodrigues MO, Pavao ML, Neve J, et al. Trace element status (Se, Cu, Zn) in healthy Portuguese subjects of Lisbon population: a reference study. *Biol Trace Elem Res.* 2004; 101(1):1-17.
17. Yuasa K, Naganuma A, Sato K, Ikeda M, Kato N, Takagi H, et al. Zinc is a negative regulator of hepatitis C virus RNA replication. *Liver Int.* 2006; 26(9): 1111-8.
18. Himoto T, Hosomi N, Nakai S, Deguchi A, Kinekawa F, Matsuki M, et al. Efficacy of zinc administration in patients with hepatitis C virus-related chronic liver disease. *Scand J Gastroenterol.* 2007;42 (9): 1078-87.
19. Poo JL, Rosas-Romero R, Rodriguez F, Silencio JL, Munoz R, Bourges H, et al. Serum zinc concentrations in two cohorts of 153 healthy subjects and 100 cirrhotic patients from Mexico City. *Dig Dis.* 1995; 13(2): 136-42.
20. Ijuin H. Evaluation of pancreatic exocrine function and zinc absorption in alcoholism. *Kurume Med J.* 1998; 45(1): 1-5.
21. Schlienger JL, Willemin B, Lang JM, North ML, Simon C, Doffoel M, et al. [Evaluation of malnutrition and immunity in alcoholic liver diseases]. *Presse Med.* 1986;15(22):1023-7.
22. Bro S, Stokholm M, Jorgensen PJ. Zinc in mononuclear leucocytes in alcoholics with liver cirrhosis or chronic pancreatitis and in patients with Crohn's disease before and after zinc supplementation. *J Trace Elem Electrolytes Health Dis.* 1989; 3(4): 243-8.
23. Aaseth J, Smith-Kielland A, Thomassen Y. Selenium, alcohol and liver diseases. *Ann Clin Res.* 1986; 18 (1): 43-7.
24. Vallee BL, Wacker WE, Bartholomay AF, Hoch FL. Zinc metabolism in hepatic dysfunction. II. Correlation of metabolic patterns with biochemical findings. *N Engl J Med.* 1957; 257 (22): 1055-65.
25. Chapman KM, Prabhudesai M, Erdman JW, Jr. Vitamin A status of alcoholics upon admission and after two weeks of hospitalization. *J Am Coll Nutr.* 1993; 12 (1):77-83.
26. Grungreiff K, Abicht K, Kluge M, Presser HJ, Franke D, Kleine FD, et al. Clinical studies on zinc in chronic liver diseases. *Z Gastroenterol.* 1988; 26(8): 409-15.
27. Yang SS, Lai YC, Chiang TR, Chen DF, Chen DS. Role of zinc in subclinical hepatic encephalopathy: comparison with somatosensory-evoked potentials. *J Gastroenterol Hepatol.* 2004; 19(4): 375-9.

28. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. *Am J Gastroenterol.* 2001; 96 (9): 2718-23.
29. Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. *Lancet.* 1984; 2 (8401):493-5.
30. Riggio O, Ariosto F, Merli M, Caschera M, Zullo A, Balducci G, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. *Dig Dis Sci.* 1991; 36(9):1204-8.
31. Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. *Eur J Med.* 1993;2(7): 414-6.
32. Blei AT, Cordoba J. Hepatic Encephalopathy. *Am J Gastroenterol.* 2001; 96(7):1968-76.
33. Quero GJ, Carmona SI, García MJ, Jiménez SM, Herrerías GJ. Hepatic encephalopathy: nomenclature, pathogenesis and treatment. *Revista española de enfermedades digestivas: organo oficial de la Sociedad Española de Patología Digestiva.* 2003; 95(2): 135-42, 27-34.

## پوخته

هه‌سه‌نگاندنا ئاستی زنکی دناڤ خوینی دا لدهف نه‌خوشین شه‌مابوونا جه‌رگی هه‌ی لپاریژگه‌ها دهوکی

**پیشه‌کی:** شه‌مابوونا جه‌رگی ئیکه ژ ده‌رئه‌نجامین نه‌خوشین دومدریژین جه‌رگی کو تیدا پیکهاته‌یی جه‌رگی دهپته گوهارتن بته‌خین ئه‌لیافا و هیدی هیدی جه‌رگ کارئ خو ژده‌ست ددهت. پتریبا جاران ژئه‌گه‌ری نه‌خوشین فه‌خوارنن کحولی یه‌سه‌ر جه‌رگی وه‌روه‌سا کولبوونا جه‌رگی یا فایروسی ژ جورئ B و C. کیمیا که‌رستی زک دناڤ خوینی یا مشه‌یه لدهف نه‌خوشین شه‌مابوونا جه‌رگی و ئه‌گه‌ری وئ ژئ دلنه‌چوونا خوارنی، کیم خوارنا پروتینی گیانه‌وه‌ری، زنده‌بوونا سایتوکاینا و هورمونین لسه‌ر زنکی کاردکه‌ن، زنده ژده‌سدانا زنکی بریکا گولچیسکا و لاواریبا هه‌لمرتنا زنکی درویفیکا دا.

**ئارمانج:** ده‌ستنیشانکرنا ئاستی زنکی لدهف نه‌خوشین شه‌مابوونا جه‌رگی هه‌ی لپاریژگه‌ها دهوکی.

**ریکن فه‌کولینی:** دئی فه‌کولینی دا حه‌فتی نه‌خوشین شه‌مابوونا جه‌رگی به‌روه‌یی هاتنه هه‌لبژارتن ژناڤ ئه‌و نه‌خوشین سه‌ره‌دانا سه‌نته‌ری نه‌خوشین جه‌رگی وکوئه‌ندامی هه‌رسکرنی کری وه‌روه‌سا ئه‌وین هاتینه نقاندن لنه‌خوشخانا ئازادی یا فیترکرنی لپاریژگه‌ها دهوکی هه‌ر ژ ئیکه کانونا دووی حه‌تا سهی کانونا ئیکه، ۲۰۱۵. دکه‌لدا ۷۰ که‌سین ساخلم وه‌ک گروپی کونترول هاتنه وه‌رگرتن. ئه‌ڤ نه‌خوشه هاتنه دیتن و نمونین خوینی ژئ هاتنه وه‌رگرتن بو دیارکرنا ئاستی زنکی لدهف وان.

**ئه‌نجام:** تیکرایئ ئاستی زنکی لدهف گروپی نه‌خوشان ۷۳.۱۱ مگم/دسلیمته‌ر به‌راوردی دکه‌ل ۸۱.۲۴ لدهف گروپی که‌سین ساخلم (قیمه‌تا P ۰.۰۰۶ بو). ژمارا نه‌خوشین کیماتیبا زنکی هه‌ی ۲۹ (٪۴۱.۰۴) بوون به‌رامبه‌ر ۱۴ (٪۲۰) ژ گروپی ساخلمه‌مان (قیمه‌تا P ۰.۰۰۶ بو). دکه‌ل زنده‌بوونا دژواریبا نه‌خوشیا شه‌مابوونا جه‌رگی کیمیا ئاستی زنکی پتر بوو کو ئه‌وژی ۲ بو (٪۱۴.۳) ل پله‌یا A و ۱۹ (٪۴۳.۲) ل پله‌یا B و ۸ (٪۶۶.۷) ل پله‌یا C یا دژواریبا نه‌خوشی و ئه‌ڤ جیاوازیبه‌یا ب بها بوو ژلایی ئاماری فه‌ (قیمه‌تا P ۰.۰۰۲ بو).

**ده‌رئه‌نجامی دوامی:** کیماتیبا زنکی گه‌له‌کا مشه‌یه لدهف نه‌خوشین شه‌مابوونا جه‌رگی هه‌ی لدهوکی. تاقیکرنا ئاستی زنکی بو نه‌خوشین شه‌مابوونا جه‌رگی بشیوه‌کی روتینی دئ پینگافه‌کا گرنگ بیت بو چاره‌سه‌رکرنا فان نه‌خوشان یا کو بشیوه‌کی به‌رچاڤ پیشه‌چوونا نه‌خوشی کیم دکه‌ت.

## الخلاصة

### تقييم مستوى الخارصين في مصل الدم لدى مرضى تشمع الكبد في محافظة دهوك

**الخلفية:** تليف الكبد هو نتيجة لأمراض الكبد المزمنة التي تتميز باستبدال نسيج الكبد بآخر ليفي مما يؤدي إلى فقدان التدريجي لوظائف الكبد. والاسباب الأكثر شيوعاً لتليف الكبد هي الإدمان على الكحول وكذلك التهاب الكبد الفيروسي نمط B أو C. انخفاض مستوى الخارصين في مصل الدم شائع لدى المرضى الذين يعانون من تليف الكبد ويبدو أن ذلك يعود إلى فقدان الشهية وقلة تناول البروتينات الحيوانية، وزيادة في السيتوكينات أو الهرمونات التي تشارك في عملية الأيض الغذائي للخارصين، زيادة فقدان الخارصين عن طريق الكلى وكذلك ضعف امتصاص العناصر الغذائية.

**هدف الدراسة:** تحديد مستوى الخارصين في مصل الدم لدى المرضى الذين يعانون من تليف الكبد في محافظة دهوك.  
**طريقة البحث:** أجريت هذه الدراسة من نوع العينة والشاهد على 70 من المرضى الذين يعانون من تليف الكبد تم اختيارهم عشوائياً من 1 كانون الثاني الى 30 كانون الأول عام 2015، ممن زاروا مركز أمراض الجهاز الهضمي والكبد ومستشفى آزادي التعليمي العام في محافظة دهوك، العراق، وكذلك 70 من الأفراد الأصحاء كمجموعة الشاهد. أجريت المقابلة مع المرضى وتم فحصهم سريرياً ومن ثم أخذت عينات من دمهم لتحديد مستوى الخارصين لديهم.

**النتائج:** كان مستوى الخارصين لدى مجموعة المرضى 73.11 مكغم/ديسيلتر مقابل 81.24 في مجموعة الشاهد (P = 0.006). وكان عدد المرضى الذين كانت لديهم نسب منخفضة من الخارصين 29 (41.4%) مقارنةً بـ 14 (20%) لدى الأصحاء (P = 0.006). كلما زادت شدة تليف الكبد، كلما ازداد انخفاض مستوى الخارصين، فكان 2 (14.3%) في الفئة A، مقابل 19 (43.2%) في الفئة B، مقابل 8 (66.7%) في الفئة C، وكانت قيمة P 0.0024.

**الاستنتاج:** انخفاض مستوى الخارصين شائع جداً لدى مرضى تليف الكبد في دهوك. الفحص الروتيني لمستوى الخارصين في مصل الدم لمرضى تليف الكبد هو خطوة مهمة في علاج هؤلاء المرضى والتي تؤدي إلى الحد من تفاقم المرض لديهم.

خزيران ٢٠١٦

پهريهندا ١٠ ژماره ١



زانكویا دهوك  
كوليژا پزیشکی

# گوقارا پزیشکی یا دهوكی

گوقارا فهرمی یا كوليژا پزیشکی یا دهوكی

VOLUME 10 ISSUE 1

Duhok Medical Journal

JUNE 2016

ISSN: 2071 - 7326